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Abstract:	  
The aetiology for sporadic pancreatic adenocarcinoma is poorly characterized. 
Familial/hereditary causes account for about 10% cases and tobacco smoking is a well-
established risk, however it is only responsible for about a third of cases. DNA repair 
mechanisms restore the genome damage caused by carcinogens including those derived 
from tobacco smoking. Increasing attention is being focused on single nucleotide 
polymorphisms, which exist amongst various physiological pathways including DNA 
repair mechanisms, and account for inter-individual variation in risk for cancer. This 
study is an effort to investigate the impact of family history of malignancy, tobacco 
smoking and selected genetic polymorphisms involved in DNA repair on pancreatic 
ductal adenocarcinoma development.  
A hospital-based case-control study of pancreatic adenocarcinoma cases and hospital-
based controls was undertaken at the Freeman Hospital between 2005-2006. Pancreatic 
cancer cases were ascertained based on histology, cytology or a combination of clinical 
findings, tumour marker levels and progressive radiological changes. All participants 
were interviewed to establish a detailed clinical, family history and tobacco smoking 
(MONICA questionnaire) A sample of peripheral blood was obtained for genotyping of 
specific Base Excision repair genotypes – hOGG1, XRCC194, XRCC280, XRCC399 
and APE148. Statistical analysis was performed on SPSS v16. Odds ratios (95% CI) 
were calculated for individual variables. 
Tobacco smoking was confirmed to be a risk factor for pancreatic cancer [OR (95% CI) 
on univariate: ever smoker [(present and past smokers) OR 3.01 (95% CI 1.73 to 5.24)] 
and multivariate analysis: present smokers [OR = 8.531 (3.198 to 22.759) and past 
smokers OR = 5.862 (2.223 to 15.460)]. Importantly a significantly decreased 
cumulative tobacco exposure was seen amongst pancreatic cancer cases with a family 
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history of cancer [mean (SD): 30.00 (24.77) pack-years] as compared those who did not 
have such a history [44.69 (28.47) pack-years p=0/023]. No specific overall increased 
risk was associated with the individual base excision repair genotypes on both uni-
variate and multi-variate analysis. 
Tobacco smoking is a risk factor and appears to play a more important role (for 
pancreatic cancer development) in the presence of a family history of cancer. Small 
risks associated with SNP’s are difficult to tease out from small studies like the current 
one. Larger multi institutional studies (as have been achieved for e.g. Lung Cancer) are 
required to confirm this latter finding and perform pooled analysis of data for specific 
sequence variants within a target biochemical pathway to uncover the risks associated 
with these genes.  
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Section	  1.1:	  Pancreatic	  cancer	  -­‐	  Epidemiology	  
Pancreatic cancer is the 13th most common malignancy worldwide, but is the 8th 
commonest cause of cancer related mortality worldwide (Fig 1.1) (Parkin et al., 2005). 
Most cases are diagnosed in the developed world (61%), where overall incidence and 
mortality rates are between 7 and 9 per 100,000 in men and 4.5 and 6 per 100,000 in 
women, with lower rates of disease identification in developing countries. It is the 5th 
most common cause of cancer related death in the developed countries. There are 
significant regional differences in the incidence worldwide with the highest incidence 
being reported in New Zealand Maoris (Phillips et al., 2002), native Hawaiians and 
black Americans and low rates from the Indian subcontinent and Nigeria (Boyle et al., 
1989). Most (80-90%) cases are diagnosed when they are unresectable. Thus the 
survival is extremely low with a case fatality ratio approaching 0.99 (Rosewicz and 
Wiedenmann, 1997, Yeo and Cameron, 1999).  
  
 Figure  1.1:  Cancer  Incidence,  Mortality  and  Prevalence  Worldwide  IARC  CancerBase  2004  
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In the UK and Ireland, pancreatic cancer was the 9th and 10th commonest cancer 
respectively in men and women in the 1990’s - age-standardised incidence rates were 
10.5 per 100,000 in males and 7.8 per 100,000 in females. In 2003 there were 2878 
males and 3021 females diagnosed with the malignancy - age standardized incidence 
rates of 11.8 and 11.9 respectively [ONS Cancer: number of new cases 2003, sex and 
age at http://www.statistics.gov.uk/statbase/ssdataset.aspvlnk=9096].  
Pancreatic cancer is rare under 45 yrs. The incidence increases with age and males 
predominate in all age groups up to 70 years. However the incidence increases in 
women beyond this age group (Fig: 1.2). 
  
Figure  1.2  Office  of  national  statistics  data  –  Incidence  of  pancreas  cancer  UK  2003  
Based on data from 1994-97 the lifetime risk (the risk to an individual that pancreatic 
cancer will occur at any time without regard to the time/age at which it will occur) of 
being diagnosed with pancreatic cancer was 1 for males and 1.1 for females in England 
and Wales (Quinn MJ et al., 2000). Reflecting the worldwide picture, survival rates are 
lower than for most other cancers. This is due to the advanced presentation and limited 
treatment opportunities available for effective treatment. For cases diagnosed during 
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1996-99, the one year relative survival was 13% and 5 year survival was 2-3% [ONS. 
Cancer Survival: England and Wales, 1991-2000 
{http://www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=7899]. 
Section	  1.2:	  Pancreatic	  cancer	  -­‐	  Clinical	  features,	  
Management	  and	  Outcome	  
 
1.2.1 Clinical Features 
  
Pancreatic ductal adenocarcinoma is a disease with a poor prognosis. The most 
important reason for this is its late presentation. The factors responsible for this are 
x Its retro-peritoneal situation 
x Lack of a specific symptom in the early stages of tumour growth 
x The absence of a specific tumour marker 
The presenting symptoms of pancreatic cancer depend on the location of the tumour 
within the gland, as well as on the stage of the disease. The organ extends from the “C” 
of the duodenum to the hilum of the spleen. The majority of tumours develop in the 
head of the pancreas on the right side of the portal vein and cause obstructive jaundice, 
which is typically painless. Vague abdominal discomfort and nausea are also common. 
Some patients may describe intermittent pain situated in the epigastrium, occasionally 
predating the onset of jaundice. However this is fleeting and most patients do not 
present with this as their main symptom. Late in the course of the disease they can 
encroach and invade the portal vein and mesenteric artery. Cancers to the left of the 
portal vein are asymptomatic until they cause pain (Nakakura and Yeo, 2006). This is 
due to infiltration of the retroperitoneal neural plexuses by the tumour before it 
encroaches on to the bile duct as compared to those on the right of the vein. The latter 
tumours being closer to the bile duct result in its early involvement and obstructive 
jaundice. Locally advanced pancreatic cancer causes dull, deep upper abdominal and 
back pain by invasion of the retroperitoneal neural structures.  
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More rarely, a pancreatic tumour may also cause duodenal obstruction or 
gastrointestinal bleeding. A striking feature of pancreas cancer is the significant weight 
loss associated with it (Wigmore et al., 1997a). Obstruction to the pancreatic duct 
causing exocrine insufficiency plays a definite role in this. There are also yet 
unidentified tumour related factors, which suppress appetite and cause weight loss 
(Cariuk et al., 1997, Wigmore et al., 1997b). Diabetes is associated with this 
malignancy both as an early manifestation and as an etiologic factor (Ben et al., 2011), 
pro-thrombotic tendency is a feature and may present with venous thrombosis (Epstein 
and O'Reilly, 2012). Acanthosis nigricans is another para-neoplastic feature, which is 
seen as black pigmentation in the flexures of the axillae (Thrash et al., 2013, Shah et al., 
2013).  
By far the commonest tumour arising in the pancreas is a ductal adenocarcinoma; the 
other carcinomas are acinar cell carcinoma and adenosquamous differentiation.  Other 
histological types are lymphoma and metastases especially from breast and renal 
cancers.  
1.2.2 Assessment, Diagnosis and Staging: 
  
Physical examination apart from jaundice may be quite unremarkable. Other clinical 
findings may include evidence of recent weight loss, cervical lymphadenopathy 
(Troiser’s sign), hepatomegaly, and ascites. The latter signs correlate significantly with 
advanced disease. Results of routine blood tests are generally nonspecific and may 
include mild abnormalities in liver-function tests, hyperglycaemia, and anaemia. 
Evaluation of a patient in whom pancreatic cancer is suspected should focus on 
diagnosis and staging of the disease, assessment of resectability, and palliation of 
symptoms. Multiphase (arterial, portal and venous), multi-detector (spiral/helical) 
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computed tomography (CT) with oral and intravenous administration of contrast 
material with thin sections (3mm) is the imaging procedure of choice for the initial 
evaluation(McNulty et al., 2001). This technique allows visualization of the primary 
tumour in relation to the superior mesenteric artery, celiac axis, superior mesenteric 
vein, and portal vein and also its relationship to adjacent organs (Mansfield et al., 2008). 
It also assesses the liver comprehensively. Overall, contrast-enhanced CT predicts 
surgical resectability with 80 to 90% accuracy (Karmazanovsky et al., 2005).  
Endoscopic ultrasound (EUS) is useful in patients in whom pancreatic cancer is 
suspected although there is no visible mass identifiable on CT (Rafique et al., 2007). It 
is the preferred method of obtaining tissue for diagnostic purposes. Although a tissue 
diagnosis is not needed in patients who are scheduled for surgery, it is required before 
the initiation of chemotherapy or radiation therapy. Endoscopic retrograde cholangio-
pancreatography (ERCP) shows the pancreatic and biliary ductal anatomy and can be 
used for purposes of biliary stent insertion and brushing, which provides tissue for 
diagnosis. We do not recommend this technique for purposes of diagnosis of pancreatic 
cancer in the first instance. Magnetic Resonance (MR) imaging is being increasingly 
used in the characterization of pancreatic masses (Shrikhande et al., 2012), especially in 
the follow-up of incidental lesions. This is not a usual mode of investigation in the 
work-up of pancreas cancer. 
In patients who have large tumours, especially in the body and tail of the pancreas, as 
well as other indications of advanced disease such as weight loss, an elevated level of 
carbohydrate antigen 19-9 (CA 19-9), ascites, or equivocal CT findings, a staging 
laparoscopy with laparoscopic ultrasound can accurately determine vascular 
involvement, peritoneal and metastatic disease. 
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Pancreatic cancer is staged according to the most recent edition of the American Joint 
Committee on Cancer tumour–node–metastasis classification, which is based on 
assessment of resectability by means of helical CT (Table 1.1) (Sobin et al., 2009). T1, 
T2, and T3 tumours are potentially resectable, whereas T4 tumours, which involve the 
superior mesenteric artery or celiac axis, are unresectable.  
  
Table  1.1:  AJCC/TNM  staging  of  Pancreas  adenocarcinoma  (Sobin  et  al.,  2009)  
Stage   Tumour stage   Node stage  
Distant 
metastasis   Characteristics  
Median 
Survival 
(months)  
1A   T1   N0   M0  
Lesion in 
pancreas, 
 d 2 cms  
24.1  
1B   T2   N0   M0  
Tumour in 
pancreas, 
 t 2 cms  
20.6  
2A   T3   N0   M0  
Tumour beyond 
pancreas but  
does not 
involve  
SMA or CA  
15.4  
2B   T1, T2 or T3   N1   M0   Regional Ln metastases   12.7  
3   T4   N0 or N1   M0  
Tumour 
involving SMA 
and or CA – 
unresectable 
disease  
10.6  
    4   T1, T2, T3 or T4   N0 or N1   M1   Distant metastasis   4.5  
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1.2.3 Management and outcome 
  
Patients with pancreatic cancer are best cared for by multidisciplinary teams that include 
surgeons, medical and radiation oncologists, radiologists, gastroenterologists, 
nutritionists, and pain specialists, among others (Pawlik et al., 2008).  
1.2.3.1	  Biliary	  decompression:  
  
Up to 70% of patients with pancreatic cancer present with biliary obstruction, which can 
be relieved by percutaneous or endoscopic stent placement. However in patients with a 
resectable malignant CBD stricture, insertion of a plastic biliary stent followed by 
delayed surgery is associated with a higher morbidity compared with early surgery and 
two RCTs have shown that overall morbidity was increased if plastic biliary drains were 
placed preoperatively compared with direct surgery (Lai et al., 1994, van der Gaag et 
al., 2010), this was however not confirmed by a Cochrane analysis (Wang et al., 2008) 
Preoperative drainage of potentially resectable malignant CBD obstruction in indicated 
only in patients who are candidates for neoadjuvant therapies, in patients with acute 
cholangitis, or in patients with intense pruritus and in whom delayed surgery is 
indicated (Dumonceau et al., 2012). Biliary stenting at Endoscopic retrograde 
cholangio-pancreatography is the preferred route (Moss et al., 2007b) for distal biliary 
strictures, which is the usual site of obstruction with head of pancreas cancers. ERCP is 
however not possible in rare occasions when the duodenum is distorted and or narrowed 
and the ampulla is not accessible endoscopically. Percutaneous approach is adopted in 
these situations; however this route is associated with an increased risk of 
complications. Plastic biliary stents have generally been preferred, however there is a 
recent trend towards short wide metal stent insertion (Moss et al., 2007a, Dumonceau et 
al., 2012).  
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Decompression is appropriate for patients in whom surgery is delayed (Tol et al., 2012), 
such as patients who are treated with neo-adjuvant therapy before resection or who are 
referred to other centres for treatment. Patients with symptoms of cholangitis require 
decompression as well as antibiotic treatment before surgery. A recent multi-centre 
randomized clinical trial from Netherlands has concluded that the delay associated with 
pre-operative biliary drainage [Mean times from randomization to surgery were 1.2 
(0.9-1.5) and 5.1 (4.8-5.5) weeks in the early surgery group and pre-operatively biliary 
drained group groups, respectively (p < 0.001)] does not impact survival (Eshuis et al., 
2010) but increases the risk of serious complications (Eshuis et al., 2010). An earlier 
study from our Unit has identified that bilirubin increases by an average of 
approximately 100 µmol/l/week (Mansfield et al., 2006) and is supportive of the 
argument for prompt action and fast-track surgery in suitable patients (French et al., 
2009). 
1.2.3.2	  Resectable	  pancreas	  cancer:	  
  
For patients with resectable disease i.e. broadly stage 1 and 2A, surgery remains the 
treatment of choice (Lillemoe, 1995). Depending on the location of the tumour, the 
operative procedures may involve pancreatico-duodenectomy (the Whipple operation), 
distal pancreatectomy, or total pancreatectomy. A minimum of 12 to 15 lymph nodes 
should be resected (Slidell et al., 2008), and every attempt should be made to obtain a 
tumour-free margin. Data from several randomized clinical trials indicate that a more 
extensive resection does not improve survival but increases postoperative morbidity 
(Yeo et al., 2002) (Michalski et al., 2007). Recent studies show that the results of vein 
resection and vascular reconstruction in patients with limited involvement of the 
superior mesenteric vein and portal vein are similar to the results in patients without 
vein involvement (Tseng et al., 2006) (Chua and Saxena, 2010) and indeed a recent 
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report (n=34) suggests that portal vein resection should be a routine part of pancreatico-
duodenectomy for cancer (Turrini et al., 2013). 
There are several factors which have positive influences on survival after pancreas 
resection: well-differentiated tumour, lower tumour stage, no duodenal or major 
vascular invasion, no perineural invasion, negative lymph node metastases (Lim et al., 
2003), R0 resection (Lewis et al., 2013), surgery at a high-volume centre (Schmidt et 
al., 2010) (Garcea et al., 2008a) (Berger et al., 2008) and low peri-operative transfusion 
requirements (Kneuertz et al., 2011). 
The following factors have no influence on disease-specific survival after pancreas 
resection: age (Riall, 2009) and extending the resection beyond that described above 
(Orr, 2010). 
Post-operative adjuvant treatment is beneficial and adjuvant chemotherapy after R0 
resection is standard. The unequivocal demonstration that postoperative treatment 
improves the outcome in these patients is one of the most important advances that has 
been made in the management of pancreatic cancer. A review has reported a 30% 
resection rate with a 5% hospital mortality (Wolff, 2003) in specialized pancreatic 
centres with a 5-year survival rate between 1-20%. Median survival of patients who 
undergo resection was 13.5 months (Yeo et al., 1997), the same randomized trial 
showed a statistically significant increase in survival to 19.5 months when post-
operative chemo-radiation was used. A review of randomized trials has however failed 
to confirm the survival advantage of this modality of treatment over surgery alone 
(Stojadinovic et al., 2003). The ESPAC-1 trial has shown that the use of adjuvant 5-FU 
and Folinic acid was associated with a survival advantage (Neoptolemos et al., 2003a). 
The median survival was 23.2 (95% CI 20.1 – 26.5) months in the ESPAC-1 adjuvant 
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5-FU and Folinic acid arm Vs. 16.8 (95% CI 14.3 – 19.2) months in surgery alone arm 
(Neoptolemos et al., 2003b). Similar results have come out of the Charite Onkologie 1 
trial. The ESPAC-3 trial (Neoptolemos et al., 2003b, Oettle, 2003) compared 5FU + 
Folinic acid Vs. Gemcitabine as adjuvant treatment following pancreatic resection for 
adenocarcinoma and no difference in disease free survival, overall survival [(5FU: 23 
(95% CI 21.1 -25 months), Gemcitabine: 23.6 (95% CI 21.4 – 26.4)] or global quality 
of life scores between the treatment groups. However, 77 (14%) receiving fluorouracil 
plus Folinic acid had 97 treatment-related serious adverse events, compared with 40 
patients (7.5%) receiving gemcitabine, who had 52 events (P < .001). Nevertheless, only 
a few patients survive for at least 5 years after R0-resection and adjuvant chemotherapy. 
The ESPAC-4 trial (scheduled to close on 11/01/2014) compares gemcitabine alone 
against combination therapy of gemcitabine plus capecitabine in patients within one 
year of a potentially curative resection. 
A recent approach in patients with resectable pancreatic cancer is the use of 
preoperative (neoadjuvant) treatment. Nonrandomized, phase 2 studies suggest that this 
approach is at least as effective as postoperative treatment and may decrease the rate of 
local failures and positive resection margins after surgery (Evans et al., 2008, 
Varadhachary et al., 2008). These findings are particularly relevant for patients who 
have so called “borderline resectable” tumours with limited vascular involvement; in 
these patients, preoperative treatment may result in tumour-free resection margins (Katz 
et al., 2008). The evidence for neo-adjuvant strategies for pancreatic cancer is further 
supported by a recent computational modelling of pancreas cancer kinetics (Haeno et 
al., 2012). In a unique study involving 2 groups of patients – one from rapid autopsy 
participants which led to a mathematical model to understand growth dynamics of 
pancreas cancer cells, which was further validated in a cohort of patients who 
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underwent curative surgery followed by adjuvant therapy; suggested that aggressive 
systemic therapy should be offered early after diagnosis regardless of the stage of the 
disease given that systemic treatments which reduce tumour growth rate early in the 
course of the disease are superior to upfront tumour resection (Haeno et al., 2012).	  
In patients who do not undergo resection the survival is poor and this scenario is 
common. A recent review (Mossner, 2010)  titled “What’s new in therapy of pancreas 
cancer?” began by stating, “The title of this review is more promising in comparison to 
reality…” Majority of these cancers present at advanced stages when palliative therapy 
is the only option. About 80% of patients are un-resectable at presentation (Fischer et 
al., 2003). Overall 5-year survival for this cancer is around 4% (Andre et al., 1998). 
Median survival after diagnosis for the vast majority of patients is around 6 months and 
most patients need palliative treatment.  
1.2.3.3	  Loco-­‐regional	  disease:  
  
This is disease, which involves the portomesenteric vasculature (extensive venous 
encasement and/ arterial involvement) with or without significant peri-pancreatic 
lymphadenopathy. Approximately 30% of patients with pancreatic cancer present with 
advanced loco- regional disease, and an additional 30% of patients will have local 
recurrence of tumours after treatment for early disease. Management options range from 
systemic chemotherapy alone to combined forms of treatment with chemo-radiation 
therapy and chemotherapy. A series of randomized trials conducted over the past two 
decades suggested that that chemotherapy was superior to best supportive care in these 
patients (Huguet et al., 2007, Sultana et al., 2007). Chemotherapy is indeed the critical 
component in the treatment approach (with gemcitabine-based approaches deemed more 
effective) and combined treatment with chemotherapy and radiation therapy is an 
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effective, though more toxic, approach (Ciliberto et al., 2013). However, randomized 
clinical trials of such combined treatments have had low recruitment, precluding a firm 
conclusion. Recently FOLFIRINOX – a combination regime of oxaliplatin, irinotecan, 
fluorouracil, and leucovorin has been found more effective than gemcitabine alone 
(Conroy et al., 2011) in locally advanced (Peddi et al., 2012) and metastatic scenarios.  
	  
	  
1.2.3.4	  Metastatic	  disease:  
  
The majority of patients experience metastatic disease, mainly in the liver and 
peritoneal cavity. The treatment of these patients with advanced disease remains 
palliative, and these patients should be offered the opportunity to participate in clinical 
trials evaluating new treatments when available. A meta-analysis of published findings 
from clinical trials showed an improvement in survival among patients who received 
chemotherapy; these findings suggest that active treatment is beneficial (Sultana et al., 
2007). Gemcitabine has been the treatment of choice on the basis of the results of the 
randomized trial of gemcitabine versus fluorouracil (Burris et al., 1997). Multiple new 
agents with diverse mechanisms of action in combination with gemcitabine have been 
tested in randomized clinical trials, with no improvement in outcome. Capecitabine has 
been used in such a combination (GemCap) demonstrated a significant survival benefit 
(Cunningham et al., 2009b) The only agent that, in combination with gemcitabine, has 
shown a small, but statistically significant improvement in survival among patients with 
advanced pancreatic cancer is erlotinib, an inhibitor of the epidermal growth factor 
receptor (EGFR) (Moore et al., 2007). However, the high frequency of KRAS2 
mutations in pancreatic cancer probably limits the benefits of an EGFR inhibitor 
(Hidalgo, 2010). As compared with erlotinib alone, the combination of gemcitabine and 
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erlotinib has more toxicity, particularly gastrointestinal symptoms. Together with the 
rather modest improvement in survival (about 14 days), the toxicity of this combination 
has limited its wide acceptance as the standard of care. A recent meta-analysis of 
randomized trials showed that patients with minimal disease-related symptoms and 
otherwise good health may benefit from combination chemotherapy with gemcitabine 
and either a platinum agent or a fluoropyrimidine (Heinemann et al., 2008, Cunningham 
et al., 2009a). Therefore the accepted treatment approach for patients with advanced 
disease is either gemcitabine given alone or gemcitabine combined with a platinum 
agent (oxaliplatin) (Louvet et al., 2005), erlotinib, or a fluoropyrimidine (5FU, 
capecitabine) (Hidalgo, 2010).  
Best supportive care includes nutritional support, therapy for pain, treatment of 
jaundice, duodenal obstruction and pain. A systematic review concluded that, in patients 
who are found to have unresectable disease at laparotomy prophylactic 
gastroenterostomy is indicated (Huser et al., 2009). Palliation of biliary obstruction with 
plastic stents is acceptable in patients with disseminated disease who have a short life 
expectancy. Stents for relief of duodenal obstruction can also be used in a similar 
patient for short-term relief of obstruction. However, most evidence favours surgical 
bypass of biliary and duodenal obstruction when life expectancy is considered to be 
more than a few months (Olgyai and Olah, 2007) (Jeurnink et al., 2007). 
Thus it is quite apparent that the best approach towards this malignancy is prevention. 
Its relationship with smoking [25% (Fuchs et al., 1996), 26%  (in Whites) and 29% (in 
Blacks) (Silverman et al., 1994)  of all pancreatic cancers are attributable to tobacco 
smoking] , which is potentially the most important avoidable cancer risk in humans, 
provides us with a unique opportunity to reduce incidence. This relationship also 
provides an opportunity to examine the role of carcinogens and their role in the 
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development of a particular cancer. Better understanding of the mechanism of 
pancreatic carcinogenesis will contribute in the early diagnosis and improve outcome. 
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Section	  1.3:	  Major	  risk	  factors	  in	  the	  development	  of	  
pancreatic	  cancer 
The causes of pancreatic cancer remain unknown. The major risk factors for pancreatic 
cancer are increasing age, tobacco smoking (HAMMOND, 1964, 2004) and family 
history of the cancer (Li et al., 2004). Several environmental factors have been 
implicated, but evidence of a causative role exists only for tobacco use. Recently an 
increased risk has been observed among patients with blood type A, B, or AB as 
compared with blood type O (Iodice et al., 2010, Wolpin et al., 2010). 
1.3.1 Heritable causes and Familial pancreatic cancer  
  
One of the greatest risk factors for pancreatic adenocarcinoma is a family history of the 
disease. A family with pancreas adenocarcinoma was described as early as in the 
1970’s. In 1987 Ehrenthral described a family with 3 successive generations of women 
with pancreas cancer. About 5-10 % of cases demonstrate a familial tendency and in 10-
20% of cases a heritable factor may play a significant role in causation (Petersen and 
Hruban, 2003). Also it is now well established that a family history of any type of 
cancer increases the risk for pancreas cancer (Ghadirian et al., 1991, Silverman et al., 
1999). 
Broadly it is felt that there are 2 categories of hereditary risk for pancreatic cancer 
1) Germline mutations and Pancreatic cancer (Table 1.2): Of pancreatic cancer cases, 5-
10% are part of a well-defined cancer-predisposing syndrome for which germ-line 
genetic alterations are known (Habbe et al., 2006). 
2) Familial Pancreatic cancer: Although there is no agreed definition, Familial 
pancreatic cancer is accepted as an inherited predisposition based on family clustering 
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in families in which there are multiple first and second degree relatives with ductal 
pancreatic adenocarcinoma in the absence of a known genetic susceptibility syndrome 
(Brentnall, 2005). FPC occurs at an earlier age (Petersen et al., 2006) is clustered in 
families (Pogue-Geile et al., 2006, Earl et al., 2006) and has the same poor prognosis as 
its sporadic counterpart.  
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Table  1.2:  Hereditary  syndromes  or  diseases  associated  with  pancreatic  cancer  
 
Syndrome 
 
Genetic defect Reference 
Hereditary pancreatitis 
Mutation in the cationic 
trypsinogen gene (PRSS1) 
(Howes et al., 2004, 
Whitcomb et al., 1999) 
Peutz-Jeghers Syndrome 
Germ line mutation in the 
tumour suppressor gene 
STK11/LKB1 
(Yee et al., 2003, Su et 
al., 1999) 
Familial atypical multiple mole 
melanoma 
Germ line mutation of the p16 
tumour suppressor gene 
(Lynch and Fusaro, 
1991, Rulyak et al., 
2003a) 
Cystic fibrosis 
Mutation in the cystic fibrosis 
trans membrane regulator 
(CFTR) gene 
(McWilliams et al., 
2005a, Sheldon et al., 
1993) 
Familial ovarian and breast cancer 
Germ line mutations of 
BRCA2 & BRCA1 
(van Asperen et al., 
2005, Lubinski et al., 
2004, Risinger et al., 
1996) 
Hereditary non-polyposis 
colorectal cancer  
Germ line mutations in DNA 
mismatch repair genes - 
MLH1, MSH2, 
MSH6, PMS1, PMS2 
(Yamamoto et al., 2001, 
Ghimenti et al., 1999) 
Ataxia Telangiectasia 
Ataxia telangiectasia mutated 
(ATM) gene 
(Yu et al., 2004a, Li et 
al., 2006a) 
Li-Fraumeni 
Germ line mutation of tumour 
suppressor p53  
(Flanders and Foulkes, 
1996, Lefrou et al., 
2006) 
Familial adenomatous                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
polyposis 
Germ line mutations in the 
adenomatous polyposis coli 
(APC) gene 
(Gupta and Mazzara, 
2005, Fendrich and 
Bartsch, 2005) 
Familial Pancreatic Cancer Unidentified 
 
(Habbe et al., 2006, 
Brentnall, 2005) 
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1.3.1.1	  Hereditary	  Pancreatitis:	  
  
This is an illness, which typically begins, in adolescent children who present with 
recurrent episodes of pancreatitis. This can result in chronic pancreatitis leading to 
subsequent pancreatic insufficiency (endocrine and exocrine) and chronic pain. The age 
of onset is a clear distinguishable feature of this condition. 
Gain of function in the cationic trypsinogen gene (PRSS1) due to mutations – over 25 
have been identified and R122H and N291 are the commonest (Finch et al., 1997),  
results in premature activation or ineffective denaturation of trypsin leading to 
parenchymal injury. Nearly half of these patients go on to develop chronic pancreatitis 
and there is a 40% risk of developing pancreas cancer in these individuals. Compared to 
the general population they have a 54-times higher risk, and in those who smoke 
tobacco this risk increases to 154-times (Lowenfels et al., 1997). 
1.3.1.2	  Cystic	  Fibrosis:	  
  
This autosomal recessive disease occurs due to a mutation in the cystic fibrosis trans 
membrane conductance regulator (CFTR) gene (located on 7q31.2), which codes for a 
chloride transport channel across the cell membrane. More than 1000 mutations in this 
gene have been described in people with Cystic Fibrosis. Prevalence of the gene is 2-4% 
- it is the most common inherited lethal disease amongst Caucasians and in Europe 1 in 
2000-3000 new borns is found to be affected by CF (WHO, 2010). Due to 
improvements in management of the respiratory manifestations of this disease, patients 
are now surviving longer and reaching their late thirties (Jackson et al., 2011) 
(http://www.cff.org/aboutCFFoundation/NewsEvents/2006NewsArchive/2711.cfm, 
2006).  
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Risk for pancreas cancer in this cohort of patients has been difficult to determine given 
the various causes of mortality in them. Risk estimates have varied from 2.6 fold 
increased risk (CF foundation data) (Maisonneuve et al., 2003) through 5.3 (SEER data) 
(Maisonneuve et al., 2007) and up to 31.5 times (Neglia et al., 1995) increased risk for 
development of pancreatic cancer. Carrying a CFTR mutation resulted in a very modest 
increased risk of 1.4 (1.04 – 1.89) for pancreas cancer (McWilliams et al., 2010). 
1.3.1.3	  Peutz-­‐Jeghers	  Syndrome	  (PJS)	  
  
PJS is an autosomal dominant condition characterised by hamartomatous 
gastrointestinal polyps and muco-cutaneous, pigmented lesions caused by a mutation in 
the serine/threonine protein kinase 11 STK11/LKB1 gene. There is a variable 
phenotype and high penetrance. The prevalence is about 1 in 50,000. The 
hamartomatous polyps are most common in the small intestine (in order of prevalence: 
in the jejunum, ileum, and duodenum) but can also occur in the stomach, large bowel, 
and upper airways. Muco-cutaneous hyper-pigmentation presents in childhood as dark 
blue to dark brown macules around the mouth, eyes, and nostrils, in the peri-anal area, 
and on the buccal mucosa. Hyper-pigmented macules on the fingers are common. The 
macules may fade in puberty and adulthood.  
Individuals with Peutz-Jeghers syndrome are at increased risk for a wide variety of 
epithelial malignancies (lung, colorectal, gastric, pancreatic, breast, ovarian, 
endometrial and testicular cancers). An important aspect of the management of PJS 
patients is screening for these malignancies. Although various screening protocols have 
been put forward for the above malignancies, the pancreas cancer programs have not 
been evaluated in trials.   
A meta-analysis of PJS studies concluded a RR for pancreatic cancer of 132 and a 
lifetime risk of 36% (Giardiello et al., 2000) whilst a more recent study concluded a 
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much lower risk of 7% cumulative risk at 60 years of age. A multi-centre study 
including n=419 individuals with PJS revealed that eleven patients (6 males and 5 
females) were diagnosed with pancreatic cancer and the risk of developing pancreatic 
cancer was 3%, 5%, 7%, and 11% at ages 40, 50, 60, and 70 years, respectively (Hearle 
et al., 2006). A systematic review (Beggs et al., 2010) has not found any evidence in 
favour for routine surveillance of these patients for pancreas cancer, furthermore routine 
surveillance and screening was expensive [USD 350000/ life saved (Latchford et al., 
2006)].  
1.3.1.4	  Familial	  atypical	  multiple	  mole	  melanoma	  (FAMMM):	  
  
This is an autosomal dominant disorder, which is associated with various germ line 
mutations and variable penetrance. In addition to atypical moles, melanoma and 
pancreas cancer they are also at high risk for cancers of breast, endometrium and lung. 
Individuals who develop pancreatic cancer carry a CDKN2A mutation and this gene 
codes for p16, a cyclin-dependent kinase inhibitor (Lynch and Fusaro, 1991, Lynch et 
al., 2002). The lifetime risk by age 75 is 17% with mean age of onset of pancreas cancer 
at 58 years of age (Vasen et al., 2000).  
A recent Endoscopic ultrasound based surveillance programme in asymptomatic 
mutation carriers amongst a Dutch family detected pancreatic tumours in all – 2 were 
invasive malignancies and the third was a side-branch IPMN (Kluijt et al., 2009). There 
is on-going debate on whether to screen and the best modality to use in these families. 
1.3.1.5	  Hereditary	  breast	  and	  ovarian	  cancer	  (HBOC)	  
  
Germ-line mutations in the BRCA1 and BRCA2 (BRCA1/2) tumour suppressor genes are 
highly penetrant for increased risks of breast and ovarian cancers. They play a key role 
in DNA damage repair and the maintenance of genomic stability and a recent 
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population-based study from Canada suggested that BRCA1/2 mutations were 
associated with a significantly increased risk of cancers overall and at sites other than 
breast and ovary (Risch et al., 2006). The Standardized incidence rate for pancreas 
cancer in BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 
carriers was 2.13 (95% CI=0.36-7.03, P=0.3) (Iqbal et al., 2012). 
Other cancers that have been shown to be associated with BRCA1/2 mutations include 
male breast cancer, prostate cancer, and melanoma. However these mutations also occur 
at increased frequency in families without a history of breast and/ovarian cancers but 
with pancreas cancer/familial pancreas cancer (Murphy et al., 2002, Couch et al., 2007).  
1.3.1.6	  Lynch	  Syndrome	  (Hereditary	  non-­‐polyposis	  colorectal	  cancer	  HNPCC)	  
  
This is the most common form of hereditary colon cancer (Colas et al., 2012) secondary 
to mutations in mis-match repair genes – MSh2, MLH1 and less commonly MSh6, 
PMS1 and PMS2 (Martin-Lopez and Fishel, 2013). There are 2 forms described – 
Lynch 1 where colon cancers only occur and Lynch 2 which is associated with extra-
colonic malignancies including stomach, small bowel, hepato-pancreato-biliary, breast, 
renal pelvis and ureter. The exact incidence and risk for pancreas cancer in this 
syndrome is unknown. 
1.3.1.7	  Familial	  adenomatous	  polyposis	  (FAP)	  
  
FAP results from a mutation in the APC gene, which is involved in cell signalling. FAP 
is not uncommon with an incidence reported to vary from 1:6,850 to 1:23,700 live 
births and leads to development of colorectal carcinoma in almost 100% of cases by 40 
years of age. FAP is characterized by the formation of hundreds to thousands of 
colorectal adenomatous polyps. Although the development of colorectal cancer is the 
prevalent complication, FAP is a multisystem disorder of growth and individuals can 
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develop thyroid and pancreatic cancer, hepatoblastomas, CNS tumours (especially 
medulloblastomas), and various benign tumours such as adrenal adenomas, osteomas, 
desmoid tumours and dental abnormalities. Pancreatic tumours in FAP patients are rare. 
In a cohort study of 1,391 patients with FAP reported in the Johns Hopkins Registry, 4 
patients were found to have developed a pancreatic adenocarcinoma (Giardiello et al., 
1993). In view of the low prevalence of pancreatic cancer and the scarcity of published 
data, surveillance is not routinely recommended. Surveillance is however recommended 
for the prevention of other intestinal malignancies, such as duodenal ampullary 
carcinomas and gastric carcinomas. 
	  
1.3.1.8	  Familial	  pancreatic	  cancer	  (FPC):	  
  
FPC is the term applied to families with two or more first-degree relatives who have 
been diagnosed with PC that is not associated with a known cancer syndrome. From a 
study at Johns Hopkins (Klein et al., 2004) it was found that any member of a kindred 
with a first-degree relative diagnosed with PC had a nine-fold increased risk of 
developing PC [OR 95% CI (4.5 – 16.1)]. Risk estimates varied by the number of PC-
affected first-degree relatives: having one affected first-degree relative increased the 
risk to 4.6 (95% CI 0.5-16.4), two affected first-degree relatives gave a risk of 6.4 (95% 
CI 1.8-16.4) and three affected first-degree relatives increased the risk 32-fold (95% CI 
10.2-74.7) (Klein et al., 2004). 
Studies on members of “Family X” – 18 cases of pancreas cancer were identified in 4 
generations – suggested that the susceptibility gene for FPC was the palladin gene at 
chromosome 4q32-34 (Eberle et al., 2002), however subsequent studies on other 
families has not confirmed this (Slater et al., 2007) . An interesting feature in “Family 
X” was the development of the cancer earlier in life in successive generations – “genetic 
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anticipation”. In a recent European study (McFaul et al., 2006) the median age at death 
in successive generations from pancreas cancer was – 70, 64 and 49 years. Also 
cigarette smoking is associated with earlier development of the disease by 10 years as 
compared to non-smokers (Rulyak et al., 2003c). 
Numerous modes of screening and its utility in the individuals belonging to FPC 
families have been studied and the role of EUS in demonstrating very small intra-
pancreatic lesions has been confirmed (Kimmey et al., 2002, Canto, 2007, Canto et al., 
2006). However on a background of the mortality and morbidity imposed by a 
pancreatic resection and the nearly 50% incidence of benign lesions (in individuals who 
underwent resection in these 2 studies) it is still not clear whether screening is beneficial 
and if it provides survival benefit. A systematic review and mathematical modelling of 
FPC kindreds comparing four separate management strategies for preventing PDAC in 
high risk individuals, namely, (1) prophylactic total pancreatectomy, (2) annual 
surveillance by EUS, (3) annual surveillance by EUS-FNA, (4) doing nothing 
concluded that the effectiveness of any screening program for FPC kindreds would 
depend greatly on the subsequent management of the 50% or more of individuals 
demonstrating findings of chronic pancreatitis by EUS (Rubenstein et al., 2007). Based 
on a 20% lifetime risk of PC, the investigators determined that the ‘doing nothing’ 
strategy actually provided the greatest quantity of remaining years of life, the greatest 
remaining quality-adjusted life years, and at the the lowest cost.  
1.3.2 Age: 
 The most reliable predictor of sporadic pancreatic cancer is age. The risk of 
development correlates with increasing age (Aoki and Ogawa, 1978). The malignancy is 
extremely rare below 45 years (Morgan and Wormsley, 1977) and 80% cases occur 
between the ages of 60 and 80 (Ahlgren, 1996, Gold and Goldin, 1998). The risk for 
those in the 8th decade of life has been quoted to be 40 times that of those in the 4th 
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decade (Li, 2002). This increase in incidence as age advances has been documented in 
nearly all countries (Fig 1-3). 
  
Figure  1.3  From:  Parkin,  D.M.,  Whelan,  S.L.,  Ferlay,  J.,  and  Storm,  H.  Cancer  Incidence  in  Five  Continents,  Vol.  I  to  
VIII  IARC  CancerBase  No.  7,  Lyon,  2005. 
1.3.3 Race:  
  
The Maoris (Fraumeni, 1975, Phillips et al., 2002) in New Zealand have the highest 
rates of pancreas cancer in the world and they do not show the increased incidence 
amongst men. Maori women have the highest rates of pancreas cancer amongst females 
in the world (Phillips et al., 2002).  The high prevalence of smoking amongst Maoris 
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has been attributed to the high incidence of lung, pancreas and kidney cancers. In sharp 
contrast the numbers of bladder cancer, which is also a smoking related cancer is low 
amongst them (McCredie et al., 2000). High rates are also detected amongst black 
Americans (Garfinkel, 1991, McCarty, 2001) in the USA, which is also true for lung 
cancer (Stellman et al., 2003). The exact reason for this has not been ascertained. A 
large case-control study concluded that the increased levels of tobacco smoking did not 
explain the increased risk amongst black Americans (Silverman et al., 1994). A western 
diet rich in animal fat (McCarty, 2001), nutritional imbalances, high-risk occupations, 
limited access to medical care and other socio-economic factors associated with poverty 
(Greenberg and Schneider, 1995) in addition to cigarette smoking are thought to be 
responsible for the higher occurrence of pancreatic cancer in Americans blacks as 
compared to whites. Another contributing factor for these racial differences could be 
differences in the ability to metabolise tobacco derived carcinogens – e.g. differences 
between Caucasians and non-Caucasians with respect to urinary metabolites of tobacco 
derived carcinogens (Richie et al., 1997). 
1.3.4 Gender:  
  
There is a higher incidence amongst males as compared to females in all cancer 
registries across the world (except Maoris) as depicted in the above graphs. However in 
some populations where the life expectancy of women is higher than men, a higher 
number of cases are being noted in the cohort of older women (UK 2003 data. Fig1.2, 
page 19) 
1.3.5 Tobacco smoking: 
  
Tobacco is one of our society’s most dangerous products. Its consumption in any form 
is detrimental to health. Nearly half of all who smoke for nearly all their life will 
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succumb to diseases directly related to it (Doll et al., 1994). This elevated mortality is 
attributed to cardio-vascular, cerebrovascular and various other forms of arterial 
diseases, COPD and cancers at various sites (Jacobs et al., 1999) (Table 1.3). Smoking 
is responsible for nearly 20-30% of all cancers (Tominaga, 1999, 1982) which include 
cancers of the oral cavity, oro- and hypo-pharynx, nasal cavities and sinuses, larynx, 
lung, oesophagus, stomach, liver, pancreas, colon and rectum, cervix and myeloid 
leukaemia. 
Table  1.3:  Health  consequences  of  tobacco  smoking  (From  Harrison’s  Principles  of  internal  medicine  15th  Edition)  
Cancers caused 
by smoking 
Other 
potentially fatal 
illnesses caused 
Non-fatal 
illnesses 
Risk in 
Pregnancy Protective 
Lung CAD PVD 
Spontaneous 
abortion 
Parkinson’s 
disease 
Upper respiratory 
sites 
COPD Cataracts 
Ectopic 
pregnancy 
 
Urinary bladder CVA Osteoporosis 
Low birth 
weight 
 
Pancreas Pneumonia 
Periodontal 
disease 
Limb reduction 
defects 
 
Oesophagus Aortic aneurysm    
Stomach 
Pancreatitis 
(Acute and 
Chronic) 
   
Kidney Diabetes    
Uterine cervix     
  
The strongest avoidable risk factor in sporadic pancreatic cancer development is 
tobacco smoking. Tobacco smoking is associated with an increased risk of pancreatic 
cancer – an overall relative risk of 1.5 to 1.76 in smokers as compared to non-smokers 
(Andre et al., 1998) (Baghurst et al., 1991). This increased risk falls to near normal 
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levels in “ever-smokers” only after 15 years of cessation of smoking (Bueno de 
Mesquita et al., 1991). There is a tobacco dose-related increase in the incidence of 
pancreatic cancer. About 30% of pancreatic cancers are smoking related (Silverman et 
al., 1994) (Fuchs et al., 1996) (Iodice et al., 2008). 
The risk of pancreatic cancer in smokers is 2.5 to 3.6 times that in non-smokers; the risk 
increases with greater tobacco use and longer exposure to smoke. Data are limited on 
the possible roles of intake of coffee, and use of aspirin as contributing factors. Some 
studies have shown an increased incidence of pancreatic cancer among patients with a 
history of diabetes or chronic pancreatitis, and there is also evidence, although less 
conclusive, that obesity (including high-fat, high-cholesterol diet) (Bracci, 2012), and 
previous cholecystectomy are associated with an increased incidence. Although earlier 
studies had not suggested a role for alcohol consumption in pancreatic cancer, recent 
evidence suggests that excessive alcohol intake does increase risk for pancreas cancer 
(Gupta et al., 2010, Duell, 2012, Lucenteforte et al., 2012). From 2009 to 2012, 3 
pooled analyses (Lucenteforte et al., 2012, Michaud et al., 2010, Genkinger et al., 2009) 
and 1 meta-analysis (Tramacere et al., 2010) have interrogated the role of alcohol and in 
summary they do suggest that individuals who consume higher levels of alcohol (>30–
40ԜgԜalcohol/d, or >3ԜalcoholicԜdrinks/d) may be at an increased risk of pancreatic cancer 
(Duell, 2012).  
     46  
1.3.5.1	  Tobacco	  derived	  carcinogens	  	  
  
Tobacco smoke contains 4000 compounds and 50 carcinogens as compared to 3000 
compounds and 30 carcinogens in processed unburnt tobacco (Hecht, 1998). The 
components of mainstream and side stream smoke are different. Both are harmful. 
These carcinogens include polynuclear aromatic hydrocarbons (PAH), tobacco specific 
nitrosamines (TSNA), aromatic amines, aza-arenes, aldehydes, other organic 
compounds like benzene, inorganic compounds like hydrazine and various metals 
(Hecht and Hoffmann, 1988). The major classes of carcinogens have been identified as 
PAH’s, TSNA’s and aromatic amines (Hecht and Hoffmann, 1988). In the context of 
pancreatic cancer TSNA’s, especially 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) are of utmost 
importance because they demonstrate organ specificity towards the pancreas and are the 
only carcinogens to induce pancreatic adenocarcinoma in animal models when given 
systemically (Rivenson et al., 1988). The most widely used and studied carcinogen 
model is Syrian gold hamsters intraperiotoneally injected with N-nitrosobis(2-
oxopropyl)amine. Other approaches use azaserine in rats and 7,12-
dimethylbenzanthracene in mice (Osvaldt et al., 2006) (Ding et al., 2010), however in 
these methods the carcinogen is directly exposed into the peritoneal cavity or onto the 
pancreas and is not administered systemically. TSNA’s are present in large quantities in 
both burnt and un-burnt tobacco. Seven compounds have been identified in the family 
of TSNA’s – Nƍ-Nitrosonornicotine (NNN), NNK, NNAL, Nƍ-Nitrosoanatabine (NAT), 
Nƍ-Nitrosoanabasine (NAB), 4-(methylnitrosamino)-4-(3- pyridyl)-1-butanol  (iso-
NNAL) and 4- (methylnitrosamino)-4-(3-pyridyl)butyric acid (iso-NNAC). Amongst 
these NNN, NNK and NNAL are the most powerful carcinogens.  Following exposure 
these carcinogens need to undergo a series of reactions in vivo – uptake, metabolic 
activation and DNA adduct formation, which subsequently leads to altered growth 
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kinetics in the target organ and development of neoplasia. NNK is rapidly distributed to 
most tissues and is rapidly metabolized. NNK and NNAL undergo carbonyl reduction, 
pyridine N-oxidation and D-hydroxylation. In humans the NNK-NNAL equilibrium 
favours NNAL. It has been shown that aromatic amines and nitro aromatic 
hydrocarbons are metabolically activated in the human pancreas (Anderson et al., 1997). 
It has been demonstrated that cotinine, NNK and its metabolite NNAL are present in the 
pancreatic juice of smokers (Prokopczyk et al., 2002). This confirms that the pancreas is 
exposed to TSNA’s and that these carcinogens may play a role in carcinogenesis at this 
site (Schulze et al., 1992). In rodents it has been shown that NNK and NNAL are 
excreted in the bile in significant concentrations (Schulze et al., 1992). If this is true in 
humans, it may be the route through which activated carcinogens reach the head of the 
pancreas (carcinogen containing bile refluxing into the pancreatic duct). This theory is 
attractive given the established fact that the pancreatic head is the most frequent site for 
adenocarcinoma (Niedergethmann et al., 2002, Conlon et al., 1996, Iakimov and 
Zheleva, 1991). A study in rhesus monkeys (n=4), however, found that biliary excretion 
of the NNK metabolites was significantly less than that predicted from rat experiments. 
(Meger et al., 1999). Very limited experiments have been performed on this route of 
TSNA excretion. 
 
1.3.5.2	  Tobacco	  derived	  carcinogens	  and	  pancreatic	  tumours	  in	  animals:	  
  
Numerous animal models of pancreas ductal cancer have been developed and these have 
proved invaluable in elucidating the kinetics of carcinogens within physiological 
systems and the pathogenesis of ductal cancer of the pancreas. In 1988, Hecht and 
Hoffman highlighted the important role of tobacco-derived carcinogens in extra-
pulmonary cancers including the pancreas in a commentary (Hecht and Hoffmann, 
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1988). The same commentary also concluded that two of the nicotine-derived 
nitrosamines, NNK and NNN, are strong carcinogens in laboratory animals and that 
they could induce tumours both locally and systemically. Analytical and dosimetric 
studies in animals and humans have confirmed that the magnitude of the total doses of 
NNK and NNN required to produce cancer in laboratory animals is similar to the total 
estimated doses which long-term snuff-dippers or heavy smokers are exposed to in their 
life-time (Hecht and Hoffmann, 1988). 
 
In F-344 rats, NNK and NNAL cause development of not only lung but also pancreatic 
adenocarcinoma. The doses of carcinogens to body weight needed to cause these 
neoplasms in rats were similar to lifetime exposure of these chemicals in heavy smokers 
(40 cigarettes/day). This was the first example of pancreatic tumour induction by a 
component of tobacco smoke. NNAL appeared to be the proximate pancreatic 
carcinogen of NNK as it induced more tumours than NNK (Rivenson et al., 1988). They 
are the only carcinogens to induce pancreatic adenocarcinoma in animal models when 
given systemically (Rivenson et al., 1988, Hoffmann et al., 1991). Also in F-344 rats 
there is evidence that following oral NNK administration, there is preferential 
metabolism of NNK to (S)-NNAL followed by its extensive retention in various target 
tissues including the pancreas of NNK- orally treated animals (Zhang et al., 2009). 
Treatment of rats with TSNA’s also resulted in the induction of pancreatic acinar cell 
and ductal cell neoplasms (Pour and Rivenson, 1989). 
 
In rodents it has been shown that NNK and NNAL are excreted in the bile in significant 
concentrations (Schulze et al., 1992). If this is true in humans, it may be the route 
through which activated carcinogens reach the head of pancreas (carcinogen containing 
bile refluxing into the pancreatic duct). This theory is attractive given that the pancreatic 
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head is the most frequent site for adenocarcinoma (Niedergethmann et al., 2002, Conlon 
et al., 1996, Iakimov and Zheleva, 1991).  
	  
	  
1.3.5.3	  Tobacco	  carcinogens	  in	  humans	  and	  their	  relevance	  to	  pancreatic	  cancer:	  
  
Most animal studies have been extrapolated to humans and the assumption is that the 
metabolism and physiological distribution kinetics of tobacco derived carcinogens is 
similar to that in rats and rodents. However there will be differences in the manner in 
which our species handles these carcinogens and a few studies have tried to elucidate 
this by various means. Essentially what has been achieved is to show that the pancreas 
is exposed to these chemicals and that these metabolites bind to pancreatic ductal cell 
DNA and result in mutations there and that various phenotypic changes occur there 
including cancer. However the exact mechanism by which these carcinogens turn a 
normal ductal cell into a malignant one has not been described.  
TSNA’s (NNK and NNAL) have been detected in the pancreatic juice of smokers in 
significantly higher quantities as compared to non-smokers confirming that the pancreas 
is exposed to these carcinogens (Prokopczyk et al., 2002). It has been shown that 
aromatic amines and nitro aromatic hydrocarbons are metabolically activated in the 
human pancreas (Anderson et al., 1997). This confirmed that the pancreas is exposed to 
TSNA’s and that these carcinogens may play a role in carcinogenesis at this site 
(Schulze et al., 1992). 
Although a strong correlation had been suggested between cigarette smoking and 
pancreatic cancer, studies on pathological changes in the pancreas of smokers are 
infrequent. A comparative autopsy study (Tomioka et al., 1990) on 73 pancreases 
obtained from 42 heavy cigarette smokers and 31 non-smoker patients revealed an 
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increased incidence of pancreatic cancer in smokers than in non-smokers, the difference 
was statistically not significant. Ductal changes, including mucinous or squamous cell 
metaplasia and papillary hyperplasia, were found with equal frequencies in both groups 
of patients and the authors concluded that the type and the incidence of these ductal 
alterations were not related to smoking but to the age. There were significant limitations 
of this autopsy study including limited number of the sections of the pancreata 
examined, as well as exclusion of other important variables, such as alcohol, diet and 
diabetes weaken the value of this study (Tomioka et al., 1990). Another autopsy study 
obtained purified DNA from human lung, liver, bladder, pancreas, breast and cervix of 
13 men and 6 women and analysed it for DNA adducts using a modification of the 32P 
post-labelling technique. Relatives were asked to provide information on smoking 
history for deceased subjects. All tissues examined except the breast had detectable 
adducts. In lung, bladder and pancreatic tissue a characteristic pattern of adducts was 
seen which had previously been reported as typical of cigarette-smoke-induced damage; 
“diagonal reactive zone” (Randerath et al., 1988). Smokers and former smokers tended 
to have higher adduct levels than non-smokers in the tissues examined but this was only 
significant for the lung. These results confirmed the finding that cigarette smoking is 
associated with DNA damage in the lung and suggested that similar damage may be 
related to tobacco-induced neoplasms of other tissues (Cuzick et al., 1990). TSNA’s 
adducts have been found in the pancreas and the levels have correlated with dose and 
time related to exposure (Randerath and Randerath, 1993). 
1.3.5.4	  Epidemiological	  studies:	  	  
  
There have been numerous case-control and cohort studies from various geographical 
areas of the world. These have demonstrated increased risk of pancreatic 
adenocarcinoma in smokers ranging from 1.96 – 5 times that of non-smokers (Appendix 
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3). The risk increases with increasing exposure in terms of pack-years (Ghadirian et al., 
1991, Harnack et al., 1997). The increased risk appears to reduce after 10-15 years of 
quitting smoking (Boyle et al., 1996). It is variously estimated that approximately 25% 
(Fuchs et al., 1996), 26%  (in Whites) and 29% (in Blacks) (Silverman et al., 1994)  of 
all pancreatic cancers are attributable to tobacco smoking. A recent meta-analysis 
(Iodice et al., 2008) demonstrated the significant strength of the association between 
cigarette smoking and pancreas cancer and calculated that the population attributable 
risk secondary to tobacco use for the malignancy was about 20%. 
One of the significant difficulties many epidemiological studies suffer from is that of 
estimation of tobacco exposure. A questionnaire, which attempts to document the 
tobacco habit, is commonly used in these studies.  
Cumulative exposure based on this method depends upon the method by which the 
questionnaire was answered – self administered/ administered by trained personnel, 
patient/next of kin answering the questions, type of questionnaire used etc. The method 
of administration of the questionnaire can have significant implications on the data 
obtained (Bowling, 2005, Choi and Pak, 2005), however until a biomarker is identified 
which can document cumulative exposure the questionnaire method will be the most 
commonly used. 
1.3.6 Environmental factors including industrial exposure to chemicals 
  
Various occupations have been associated with a high risk of pancreatic cancer ranging 
from – administration and management to leather tanning, rubber workers, petroleum 
industry and dry cleaning. Most environmental factors which are associated with an 
increased risk of pancreatic cancer are probably due to exposure to aromatic amines, 
chlorinated hydrocarbon, silica, cadmium and nickel (Weiderpass et al., 1998). 
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Section	  1.4:	  Pancreatic	  carcinogenesis	  
  
The primary aetiology of pancreatic ductal adenocarcinoma is poorly understood. Both 
genetic and environmental factors play a role as shown by various epidemiological, 
molecular epidemiological and molecular genetic studies. There are genetic disorders in 
which pancreatic adenocarcinoma is a major feature and familial pancreatic cancer is a 
well-recognized pathological entity. Over the past 10-15 years extensive work into the 
development of pancreatic cancer has been carried out. A model of step-wise 
progression from normal to malignant cells and the molecular alterations involved in 
these has been suggested (Hruban et al., 2000) (Figure 1.4). 
1.4.1 Molecular progression model 
  
Very similar to the adenoma-carcinoma sequence in the colon, neoplastic progression in 
the pancreatic ducts has been proposed (Hruban et al., 2000, Goggins et al., 2000, 
Wilentz et al., 2000a, Wilentz et al., 2000b). This progression from a normal pancreatic 
ductal cell to an infiltrating carcinoma is thought to involve sequential multiple genetic 
alterations and is pictorially depicted in Figure 1.4. The genetic changes include 
activating point mutations in K-ras, overexpression of HER-2neu, and inactivation of 
p16, p53 DPC4 and BRCA2. A gatekeeper gene for the initiation of pancreatic 
neoplasia has not been identified and the cause of the ignition of change in a normal 
ductal cell towards neoplasia is under investigation.  
The various histological changes in the pancreatic ducts were classified systematically 
by a Pancreatic Cancer Think-Tank (http://pathology.jhu.edu/pancreas_panin.), which, 
was sponsored by the National Cancer Institute in 1999 and the term PanIN (pancreatic 
intra epithelial neoplasia) was introduced.  
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1.4.1.1	  PanIN-­‐1A	  (Pancreatic	  Intraepithelial	  Neoplasia	  1-­‐A)	  	  
  
These are flat epithelial lesions composed of tall columnar cells with basally located 
nuclei and abundant supranuclear mucin. The nuclei are small and round to oval in 
shape. When oval the nuclei are oriented perpendicular to the basement membrane. It is 
recognized that there is considerable histologic overlap between non-neoplastic flat 
hyperplastic lesions and flat neoplastic lesions without atypia. Therefore, some may 
choose to designate these lesions with the modifier lesion ("PanIN/[L]-1A") to reflect 
the fact that the neoplastic nature of many cases of PanIn-1A has not been established.  
1.4.1.2	  PanIN-­‐1B	  (Pancreatic	  Intraepithelial	  Neoplasia	  1-­‐B)	  
  
These epithelial lesions have a papillary, micro papillary or basally pseudo-stratified 
architecture, but are otherwise identical to PanIN-1A.  
1.4.1.3	  PanIN-­‐2	  (Pancreatic	  Intraepithelial	  Neoplasia	  2)	  
  
Architecturally these mucinous epithelial lesions may be flat or papillary. Cytologically, 
by definition, these lesions must have some nuclear abnormalities. These abnormalities 
may include some loss of polarity, nuclear crowding, enlarged nuclei, pseudo-
stratification and hyperchromatism. These nuclear abnormalities fall short of those seen 
in PanIN-3. Mitoses are rare, but when present are non-luminal (not apical) and not 
atypical. True cribriforming luminal necrosis and marked cytologic abnormalities are 
generally not seen, and when present should suggest the diagnosis of PanIN-3.  
1.4.1.4	  PanIN-­‐3:	  (Pancreatic	  Intraepithelial	  Neoplasia	  3)	  
  
Architecturally these lesions are usually papillary or micro papillary, however, they may 
rarely be flat. True cribriforming, budding off of small clusters of epithelial cells into 
the lumen and luminal necrosis all suggests the diagnosis of PanIN-3. Cytologically, 
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these lesions are characterized by a loss of nuclear polarity, dystrophic goblet cells 
(goblet cells with nuclei oriented towards the lumen and mucinous cytoplasm oriented 
toward the basement membrane), mitoses which may occasionally be abnormal, nuclear 
irregularities and prominent (macro) nucleoli. 
Normal duct epithelium is proposed to progresses to infiltrating cancer (left to right in 
Figure 1.4) (Hruban et al., 2000) through a series of histologically defined precursors 
(PanINs). The over expression of HER-2/neu and point mutations in the K-ras gene 
occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of 
p53, DPC4, and BRCA2 occur relatively late (Table 1.4). 
  
  
    Figure  1.4  Progression  of  precursor  lesions  to  invasive  cancer  (Hruban  et  al.,  2000)    
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Table  1.4:  Frequencies  of  genetic  alterations  in  infiltrating  ductal  adenocarcinoma  and  its  precursors 
  
Gene Normal PanIN1A PanIN1B PanIN2 PanIN3 Ca Selected References 
K-ras 0-15% 35% 86% 92% 100% 90% 
(Moskaluk 
et al., 1997, 
Caldas et 
al., 1994) 
(Tada et al., 
1996) 
Her-
2neu 
5% 82% 86% 92% 100% 69% 
(Day et al., 
1996) 
P16 
0 
24% 19% 55% 71% 95% 
(Wilentz et 
al., 1998) 
P53 0 0 0 NA 21 75 
(DiGiuseppe 
et al., 1994) 
DPC54 0 0 0 0 31 55 
(Wilentz et 
al., 2000b) 
BRCA2 0 0 0 0 0 7 
(Goggins et 
al., 1996) 
 
1.4.2 Neoplastic pancreatic cysts: 
  
Whilst discussing pancreatic carcinogenesis, it is important to discuss the other 
precancerous/precursor lesions associated with it, i.e. Intraductal papillary mucinous 
adenoma (IPMN). Cystic lesions are increasingly detected given the growing 
availability and use of cross-sectional imaging techniques. The prevalence of these 
lesions is difficult to estimate, as the majority are asymptomatic and are detected when 
imaging is performed for unrelated symptoms. It is estimated that the prevalence of 
cystic lesions of the pancreas is about 20% in patients undergoing imaging for non-
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pancreatic illnesses (Zhang et al., 2002) and 25% in an autopsy study from Japan 
(Kimura et al., 1995). Out of these 10-15% are cystic neoplasm’s whilst the remainder 
are pseudocysts (Warshaw and Rutledge, 1987). Table 1.5 depicts the clinic-
pathological classification of neoplastic pancreatic cysts 
Table  1.5:  Classification  of  neoplastic  pancreatic  cysts  (Adapted  from  Hutchins  and  Draganov,  Surg  Clinic  N  Am  
April  2010) 
 
Serous tumours 
Serous cystic tumours 
 
Serous cystadenoma 
Serous cystadenocarcinoma  
(Very rare) 
Mucinous cystic 
tumours 
Mucinous cystic 
tumours 
Mucinous cystadenoma 
Mucinous cystadenoma with moderate 
dysplasia 
Mucinous cystadenocarcinoma 
Non-infiltrating 
Infiltrating 
IPMN 
Intraductal papillary mucinous 
adenoma 
IPMN with moderate dysplasia 
Intraductal papillary mucinous 
carcinoma 
Non-infiltrating 
Infiltrating 
Solid 
pseudopapillary 
tumours 
Solid pseudopapillary 
tumours 
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After an inflammatory cyst (pseudocyst) has been excluded the distinction between the 
neoplastic cysts is important to make as the malignant potential associated with the 
lesion depends upon this. 
	  
1.4.2.1	  Mucinous	  cystic	  neoplasms:	  
  
The 2 main types of cystic lesions seen in the pancreas are the serous and mucinous 
cystadenomas (MCN). The serous lesions are largely benign lesions, which are 
managed non-surgically. The important distinction in these classes of pancreas tumours 
is the one between MCN and intraductal papillary mucinous neoplasms (IPMN). This 
depends on clinical and pathologic factors. Clinically, main duct IPMN with malignant 
transformation is seen archetypically in the head of the pancreas in an elderly male 
whereas side branch IPMN are not sex-specific and are distributed throughout the 
pancreas. Main duct IPMN has a characteristic grape-like clustered appearance of 
individual cysts on imaging whilst MCN has the appearance of multiple cysts within 
cysts. The lesion communicates with the pancreatic duct. MCN is typically seen in a 
middle-aged female and is located in the body and/tail of the pancreas. Pathologically 
the best differentiating feature (from IPMN) is the presence of an ovarian stroma in 
MCN (Volkan Adsay, 2007) and it is suspected that MCN arise from ovarian rests 
within the pancreas. 
Of the MCN 6-36% are malignant (Reddy et al., 2004) and result in mucinous 
cystadenocarcinoma. Various features have been described which predict malignancy – 
thickened and or irregular cyst wall, papillary projections, mixed solid and cystic 
components, symptomatic lesions, tumours with radiologically visualised calcification, 
hyper-vascularity and major vascular involvement.  
     58  
1.4.2.2	  Intraductal	  papillary	  mucinous	  neoplasms	  (IPMN):	  
  
Intraductal papillary mucinous neoplasms are an increasingly recognised group of 
neoplasms, which differ from mucinous cystic tumours by their diffuse/multi focal 
nature. Therefore they are considered to represent a “field change” within the pancreatic 
duct system (Sohn et al., 2004). Based on extent of involvement of the duct system they 
are classified into – main duct type, branch duct type and mixed.  They are pre-
malignant and main duct-IPMN is associated with malignancy in 57 – 92%, branch duct 
-IPMN with 6-46% of and mixed-IPMN is associated with malignancy in 35-40% 
resected cases (Sohn et al., 2004, Schnelldorfer et al., 2008, Salvia et al., 2004). 
Depending upon degree of dysplasia increasing grades are classified – adenoma, 
borderline dysplasia, and carcinoma.  IPMN’s with severe dysplasia are designated as 
carcinoma even in the absence of invasion. They are presumed to progress from 
adenoma to invasive cancer in a manner similar to the colon adenoma-carcinoma 
sequence – varying degrees of dysplasia exist within one single tumour and older 
patients with IPMN have an increased risk of harbouring cancer within them (Hruban et 
al., 2005). 
The diagnosis of IPMN is made on triple phase pancreas CT and or MRCP, both of 
which demonstrate the pancreatic ductal abnormality accurately. MR is more accurate in 
demonstrating the communication between BD-IPMN (branch duct IPMN) and the 
ductal system. Features of malignancy – bulging papilla, presence of a solid component, 
local invasion, mural nodules, diffuse/multifocal involvement of the duct, 
calcification/attenuating intraluminal content are all equally well seen on CT and MR 
(Ogawa et al., 2008, Fukukura et al., 2003). IPMN is easily differentiated from 
mucinous cystic neoplasm, as MCN is a unifocal, round cystic lesion, which does not 
communicate with the PD. 
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Endoscopic Ultrasound (EUS) with Fine-needle aspiration (FNA) is used to confirm the 
diagnosis and differentiate it from other cystic neoplasms (Kobayashi et al., 2012, Ohno 
et al., 2012). It can visualize the ductal dilation, papillary projections and mural nodules 
that are typical of IPMN. The main advantage of EUS is the ability to perform an FNA 
at which cyst fluid can be macroscopically, microscopically, cytologically and 
biochemically examined. Peroral pancreatoscopy and intraductal ultrasound are newer 
modalities, which may be useful in the future.  
Carcino-Embryonic Antigen (CEA) greater than 192 ng/mL (Brugge et al., 2004), 
papillary fragments, parachromatin clearing, atypical clusters, hypercellularity and 
necrosis suggest malignancy (Michaels et al., 2006). Other factors which predict 
malignancy in IPMN’s include type (main duct type has higher risk), larger tumour 
diameter (more than 30 mm), proximal location, involvement of a dilated main 
pancreatic duct which is more than 7 mm, presence of mural nodules, protruding lesions 
in dilated side branch ducts, thickened cyst walls, patulous papilla with mucin seepage 
from it and a raised CA 19-9 level, older age, presence of jaundice, diabetes and 
episodes of pancreatitis (Garcea et al., 2008b, Salvia et al., 2004, Fujino et al., 2007). 
IPMN malignancies grow less aggressively, have lower nodal spread with less 
incidence of perineural and vascular invasion as compared to ductal adenocarcinoma 
(Sohn et al., 2004).   
Management can vary from observation to pancreatic resection. The risk of malignancy 
dictates the course of action. Main and mixed IPMN in fit individuals are considered for 
resection, given the significant risk of malignancy. In BD-IPMN the presence or 
absence of factors which suggest/refute malignancy are crucial in the decision making 
process. The International Association of Pancreatology (IAP) guidelines (Sendai 
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guidelines) (Tanaka et al., 2006) are an important source of guidance in the 
management of these complex lesions. 
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Section	  1.5:	  DNA	  Repair	  	  
DNA undergoes damage due to both endogenous and exogenous mutagens. It is most 
essential that the damaged DNA is repaired to avoid unplanned apoptosis, changes in 
cellular differentiation and proliferation and thereby the development of neoplasms 
(Barnes and Lindahl, 2004). Genetic syndromes, which result in cancer due to a defect 
of the DNA repair mechanisms are described: notably Xeroderma pigmentosa (Kraemer 
et al., 1994), Lynch syndrome (Hassen et al., 2012) etc. Various mechanisms exist in 
both mammalian and lower forms of life (including bacteria i.e. prokaryotes) and have 
been conserved through evolution to recognize and repair the damage caused to DNA 
(Taylor and Lehmann, 1998). At least 4 different pathways have been identified and 
they repair different types of damage. Each type of repair involves various molecules 
and enzymes, which act in a series of steps. The type of repair initiated depends on the 
nature of the mutagen. 
1.5.1 Base excision repair (BER):  
  
Base excision repair recognizes and removes small DNA lesions which are typically 
oxidised or reduced bases, fragmented or non-bulky adducts and those produced by 
methylating agents (Fig 1.5). The single damaged base is removed by a specific DNA 
glycosylase and replaced by an endonuclease (figure below). The molecules involved 
are APEX/APE (apurinic/apyrimidinic endonuclease), DNA polymerase-E and XRCC1 
(X-ray complementing cofactor 1). BER plays an important role in preventing 
mutations associated with a common product of oxidative damage to DNA, 8-
oxoguanine. X-Ray Repair Cross-Complementing Group 1 (XRCC1), located on 
19q13.2, is a polymorphic BER gene that has been the most extensively examined in 
molecular epidemiologic studies of the risk of various cancers (Hung et al., 2005c). The 
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XRCC1 protein is essential for mammalian viability (Thompson et al., 1990)  and its 
deficiency in mice results in embryonic lethality (Thompson and West, 2000), and 
XRCC1 is required for the efficient repair of single- strand breaks and damaged bases in 
DNA. XRCC1 has no known enzymatic activity but is thought to act as a scaffold 
protein for both single-strand break repair and base excision repair activities (Lindahl 
and Wood, 1999). XRCC1 has been shown to physically interact with DNA polymerase 
b, polyadenosine diphosphate-ribose polymerases 1 and 2, APE1/APEX1, OGG1, and 
proliferating cell nuclear antigen, poly ADP-ribose polymerase (PARP), DNA ligase III, 
DNA polymerase-b etc (Caldecott, 2003, Fan et al., 2004). The functional significance 
of XRCC1 280 has not been established, although, the 280His allele was suggested in a 
small study (n = 80) to be associated with higher bleomycin sensitivity (Tuimala et al., 
2002).   
  
Fig  1.5:  Base  Excision  Repair  
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A DNA glycosylase such as OGG1 (Human 8-oxoguanine DNA glycosylase 1) initiates 
BER by releasing the altered base (in the case of OGG1 it is 8-oxo-guanine). There are 
about 11 such glycosylases in mammals (Barnes and Lindahl, 2004) each of which 
performs a specific function. Some glycosylases (bifunctional glycosylases) have an 
associated apurinic/apyrimidinic lyase activity and further catalyse the cleavage of the 
sugar-phosphate chain and excise the abasic site. Thus a single nucleotide gap results, 
which is filled by DNA polymerase E and the chain is sealed by DNA ligase 3/XRCC 1 
complex. Certain glycosylases have no associated lyase activity and when such 
enzymes initiate BER, the subsequent step is carried out by a dedicated 
apurinic/apyrimidinic endonuclease (APE1/APEX1). This is called short-patch BER as 
one single nucleotide is replaced (Dianov et al., 2003). Long-patch repair is a variant of 
BER which results in the replacement of several nucleotides – when the sugar-
phosphate residue at the abasic site is resistant to cleavage, a few more nucleotides are 
added to the 3’ end by a polymerase and a flap is generated containing the 5’ sugar 
phosphate. This flap is removed by flap endonuclease 1 (FEN1) and DNA ligase 
completes the repair (Dianov et al., 2003). 
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Fig  1.6:  BER  -­‐  Long  and  short  patch  (Dianov et al., 2003) 
Sequence variants in DNA repair genes have been thought to modulate DNA repair 
capacity and thereby are suggested to be associated with altered cancer risk. However 
the results from epidemiological studies have been inconsistent. This is possibly due to 
(Hung et al., 2005c) 
x Low statistical power for detecting a moderate effect (i.e false negative results) 
x False-positive results 
x Heterogeneous study populations 
x Failure to consider effect modifications such as environmental exposures 
x Publication bias – including the absence of publication of negative studies 
There is therefore a need for studies to address the above issues. It is also important for 
large consortiums to undertake such molecular epidemiological studies, which will 
enable nearly all of the above problems to be overcome.  
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There has been a paucity of studies investigating the role of DNA repair in pancreatic 
carcinogenesis, though there are indications that DNA repair plays an important role in 
development of pancreatic cancer 
1.5.2 Nucleotide Excision Repair (NER):  
  
Nucleotide excision repair repairs bulky lesions such as pyrimidine dimers, large 
chemical adducts (PAH adducts) and cross-links between DNA. Photo-damage by UV 
light and radiation induced damage is also repaired by NER. This pathway involves at 
least 4 steps (Figure 1.7).  
x Damage recognition by various proteins including XPC 
x Unwinding of the DNA by TFIIH complex (which includes XPD) 
x Removal of the damaged single strand which involves ERCC1 and XPF complex 
x Synthesis of a new oligo-nucleotide chain by DNA polymerases 
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Fig  1.7:  Nucleotide  Excision  Repair  ((Wood,  1997) 
1.5.3 Double Strand Break Repair (DSB): 
  
Double strand break repair can be produced endogenously by replication errors and by 
exogenous agents such as radiation. The repair of such lesions is much more complex 
than other types of damage, mainly because there is no undamaged template with which 
to deduce the damaged strand. Two pathways of DSB repair are known homologous 
recombination (Fig 1.8) and non-homologous end joining. Homologous recombination 
involves resection of the ends of the damages DNA, invasion of the undamaged strand 
of the double helix by the 3’ends of the newly resected DNA strand, extension by 
polymerases and exchange of strands resulting in 2 intact molecules (Khanna and 
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Jackson, 2001). This involves the products of various genes including BRCA1, BRCA2 
and XRCC3. Non-homologous end joining involves direct ligation of the DNA ends and 
also involves numerous molecules (Khanna and Jackson, 2001). 
	  
Fig  1.8  DSB  repair  Homologous  recombination  
 
1.5.4 Mis-Match Reapir (MMR):  
  
The mismatch repair (MMR) mechanism (Fig 1.9) is a highly conserved group of 
proteins from bacteria to humans) that function in maintenance of the genome and avoid 
mutation. They correct replication errors caused by DNA polymerase errors. These are 
base-base mismatches or insertion-deletion mismatches (Aquilina and Bignami, 2001) 
and DNA loops that contain repeated sequences (Parsons et al., 1995). These 
mismatches arise endogenously during replication and homologous recombination. 
Mismatches can also result from exogenous DNA damage. MMR proteins are also 
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involved in regulation of meiotic chromosomal pairing and immunoglobin class 
switching. There is also recent evidence that 8-oxo-guanine, which is a major lesion 
resulting from oxidative damage to DNA, mismatches to Adenine. This 8-GO:A 
mismatch is repaired by MMR in E.Coli (Lu et al., 2001). The genes involved in MMR 
are MSH-2, MSH-3, MSH-6, hMLH1 (Kolodner and Marsischky, 1999). The region of 
chromosome 3p21 has recently been shown to be sensitive to tobacco smoking induced 
damage and is also the locus for hMLH1 and loss of heterozygosity at this region has 
been demonstrated (Hirao et al., 2001). 
	  
Fig  1.9  Mechanism  of  Mis-­‐match  repair    
Cells deficient in MMR exhibit a mutator phenotype in which spontaneous mutation 
rates are highly increased in many genes due to uncorrected errors in DNA replication. 
When the DNA template strand becomes disassociated from the strand that is being 
synthesized, repeated sequences may not reassociate correctly, resulting in loops and 
slipped mispairing. Uncorrected loops result in deletions and insertions in the repeat 
region. Deficient mismatch repair, due to a mutation in the MMR genes would lead to 
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no or reduced efficiency of repair of the mis-matched bases. Tumours with this type of 
phenotype display microsatellite instability. A panel of 5 markers - BAT-25, BAT-26, 
D2S123, D5S346 and D17S250, called the Bethesda panel of markers are used to 
distinguish high frequency of microsatellite instability (MSI-H – 2 or more unstable 
markers) from MSI-L [(low) – 1 unstable marker] and MSS (no unstable marker) 
(Boland et al., 1998). The classical disease of MMR deficiency is HNPCC – hereditary 
non-polyposis colorectal carcinoma, which is secondary to a heritable mutation in 
MSH-2 or MLH-1. The colo-rectal cancers in HNPCC are universally MSI-H. MSI-H is 
also seen in 15% of sporadic colonic cancers, endometrial carcinoma, pancreatic 
adenocarcinoma, prostatic adenocarcinoma, small cell lung carcinoma and renal cell 
carcinoma (Toft and Arends, 1998). 
 
1.5.5 Diseases caused by inherited defects in DNA repair genes 
  
Since DNA repair systems play such a crucial role in the maintenance of the genome, 
deficiency of these repair mechanisms can have significant pathological consequences. 
A number of diseases are associated with specific defects in DNA repair as detailed in 
the table 1.6 below. 
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Table  1.6:  Inherited  defects  in  DNA  repair  mechanisms  and  consequent  illness  
Disease DNA repair defect Phenotype 
Type of genomic 
instability 
Xeroderma pigmentosa NER Cancer Mutations 
Trichothiodystrophy NER/TCR 
Brittle hair, 
developmental 
defects 
Mutations 
Cockayne Syndrome TCR/BER 
Neurological 
defects, Premature 
ageing 
Mutations 
Bloom Syndrome HR Cancer Chromosomal aberrations 
Werner Syndrome HR/NHEJ Cancer, Premature ageing 
Chromosomal 
aberrations 
HNPCC MMR Cancer Mutations 
Ataxia telangiectasia unknown Neurological defects 
Chromosomal 
aberrations 
Hereditary breast 
cancer 
BRCA1 & 2 play 
a role in DNA 
repair 
Familial breast 
cancer Mutations 
Fanconi anaemia 
unknown. 
Possible HR/Inter 
strand cross link 
repair 
Cytopenia,  
short stature, 
hypersensitivity to 
UV light 
unknown 
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1.5.6 Cancer due to DNA repair gene mutations 
  
At least 3 cancer causing syndromes occurring due to mutations in the DNA repair 
genes have been described 
Xeroderma pigmentosa – Mutation in NER genes leads to a high incidence of basal cell 
carcinoma 
HNPCC – Mutation in the MMR genes leads to hereditary colon cancer and also an 
increased risk of other cancers including pancreatic cancer 
Hereditary breast cancer – BRCA 1 and BRCA 2 gene mutations cause familial breast 
cancer and also predispose to other cancers in the affected families, which includes 
pancreatic cancer. These genes have been shown to play a critical role in DNA repair 
(Sharan et al., 1997). The BRCA2 protein is able to bind to the human homologue of the 
yeast RAD51 protein. In yeast this protein participates in the DNA repair of double 
strand break and recombination.  
The database of DNA repair genes is not yet complete and new members will continue 
to be identified. 
 
     72  
Section	  1.6:	  Inter-­‐individual	  variation	  in	  risk	  for	  
carcinogenesis	  
  
Cancer is a complex disease and results from the accumulation of genetic changes, 
therefore could be considered primarily to be a genetic disease. Accumulation of DNA 
damage results in disruption of normal cellular function, cellular differentiation and 
proliferation resulting in the development of an abnormal clone of cells, which undergo 
expansion and form a neoplasm. Indeed some cancers are purely genetic ie the result of 
a genetic abnormality (HNPCC) whilst the majority are a result of some external 
carcinogen (chemical, viral etc). In non-familial carcinogenesis it is a well-established 
fact that individuals vary in their susceptibility to the development of cancer. 
Carcinogens enter the human body from a variety of sources, but most need to undergo 
metabolic activation before they can damage DNA. This ability of the carcinogens is 
balanced by multiple protective functions within the human body and these include – 
carcinogen detoxification, DNA repair and programmed cell death of irreparably 
damaged cells. All these mechanisms exhibit wide inter-individual variation and thus 
are the source of the wide variation in cancer risk (Fig 1.10) (Lai and Shields, 1999). 
The role of gene-environment interaction is of utmost importance in the understanding 
of carcinogenesis in specific organs and therefore of identification of high-risk 
individuals. 
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Fig  1.10:  The  role  of  inter-­‐individual  variation  in  human  carcinogenesis  (Lai and Shields, 1999) 
 
Epidemiological studies have demonstrated that cancer risks vary in different 
populations, however it is remarkable that only certain individuals within the same 
population who are exposed to the same amount of carcinogen develop a particular 
neoplasm whilst others develop an other illness related to that chemical or do not 
develop any illness at all. These differences are most likely to be due to inherited traits 
as discussed in a 1989 commentary (Harris, 1989). 
Most of these inter individual differences in cancer susceptibility are thought to be due 
to variations in the ability to metabolise carcinogens and excrete them from the human 
body (Phase 1 and 2 enzymes) and also to differing capacities for DNA repair (Bartsch 
and Hietanen, 1996, Collins, 1998). Some of these differences are secondary to 
variations in the coding genetic sequence of the genes for the enzymes and proteins 
involved in these functions. Some genetic variants result in complete absence of a gene 
whilst others result in the presence of an enzyme/protein with reduced activity. If a 
genetic variant occurs in !1% of the population then it is considered to be a genetic 
polymorphism (Lai and Shields, 1999). A single base change in the gene may result in a 
different amino acid sequence, which might substantially affect activity of the gene 
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product. These single base changes are called Single Nucleotide Polymorphisms 
(SNP’s). They are common and are the subject of intense investigation.  
Apart from a few direct acting carcinogens most need to be metabolically activated 
before they can exert their harmful action. This metabolism is governed by natural 
processes, which exist to rid the body of foreign compounds. Phase 1 enzymes convert 
inert chemicals into electrophilic intermediates by oxidation reactions. Phase 2 enzymes 
remove the activated intermediates by conjugation with carriers like glutathione. 
Various studies of polymorphisms of phase 1 and 2 enzymes have been  
performed and are not detailed here. Base excision repair is an important mechanism 
which repairs damage caused to DNA as detailed earlier (vide supra) and the SNP’s in 
this system have been the subject of extensive investigation and are discussed below. 
1.6.1 BER gene variants and their role in development of malignancy 
1.6.1.1	  hOGG1	  
  
The OGG1 gene is located on chromosome 3p26.2. This is a region that demonstrates 
loss of heterozygosity (LOH) in several human cancers (Shinmura and Yokota, 2001, 
Kohno et al., 1998). 8-oxoguanine and its tautomer 8-hydroxyguanine are one of the 
most mutagenic lesions occurring due to base damage by reactive oxygen species.  
8-oxoguanine base pairs with adenine and causes G:C o T:A transversions in repair 
deficient bacteria and yeast (Shinmura and Yokota, 2001). At least 20 validated 
sequence variants have been described and a C o G sequence variant leading to an 
amino acid change from Serine to Cysteine at codon 326 has been most extensively 
studied – dbSNP no: rs1052133. Various studies have examined the association 
between genotype variants of OGGI and enzyme activity both in vivo and in vitro and 
results have been inconsistent (Weiss et al., 2005a). However one paper suggested a 
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seven-fold higher activity for repairing 8-oxoguanine by 326Ser containing OGG1 to 
that demonstrated by the 326Cys genotype (Kohno et al., 1998). 
From a recent extensive review by Hung et al (Hung et al., 2005c) published in October 
2005, the summary Odds Ratio (OR) for lung cancer was 1.09 [95% (CI) 0.86-1.40] for 
Ser/Cys, and 1.37(CI 1.02-1.82) for Cys/Cys. One outlying study (Park et al., 2004) was 
removed from the analysis when it was apparent that it was contributing most to the 
heterogeneity of the data, it was still apparent that there was an increased risk of lung 
cancer for Cys/Cys carriers with an OR of 1.24 (95% CI 1.01-1.53). This was based on 
analysis of 3253 cases and 3371 controls from 7 studies. Five studies of upper aero- 
digestive tract cancers were identified. One study each was excluded due to a very large 
variance (Elahi et al., 2002) and heterogeneity (Xing et al., 2001). The OGG1 
Ser326Cys polymorphism is slightly more prevalent among Asians (39.4–60.6 percent 
carry the heterozygous variant; 13.4–38.2 percent carry the homozygous variant) than 
among persons of European descent (23.0–41.0 percent heterozygotes, 1.8–8.6 percent 
homozygotes).  The authors (Hung et al., 2005c) calculated summary odds ration for 
Asian and Caucasian populations which were 1.16 (95% CI 0.98-1.40) and 1.15 (95% 
CI 0.90-1.46) respectively.   
The summary OR for Asp148Gln APE1/APEX1 was 0.94 (95% CI 0.77-1.14), based on 
three studies reported until Feb 2005 (Hung et al., 2005c). One study in patients with 
oesophageal cancer has not demonstrated an association between the Asp148Glu allele 
of APE/APEX1 and cancer risk (Hao et al., 2004). Recently studies in patients with 
prostate (Chen et al., 2006) and bladder cancer (Terry et al., 2006) have been reported 
and effect modification in smokers has been demonstrated in both studies though an 
increased risk with the variant allele of APE1/APEX1 was not found. 
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1.6.1.2	  XRCC1	  Arg194Trp	  
  
There was no association between risk of lung cancer and upper aerodigestive tract 
cancer and this genotype of XRCC1 (Hung et al., 2005a). But when data on all tobacco 
related cancers from 16 studies were pooled and analysed (4895 cases and 5977 
controls) the 194Trp allele was associated with decreased risk – OR 0.86 (95% CI 0.77-
0.95). There appeared to be a protective effect among ever-smokers [OR 0.77(95% CI 
0.78-1.03)]. No ethnic differences were noted in the risk.  
1.6.1.3	  XRCC1	  Arg280His	  
  
No association between this genotype and risk of lung (3 studies), upper aerodigestive 
(3 studies) or all tobacco related cancers (8 studies) combined were found in a recent 
meta-analysis (Hung et al., 2005c). 
 
1.6.1.4	  XRCC1	  Arg399Gln	  
  
Thirteen studies which included 6129 cases and 6895 controls did not reveal an 
association between the 399Gln allele and risk of lung cancer, breast cancer (11 studies) 
or skin cancer (3 studies) (Hung et al., 2005c). There was a non-significant decreased 
risk of upper aero-digestive cancers with an OR of 0.88 (95% CI 0.78-1.01). This 
pooled analysis included 7 studies, on other study(Yu et al., 2004b) was excluded from 
this review due to heterogeneity.  Arg/Gln or Gln/Gln was associated with an summary 
OR of 1.12(95% CI 0.95-1.33) for risk of bladder cancer, on pooling data from 4 studies 
with one study exclusion (Matullo et al., 2001a). With regard to the effect of tobacco 
smoking and risk of tobacco related cancers, the 399Gln allele appeared to increase risk 
for light smokers [OR 1.20 (95%CI 1.03 – 1.40)], while decreasing the risk for heavy 
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smokers [OR 0.81(95% CI 0.64 – 1.04)]. The decreased risk was more pronounced with 
the Gln/Gln genotype [OR 0.71(95% CI 0.51-0.99)]. 
1.6.1.5	  Summary	  
  
To summarize an increased risk of lung cancer with the OGG1 Cys/Cys genotype is 
found. This is consistent with experimental evidence that this gene product exhibits 
decreased BER activity(Kohno et al., 1998, Dhenaut et al., 2000). The XRCC1 194Trp 
is protective against risk for tobacco related cancers. This is in keeping with the lower 
mutagen sensitivity which has been demonstrated with this genotype (Wang et al., 
2003). It is to be noted that this effect is seen only in heterozygotes but not in 
homozygotes. There is evidence for effect modification of the XRCC1 399Gln allele by 
tobacco smoking. This allele is associated with higher mutagen sensitivity (Wang et al., 
2003) and with non-significantly elevated levels of DNA adducts in never smokers and 
lower adduct levels amongst current smokers (Matullo et al., 2001b). An increased risk 
of tobacco related cancers is seen amongst light smokers, which is compatible with in 
vitro studies. The converse of decreased risk among heavy smokers has not been 
demonstrated epidemiologically.  This could be explained by the increased levels of 
DNA damage resulting from heavy smoking leading to increased apoptosis at cell 
division and this manifesting as a reduced risk of exposure induced cancer (Nelson et 
al., 2002). An alternative explanation is that increased tobacco exposure might induce 
DNA repair capacity in response to DNA damage. This has experimental support in the 
form of lower chromosome breaks in healthy heavy smokers (Wang et al., 2003).  
Lower levels of 8-oxoguanine in lymphocytes of smokers as compared to non-smokers 
provide additional support for this theory (van Zeeland et al., 1999, Besaratinia et al., 
2001). 
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The etiologies of the various molecular alterations involved in pancreatic carcinogenesis 
are poorly understood. The contributions of genotoxic injury and poor repair of these 
sites of genomic damage to the development of cancer have not been quantified. 
Recently it has been shown that codon 12 of human K-Ras may be the preferential 
“hotspot” for DNA damage by tobacco-derived carcinogens and that poor repair of the 
carcinogen-DNA adduct at this site may play an important role in initiation of neoplasia 
(Feng et al., 2002). Tobacco-derived carcinogens play a role in at least one-third of 
pancreatic cancers. In spite of this very few studies on the role of DNA repair in 
pancreatic carcinogenesis have been reported. There has been work done on the genetic 
polymorphisms of   carcinogen metabolizing enzymes, which have tried to stratify the 
varying risks of developing pancreatic cancer in relation to the presence of 
polymorphisms of the carcinogen metabolizing enzyme systems (Ockenga et al., 2003, 
Duell et al., 2002a). A population based study, concluded that the combination of heavy 
smoking and a deletion polymorphism in Glutathione S-Transferase T1 genotype, 
specifically the presence of the null-genotype and heavy smoking was associated with 
an increased risk of pancreatic cancer among Caucasians, with the association being 
possibly stronger in women than men. The same group of scientists recently published 
another study that analysed the polymorphism in a base excision repair (BER) protein – 
XRCC1 (X-ray repair cross complimenting group 1) which plays a role in the repair of 
DNA strand breaks and DNA base damage from a wide spectrum of chemicals, one of 
which is tobacco smoke (Duell et al., 2002b).  This study suggested that the presence of 
the XRCC1 allele in smokers was a potentially important determinant of susceptibility 
to pancreatic cancer. 
Increasing age is the strongest risk factor for pancreatic cancer and DNA repair 
decreases with age. It is established that the bulk of DNA repair capacity decreases with 
age (Bohr and Anson, 1995, Kruk et al., 1995). A study by Wei (Grossman and Wei, 
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1995) reported a 1% decrease in DNA repair capacity with advancing age. Tobacco 
smoking has the strongest life-style association with pancreas adenocarcinoma. Studies 
have recently demonstrated that a sub-optimal DNA repair capacity increases the risk of 
non-small cell lung cancer associated with smoking (Shen et al., 2003, Gackowski et al., 
2003). Similar results have been demonstrated for other tobacco-induced cancers. This 
evidence makes it attractive to speculate that poor DNA repair plays a major role in the 
development of pancreatic cancer.   
1.6.2 DNA repair, pancreatic adenocarcinoma & need for further studies  
 
Numerous lines of evidence exist in support of a significant role for altered DNA repair 
in the development of pancreatic cancer. The aetiologies of the various molecular 
alterations involved in pancreatic carcinogenesis are poorly understood and the 
contributions of genotoxic injury and poor repair of the sites of genomic damage to the 
development of cancer have not been quantified. It is pertinent to recall that nearly all 
pancreatic cancers are associated with a mutant K-ras very early in their development 
(vide supra).  Increasing age is the strongest risk factor for pancreatic cancer and DNA 
repair decreases with age (Bohr and Anson, 1995, Kruk et al., 1995). Studies have 
recently demonstrated that a sub-optimal DNA repair capacity increases the risk of non-
small cell lung cancer associated with smoking (Shen et al., 2003, Gackowski et al., 
2003). Similar results have been demonstrated for other tobacco induced cancers in both 
animals (Russo et al., 2004) and humans (Hung et al., 2005c). 
It is therefore attractive to speculate that poor DNA repair plays a major role in the 
development of pancreatic cancer and therefore to investigate gene and gene variants 
involved in DNA repair mechanisms and their interaction with known environmental 
risk factors in an attempt to define susceptibility groups for the development of 
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pancreatic cancer. Identification of high-risk groups in this manner may enable targeted 
screening which could result in earlier diagnoses and improved outcome. Up to the 
present, few studies concerned with polymorphisms affecting DNA repair genes have 
been published. The most widely studied polymorphism has been the Arg399Gln 
polymorphism in XRCC1, which is involved, in base-excision repair. This 
polymorphism was not a risk factor for pancreatic cancer when cases and controls were 
compared directly. However, there was evidence for interaction between XRCC1 and 
smoking and also with a double null GSTM1/T1 genotype (Duell et al., 2002b). In a 
more recent study which did not genotype for metabolic polymorphisms, 
XRCC1Arg194Trp was found to interact with polymorphisms in two other repair genes, 
Asp148Glu in Ape1 and Leu84Phe in MGMT (Jiao et al., 2006a). There is also 
evidence that DNA repair plays a role in determining response to chemotherapy (Nio et 
al., 1998, Nio et al., 2001) and that genotype for various DNA repair genes may thereby 
affect survival of pancreatic cancer patients (Li et al., 2006b, Li et al., 2006a).  
Various prospective cohort studies have estimated a 2-3 fold increased risk of the 
development of pancreatic adenocarcinoma in smokers and that the risk increases with 
the number of cigarettes smoked and the duration of smoking (Engeland et al., 1996, 
Fuchs et al., 1996, Harnack et al., 1997, Nilsen and Vatten, 2000). Its relationship with 
smoking (nearly 25 - 30% of pancreatic cancers are thought to be smoking related 
(Fuchs et al., 1996), which is potentially the most important avoidable cancer risk in 
humans, provides us with a unique opportunity to reduce incidence.  This aetiological 
relationship also provides an opportunity to examine the role of tobacco derived 
carcinogens and gene-environment interaction in the development of pancreatic cancer. 
Better understanding of pancreatic carcinogenesis will hopefully contribute to its earlier 
diagnosis and improved outcome.  
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Increasing work is now being carried out into genetic susceptibility factors responsible 
for tobacco-related malignancy and specifically into genetic polymorphisms and the risk 
of pancreatic cancer. The results up to now have been inconsistent. This is probably 
because most studies have been small and limited to single centres. Also in most cases 
the gene variants studied have been single polymorphisms of one gene from one 
pathway out of the multiple pathways involved in cancer development. It is difficult to 
detect the difference a SNP makes to the phenotype i.e. development of cancer, which 
involves multiple mechanisms and pathways regulating absorption, metabolic activation 
and excretion of carcinogens, DNA repair, cell-cycle control and regulation of the local 
environment etc (Wu et al., 2004). Studying multiple SNP’s from a single pathway, 
therefore, may be more beneficial in being able to elucidate the role that the particular 
pathway plays in the development of that particular cancer. Obviously the pathway of 
study needs to be selected carefully, taking into account the individual environmental, 
genetic and epigenetic events relevant to the organ. In the case of pancreatic cancer, 
DNA repair mechanisms appear to be good candidates for further study.  
Pancreatic ductal adenocarcinoma is a disease with an overall poor prognosis mainly 
due to its late presentation. The best approach towards this malignancy is prevention. It 
is possible that a significant difference to outcome from pancreatic cancer will be made 
through earlier diagnosis. Delineating the role of gene-environment inter actions in 
pancreatic carcinogenesis will be the key to stratifying risk for individuals and thereby 
improving survival not only by earlier diagnosis but also by modifying treatment based 
on individual genotype. 
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Section	  2.1	  Aims	  	  
The aims of this study were to 
1) Ascertain risk conferred by tobacco smoking and a family history of malignancy 
for development of pancreatic cancer 
2) Explore the relationship and interaction between tobacco smoking and a family 
history of cancer between pancreatic cancer cases and controls 
3) Quantify risk for pancreatic cancer by genotype for polymorphisms in genes 
relevant to DNA repair, namely hOGG1 Ser326Cys, APE/APEX1 Asp148Glu, 
XRCC1 Arg194Try, XRCC1 Arg280His and XRCC1 Arg399Gln. 
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Section	  2.2	  METHODS	  	  
This is a prospective case-control study in patients with ductal adenocarcinoma of the 
pancreas. Cases were index patients with pancreatic adenocarcinoma presenting to the 
Hepato-Pancreato-Biliary (HPB) Unit at the Freeman Hospital. Our Unit is the tertiary 
referral centre for HPB illnesses in the North of England and we cater to a population of 
3.5 million. The large numbers of patients with pancreatic cancer being assessed and 
treated here made this study design possible.  
Most diagnoses were confirmed either histologically or cytologically. In some patients 
we have accepted radiological features in combination with clinical progression and 
biochemical evidence of malignancy.  
Controls were identified from patients presenting to the Freeman Hospital with non-
malignant illnesses of the pancreas and liver and with other medical illnesses. We also 
approached the spouse of the index case patient for participation in our study as 
controls. These patients recruited, as controls were those scheduled for elective non-
urgent surgery e.g. hernia operations, varicose vein surgery, day-case local anaesthetic 
procedures like removal of sebaceous cysts etc. In addition we identified patients 
attending the anti-coagulation clinic at the Freeman Hospital to discuss possible 
participation in our study. These were carefully screened to ensure that they did not 
have malignancies and or chronic long-term illnesses. Most of these patients were 
individuals with cardiac rhythm abnormalities on anti-coagulation. We have deliberately 
excluded patients with peripheral vascular disorders and also patients with suspected 
urological malignancies. This is due to the high incidence of tobacco smoking in 
patients with peripheral vascular disease and various recent studies implicating deficient 
DNA repair in bladder and prostate malignancies and as such their inclusion might have 
led to a selection bias amongst controls. We also excluded individuals as controls if any 
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of their first degree relatives were currently being treated at our Unit for 
Liver/Pancreas/Gall bladder related problems to address the issue of relatedness 
between cases and controls. Controls were recruited from hospital patients due to 
limitations on finances, time and logistics. Ideally an age and sex matched population 
based healthy control group should have been recruited but this was not possible.  
2.2.1 Recruitment of cases 
  
The criteria for recruitment of cases was 
1) Cytological or histological confirmation of ductal adenocarcinoma of pancreas 
or 
2) Clinical findings and progressive radiological disease with biochemical (tumour 
marker) evidence of ductal adenocarcinoma of pancreas.  
Suitable patients were approached and the research project was discussed with them. A 
patient information sheet was provided which served to reinforce the oral discussion. 
Contact numbers were provided to the patient in case he/she needed further 
information/wished to retract the consent for the study. After securing informed written 
consent a detailed tobacco-smoking questionnaire was administered and further details 
on alcohol consumption, occupation and family history of any neoplasms were 
recorded.  
Ethical approval for this project was secured in June 2005 from Gateshead LREC and 
recruitment commenced immediately.   
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2.2.2 Questionnaire on Tobacco smoking and Family history of cancer  
  
The World Health Organization Monitoring of Cardio-vascular risks (MONICA) 
questionnaire was used to record detailed tobacco exposure. The MONICA 
(Multinational MONItoring of trends and determinants in CArdiovascular disease) This 
project was established in the early 1980s in many centres around the world and 
administered by the WHO to monitor trends in cardiovascular diseases, and to relate 
these to risk factor changes in the population over a ten-year period. We have used their 
validated smoking questionnaire (MONICA smoking questionnaire 1992 Appendix 5) 
to collect data on tobacco smoking. This enabled us to calculate cumulative tobacco 
exposure in individuals and to arrive at total pack-years of exposure. Individuals were 
considered smokers (current and ex) if they had smoked at least 100 cigarettes in their 
lifetime and non-smokers if they had not smoked this amount. They were considered 
ex-smokers if they had stopped smoking for a period of one year prior to recruitment.  
A detailed family history relating to malignant disease in their first-degree 
relatives was also obtained directly from the patient. First-degree relatives were defined 
as biological parents, siblings and offspring. Cases and controls were divided into 2 
groups on the basis of a positive family history in first-degree relatives (FDR): FDR+, 
in whom there was history of malignancy (other than dermatological and primary brain 
malignancies) in first degree relatives; and FDR-, in whom there was no such history. 
FDR1 denoted index cases with a single FDR with malignancy; FDR>1 denoted those 
with more than one FDR with malignancy. However we have not secured information 
on number of FDR’s, their ages at diagnosis of cancer (if any) and their current health 
status. This has implications, as we are not able to calculate person-years of risk. 
Although heavy alcohol consumption is now a known risk factor, (Tramacere et al., 
2010) for pancreas cancer data on alcohol consumption was not collected in a detailed 
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and comprehensive manner when our cases and controls were recruited (2005-06).  
However an attempt was made to collect information on alcohol consumption but due to 
various factors including lack of time, logistics and importantly the absence of a 
structured questionnaire, which measures long-term alcohol consumption, this was not 
possible. Also in the patients in whom we attempted this, we found that the individuals 
found it difficult to recall details regarding alcohol consumption from many years ago 
and the information obtained was really not of much use for scientific analysis. 
We also collected data on the mode of diagnosis of the adenocarcinoma of pancreas. 
2.2.3 Collection of peripheral blood 
  
A sample of peripheral blood was collected into 2 separate EDTA tubes (resistant to -
80q C), at time of phlebotomy for routine investigations/when intravenous access was 
obtained for treatment purposes. In a few instances venepuncture specifically for the 
purpose of obtaining blood for the research was performed.  
2.2.4 Storage of samples 
  
After appropriate coding the peripheral blood samples were stored in a secure -80q C 
freezer until DNA extraction. A database was maintained with records of the details of 
the patient with the code relating to the sample.  
2.2.5 Preparation of DNA from peripheral blood  
  
DNA from peripheral blood was prepared exactly as described earlier (Daly et al., 
2006). It involved lysing 5 ml blood with 35 ml cell lysis buffer containing 10 mM Tris-
HCl pH 7.4, 320 mM sucrose, 5 mM magnesium chloride and 1% Triton-X100 
followed by centrifugation at 3000rpm for 10 minutes. The nuclear pellet was 
resuspended in nuclear lysis buffer (2 ml), which contained 400 mM Tris-HCl pH7.4, 
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60 mM EDTA, 150 mM sodium chloride and 1% sodium dodecyl sulphate. 0.5 ml 5 M 
sodium perchlorate was then added. The sample was rotary mixed at room temperature 
for 15 min and then incubated at 65 C for 30 minutes. To this 2 ml chloroform was 
added and further rotary mixing (at room temperature) was carried out. The sample was 
centrifuged at 3000g for 10 minutes when the DNA containing phase came out 
uppermost. This phase was transferred to another 15 ml tube and 2 volumes of 100% 
ethanol was added. The DNA came out of solution on gentle inversion and could be 
spooled out on to a loop. This was air dried and dissolved in 0.2-0.4 ml of 10 mM Tris-
HCl pH 7.4 buffer by incubating at 60° C overnight. The sample was then stored at 4q 
C. The DNA concentration was determined by use of a Nanodrop spectrophotometer to 
measure the absorbance at 280 nm.  
2.2.6 Genotyping protocols 
  
Following extraction of DNA, a private company KBioSciences was engaged to 
perform genotyping for all samples by an allelic discrimination technique 
(http://www.kbioscience.co.uk/lab%20services/SNP%20Genotyping/xml%20data.html. 
Details of the polymorphism and DNA samples were provided to the company who 
generated a spreadsheet of results. We however performed PCR-RFLP on selected 
samples (every fifth) to confirm results from KBioSciences. All genotyping data used 
for statistical analysis was that obtained from the genotyping analysis performed by 
KBioSciences. 
2.2.6.1	  Polymerase	  Chain	  Reaction	  methodology	  
  
50ng of genomic DNA was amplified in a total reaction volume of 25 Pl, containing 1 X 
reaction buffer (Promega, UK), 0.25 PM forward primer, 0.25 PM reverse primer 
(Eurofins DNA, UK), 0.2 mM dNTPs (VH Bio) and 0.5 U Taq polymerase (New 
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England Biolabs) and  1.5 mM MgCl2.  Reactions were performed in 0.2 ml thin walled, 
flat top sterile tubes (Fisher Scientific).  Thermal cycling was conducted in an Applied 
Biosystems 2720 Thermal Cycler.  All PCR conditions were as published earlier by Hu 
et al (Hu et al., 2001) and by Tuimala et al (Table 2.1 – at end of Section).  The 
efficiency of PCR was checked by running 5 Pl of the PCR product with a 2Log ladder 
on 2% agarose gel (see below). Assays were typically run in batches of 20 with each set 
including 3 controls of known genotype. 
2.2.6.2	  Primers	  
  
Primers were purchased from Eurofins DNA, UK.  The lyophilised primers were re-
suspended to 200 PM with sterile water for injection (Fresenius Kabi Limited, Chesire, 
UK).  Working 25 PM stock dilutions were made up and kept at 4°C, whilst frozen 
stocks were kept at -20°C. 
2.2.6.3	  Restriction	  fragment	  length	  polymorphism	  analysis	  
Restriction	  enzyme	  digestion	  of	  PCR	  products	  
  
Restriction enzymes were purchased from either Fermentas or NEB. Typically 2 U of 
enzyme was used to digest 20 Pl PCR product in the digestion buffer provided, 
overnight at the temperature specified by the manufacturer.   
Electrophoresis,	  PAGE	  and	  visualisation	  of	  DNA	  
Agarose	  gel	  electrophoresis	  
  
2% agarose gels were made using DNase and RNase free agarose tablets (Bioline,UK) 
in 1 X TBE, containing ethidium bromide (0.5 Pg/ml).  2 Pl of gel loading dye was 
added to 5 Pl of DNA product, and samples were loaded alongside 2 Log Ladder (NEB) 
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for size determination of the products.  Electrophoresis was generally carried out for 15-
30 minutes at ~80V.   
Polyacrylamide	  gel	  electrophoresis	  (PAGE)	  and	  ethidium	  bromide	  staining	  
  
10% (w/v) polyacrylamide gels were made using 30% (w/v) acrylamide-bis acrylamide 
29:1 (Fisher) in 1X TBE buffer, 0.4 mg/ml ammonium persulphate and 0.1% (v/v) 
TEMED, to a final volume of 50 ml.  The gel solution was poured between two 
200mmx200mm sealed glass plates and left to set for 30 minutes.  3 Pl of gel loading 
buffer was added to 25 Pl DNA digestion products and applied to the wells.  Gels were 
run at 150V for 4-6hrs.  Gels were then post-stained in 1XTBE and ethidium bromide 
(0.5 Pg/ml) for 30mins. 
	  
  
	  
  
Gel	  visualization	  
  
Gels were visualised and photographed on a BioRad gel documentation system and 
photographed using Fluor S-Multi imager Quantity One software. 
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hOGG1	  
  
KBiosciences performed genotyping for all samples by an allelic discrimination 
technique for a tagged SNP rs2072668. In some selected samples genotyping of this 
polymorphism was performed by PCR-RFLP as described in Section 2.2.6 to confirm 
the KBiosciences data was correct. 
	  
Figure  2.1:  hOGG1  Ser326Cys  PCR-­‐RFLP  
A typical digestion pattern is depicted where  FNU4H1 digested products of 
hOGG1resoved at 691, 691/417/244 and 417/244; lanes 1,4,5,7 are homozygous 
mutants whilst lanes 2,3,6,8,9 are heterozygotes. 
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XRCC	  Arg194Try	  
  
KBiosciences performed genotyping for all samples by an allelic discrimination 
technique. In some selected samples genotyping of this polymorphism was performed 
by PCR-RFLP as described in Section 2.2.6 to confirm the KBiosciences data was 
correct. 
  
Figure  2.2:  XRCC1  Arg194Try  PCR-­‐RFLP  
A typical digestion pattern is shown where Pvu2 digested products of XRCC1 codon 
194 Arg/Arg, Arg/Trp and Trp/Trp resolved at 490, 490/294/196 and 294/196 bp on 2% 
agarose gel. Therefore lanes 3 and 5 are heterozygotes while the rest are homozygous 
wild-type genotype. Lane 10 is a 100 bp marker.
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XRCC	  Arg399Gln	  
  
KBiosciences performed genotyping for all samples by an allelic discrimination 
technique. In some selected samples genotyping of this polymorphism was performed 
by PCR-RFLP as described in Section 2.2.6 to confirm the KBiosciences data was 
correct. 
A typical digestion pattern is shown in Figure 2.3 
  
Figure  2.3  XRCC1  Arg399Gln  PCR-­‐RFLP  
Hpa 1 (isoschizomer of Msp1) resolved products of XRCC1 codon 399 Arg/Arg, 
Arg/Gln and Gln/Gln had band sizes of 269/133, 402/269/133 and 402 bp on 2% 
agarose gel. The wild type gene is digested by Hpa1, therefore sample 38, 36 and 34 in 
lanes 1, 3 and 4 are homozygous wild-type genotype, while sample 37 in lanes 2 is a 
homozygous mutant and sample 32 in lane 32 is a heterozygote. Lane 11 is a 100bp 
marker.  
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XRCC 280  
KBiosciences performed genotyping for all samples by an allelic discrimination 
technique. A few selected samples of XRCC1 Arg280His were genotyped by PCR-
RFLP as described in Section 2.2.6. 
  
	  
Figure  2.4  XRCC1  Arg280His  PCR-­‐RFLP  
A sample digestion pattern is depicted. The digestion products resolved at 420, 
420/280/140, 280/140 bp sizes, lanes 1 and 6 are homozygous mutants whilst lanes 2, 3, 
4, 5, 7, 8 and 9 are heterozygotes. 
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2.2.7 Power calculation 
  
Using an online statistical power calculator (http://statpages.org/proppowr.html), a 
power calculation was performed for each individual polymorphism based on the 
number of samples available before the genotyping studies were initiated.  
hOGG1 Ser326Cys :The use of 67 cases and 67 controls provided a statistical power of 
80% to detect a change in the proportion of the frequency of the minor allele from 29% 
to 58 % [Odds ratio (95% CI) 3.38 (1.8803 to 6.0795)] at a significance level of p=0.01.   
XRCC1 Arg194Try The use of 142 cases and 142controls provided a statistical power 
of 80% to detect a change in the proportion of the frequency of the minor allele from 
7% to 21 % [Odds ratio (95% CI) 3.53 (1.42 to 8.74)] at a significance level of p=0.01. 
XRCC1 Arg280His The use of 130 cases and 130 controls provided a statistical power 
of 80% to detect a change in the proportion of the frequency of the minor allele from 
15% to 33 % [Odds ratio (95% CI) 2.42 (1.22 to 4.81)] at a significance level of p=0.01. 
XRCC1 Arg399Gln The use of 143 cases and 143 controls provided a statistical power 
of 80% to detect a change in the proportion of the frequency of the minor allele from 
35% to 55 % [Odds ratio (95% CI) 2.26 (1.28 to 4.01)] at a significance level of p=0.01. 
APE1 Asp148Glu The use of 139 cases and 139 controls provided a statistical power of 
80% to detect a change in the proportion of the frequency of the minor allele from 49% 
to 70 % [Odds ratio (95% CI) 2.42 (1.35 to 4.33)] at a significance level of p=0.01. 
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Table  2.1:  Genotyping  details  -­‐  PCR  and  digestion  conditions  for  individual  genes  
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2.2.8 Statistical analysis 
  
Continuous variables (checked for normality or otherwise by Shapiro-Wilk test) were 
compared by the student t-test and ANOVA for parametric variables and the Mann-
Whitney U test and Kruskal-Wallis tests for non-parametric variables. Associations 
were tested using the by Fisher’s test (2-tailed p) and Pearson’s chi-square test. 
Goodman and Kruskal Tau/Somers gamma was used when ordinal data were used in 
cross-tabulation. Directional measures were employed as necessary. To confirm the data 
was in Hardy-Weinberg equilibrium, an online calculator available at 
http://www.oege.org/software/hwe-mr-calc.html (Rodriguez et al., 2009) was used. 
Odds ratios with 95% confidence interval were calculated to quantify relative risk for 
individual enzyme polymorphisms and statistical significance was assessed. In addition, 
conditional logistic regression was used to adjust for effects of age (used as a 
categorical variable), gender, family history and smoking status between cases and 
controls. Hosmer Lemeshow test was used to check the model for adequacy of fit during 
logistic regression. We did not use any censoring in our analysis. Regarding age of 
individuals (FDRs), we did not have age of onset of cancer in them and therefore were 
not able to calculate person-years of risk for FDR’s. 
SPSS for Windows (Rel. 16.0.1. 2008. Chicago: SPSS Inc) was the software platform 
used for computing these tests. Professional advice was sought on the use of statistical 
tests and method of analyses (specifically including aspects of data coding, cross-
tabulation, significance testing, regression analysis) on the SPSS platform from Laerd 
Statistics (https://statistics.laerd.com/).   
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CHAPTER	  3:	  RESULTS	  -­‐	  INFLUENCE	  OF	  A	  CUMULATIVE	  TOBACCO	  
EXPOSURE	  AND	  FAMILY	  HISTORY	  OF	  CANCER	  IN	  INDEX	  CASES	  OF	  
PANCREATIC	  CANCER
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3.1	  Introduction	  
 
Over a period of 14 months (June 2005 to September 2006), both cases and controls 
were recruited into this study and here we present the demographics and explore the 
data obtained. 
  
A total of 181 patients were referred to the Unit with a suspected diagnosis of 
pancreas cancer and 178 agreed to take part in the study. Out of these, 13 were found to 
have diagnoses other than ductal adenocarcinoma of the pancreas. One patient with a 
diagnosis of Li-Fraumeni syndrome was excluded from the data analysis, since this 
condition predisposes to pancreatic cancer. Therefore there were 164 cases in the study. 
The mode of diagnosis of pancreatic malignancy was: cytological and or histological 
evidence of pancreatic ductal adenocarcinoma in 122 patients (74%) and a combination 
of radiological and/ clinical progression with biochemical (serially rising CA19-9) 
evidence in 42 (26%) patients (Fig 3.1).  
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181 individuals 
approached 
	  
3 did not participate 
178 enrolled 
 Pancreas cancer 
cases,  
n =164 
	  
Cytology/Histology, 
n =122 
Imaging, ntumor 
markers and clinical 
picture, n = 42 
13,  other  pathology/  
unconfirmed  
Li-Fraumeni 
syndrome 
 n = 1, excluded 
Fig  3.1:  Chart  depicting  enrolment  and  mode  of  diagnosis  of  cases    
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We recruited 126 controls from the Freeman Hospital. They included spouse 
controls, patients from the in-patient wards and outpatient clinics. Spouse controls were 
n =34. The majority of these were individuals attending the anti-coagulation clinic 
(indications included cardiac arrhythmia, prosthetic cardiac valves; n = 75), patients 
attending for elective hernia repair surgery (n=5), cholecystectomy (n=8) and 
endoscopic treatment of bile duct stones and/or benign biliary strictures (n=4). Later in 
the study period we included 50 controls from an erstwhile molecular epidemiological 
study, from whom we had consent to do so (historical controls). These individuals had 
provided blood samples from which DNA had been isolated and stored. They had also 
provided tobacco smoking status information, although detailed data on intensity of the 
exposure was not available. There was also no information on age, gender and family 
history of malignancies. Therefore these controls were included only for genotyping 
analysis and they had to be excluded for other analyses (this is detailed in subsequent 
sections)
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* Historical/MW controls 
Total controls 
included in 
study, n=176 
Invitation to participate 
in study, informed 
consent and enrolled  
n = 126  
  
Historical controls 
from previous study 
study, n=50* 
From anti-
coagulation 
clinic, n=75 
  
Spouse 
controls 
n = 34 
  
Other benign illnesses, incl 
benign HPB disorders (e.g. 
cholelithiasis), inguinal 
hernia etc, n=17 
  
Fig  3.2:  Chart  depicting  enrolment  and  inclusion  of  controls  into  study  
 
     103  
3.2	  Cases	  and	  controls	  	  
3.2.1 Gender 
  
Table 3.1 depicts the frequency of each gender class amongst cases and controls 
Table  3.1:  Gender  grouping  amongst  cases/controls  
 Frequency Percent 
Control 
 
Female 70 39.8 
Male 56 31.8 
Not av* 50* 28.4 
Total 176 100.0 
Case 
 
Female 73 44.5 
Male 91 55.5 
Total 164 100.0 
 
*These are historical controls included later in the study on which gender information 
was not available. In analyses, which have included gender as a variable, we have 
excluded these controls, and Fisher’s test, p=0.075. Therefore there is no association 
between case/control status and gender. 
3.2.2 Age: 
  
We did not have age information on the historical controls (n=50) included in the latter 
period of the study; we have therefore excluded these individuals from analyses where 
age was a variable. The data were distributed in a non-normal fashion (Shapiro-Wilk 
test p=0.001). The mean (95% CI) age of cases (n=164) was 65.36 (63.69 to 67.03) 
years, whilst that for the controls (n=126) was 61.93 (59.58 to 64.28) years (Mann-
Whitney test p=0.040) The median ages were 64 (34 to 87) and 66 (36 to 88) years 
respectively. Again this finding is probably secondary to the design of the study and not 
a result of the same.  
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3.2.3 Smoking status: 
  
There were some individuals from whom a complete tobacco smoking history could not 
be obtained; from the historical controls we could only obtain information on smoking 
status (present, past or non-smoker). These subjects did not have complete tobacco 
exposure history and therefore although they were included in analyses in which 
smoking status was a variable, we excluded these controls when smoking intensity (or 
other tobacco exposure details) was a variable. In some the MONICA questionnaire was 
incompletely filled and these are depicted in the penultimate row of Table 3.2.  
Table  3-­‐2:  Tobacco  smoking  status    
 
 
Control Case Total 
Smoking status  Present-smoker 67 85 152 
Past-smoker 45 59 104 
Non-smoker 44 10 54 
Incomplete data 20 10 30 
Total 176 164 340 
 
Cross-tabulation suggests a relationship between case/control status and smoking status, 
Ordinal Chi-square p=0.0001 (very weak relationship; lambda =0.195, case/control 
status dependent variable). Telescoping smoking status into 2 categories – Ever smokers 
(group consisting of past and present smokers) vs. Non-smokers and excluding subjects 
who have incomplete data, we obtain a p=0.0001 (Fishers test) and Odds Ratio (95% 
confidence interval) [OR (95% CI)] for smoking for development of pancreas cancer = 
3.429 (1.612 to 7.291). This suggests that tobacco smoking is a risk factor for pancreas 
cancer in our study population.     
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Comparing intensity of smoking in terms of pack-years of tobacco exposure between 
the 3 smoking statuses (Table 3.3): 
Table  3.3:  Tobacco  exposure    (pack-­‐years  of  smoking)  Cases  and  Controls  (excluding  missing  data)  
  N Mean Std. Deviation Mann-Whitney test p 
Ever Smokers Pack yrs 
Control 112 36.3329 25.37667 
0.120 
Case 144 47.1324 38.25516 
Present Smokers 
Pack years 
Control 67 37.8875 25.11526 
0.200 
Case 85 50.3047 40.29715 
Past Smokers 
Pack yrs 
Control 45 34.4207 25.89296 
0.725 
Case 59 39.4262 35.11719 
 
Smoking intensity is distributed in a non-normal manner (Shapiro-Wilk; Ever Smokers 
pack years p= 0.0001, Present Smokers Pack-years p = 0.0001, Past Smokers Pack years 
p = 0.0002). 
All individuals with missing values were excluded for this analysis, and there was no 
significant difference between tobacco exposure between ever-smokers amongst cases 
(47.13 pack-years) and controls (36.33 pack-years). This was true for present and past 
smokers too.  
3.2.4 Family history: 
  
Of the 164 cancer patients, 134 with reliable family history were included into this 
analysis (family history data being unavailable in 21 and incomplete in 9). A full 
smoking history was available in all these individuals. Historical controls were 
excluded from this part of the analysis, as we did not have family history data on them. 
Table 3.4 depicts the frequencies of individuals with a positive (FHP), negative (FHN), 
incomplete (FHIncomp) and unavailable (FHUnavail) family history of cancer in their 
first-degree relatives. 
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Table  3.4:  Family  history  of  malignancy  amongst  Cases  and  Controls  
 
Family history 
FHP FHN FHIncomp FHunav Total 
Cases & 
Controls 
Case 78 56 16 14 164 
Control 39 70 15 52* 176 
Total 110 133 31 66 340 
*historical controls included 
 
Excluding missing values (FHIncomp and FHUnav), there is a significant relationship 
between family history of malignancy and case/control status (Fisher’s test p=0.041) 
and calculating odds ratio for individuals with family history of malignancy we obtain 
OR (95% CI) of 2.023 (1.205 to 3.396). However this analysis is limited by the non-
availability of person-years of risk in the FDR’s. 
There were 78 cases with FDR+ (first degree relatives with a positive) for history of 
malignancy with a total of 107 malignancies; FDR’s with 1 malignancy (FDR1) n = 51, 
17 had 2 relatives, 6 had 3 and one had 4 relatives with cancer. There were 39 FDR+ 
controls with a total of 59 malignancies; FDR1 n = 39 and FDR1+ = 12. The following 
Figure 3.3 details the frequency of the individual’s cancer types amongst FDR+ cases 
and controls.  
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Figure  3.3:  Types  of  malignancies  in  caFDR+  (n=78)  &  coFDR+  (n=39)  
  
  
Tobacco smoking is a risk factor for pancreas cancer and so is family history of 
malignancy (vide supra). The relationship between these factors was investigated by 
comparing groups of patients with tobacco exposure but with different genetic 
backgrounds i.e. family history.  
  
The mean (SD) age at diagnosis for pancreatic cancer cases was 66.1 (10.67) years. 
There was no difference (p=0.35) in the mean (SD) age between caFDR+ and caFDR- 
groups (65.93 (8.90) and 62.23(13.65) years respectively). The overall gender ratio was 
77:57 (m: f), (45:32 for caFDR+ and 32:24 for caFDR-). 
 The controls numbered 172, of which 119 were included for this analysis due to 
constraints of reliability or completeness of family history: coFDR+ = 44, coFDR- = 75, 
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unavailable = 5, incomplete = 7. Mean age of controls was 62.07 (14.34) years. There 
was no significant difference between the ages of coFDR+ and coFDR- groups. The 
overall gender ratio was 60:59 (m: f) (25:19 for coFDR+ and 39:36 for coFDR-). 
Table 3.5 summarizes the demographics, smoking behaviour, cumulative tobacco 
consumption, (overall consumption and stratified by FDR status, of our study 
population (total 253; cases 134 and controls 119). 
 
3.3	  Tobacco	  exposure	  and	  risk	  of	  pancreatic	  cancer	  
 
There were 114 pancreatic cancer patients who had experienced significant tobacco 
exposure at some point in their lives; 70 were current smokers and 44 were ex-smokers 
who had stopped smoking at a mean (SD) of 19.19 (14.48) years prior to diagnosis of 
adenocarcinoma of pancreas. The mean (SD) cumulative tobacco exposure in these 97 
individuals was 37.62 (22.45) pack-years. There were 20 non-smokers. The mean (SD) 
cumulative tobacco exposure in all controls that had experienced tobacco exposure (n = 
78, current smokers = 47 and ex smokers = 31) was 22.45(29.04) pack-years and this 
was significantly lower (p=0.002) than that in pancreatic cancer cases.  There were 41 
non-smokers amongst the control population.  There was no significant difference in the 
number of past smokers between the cases and controls but significant differences were 
seen in the numbers of Ever- and non-smokers (Table 3-5 and Figure 3.4).  
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Figure  3.4:  Frequency  of  Tobacco  smokers  -­‐  Cases  and  Controls  
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Table  3-­‐5:  Detailed  tobacco  exposure  data  -­‐  cases  and  controls  stratified  by  Family  history 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Cases 
 
Controls 
 
p value 
Total 164 176 
 
Included into 
analysis 134 119 
Male 77 60 
0.312 (Fisher’s test) 
Female 57 59 
Mean Age 66.1 (10.67) 62.07(14.34) 0.421 (t-test) 
Current smokers 70 47 
0.881 (Fisher’s Test) 
Past smokers 44 31 
Ever-smoker 
 (Present + Past) 114 78 0.0004 
Non smokers 20 41 
FDR+ 78 39 
0.0008 (Fisher’s test)) 
FDR- 56 70 
FDR+ 
Smoking PyYrs  32.79(24.77)* 23.51(12.98)** 0.129 (Mann-Whitney) 
FDR- 
Smoking PackYrs 45.69(24.56)* 19.33(16.11)** 0.001 (Mann-Whitney) 
Overall  
Smoking PackYrs 37.62(22.45) 22.45 (19.04) 0.002 (Mann-Whitney) 
 *p  = 0.023  (Mann-Whitney) 
**p  = 0.193 
(Mann-Whitney  
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No allowance for alcohol exposure is included, as the data on this was not collected (as 
discussed in 2.2.2 (pages 86/87). 
The odds ratio for an ever smoker (current and ex) for the development of pancreatic 
cancer is nearly 3 times that of a non-smoker [OR 3.01 (95% CI 1.73 to 5.24)]. There 
was no significant difference in the mean age between the cases and controls; however 
there was a definite early onset of adenocarcinoma of pancreas in current smokers. A 
consistent early occurrence of adenocarcinoma of pancreas by about 6 - 7 years was 
seen amongst current smokers, which is independent of family history of cancer (Table 
3.7).  However this finding could be a result of the design of the study. FDR status did 
not affect the age of onset of pancreatic cancer. Again this analysis is hampered by the 
non-availability of age of onset of the malignancy in the FDR’s. 
Table  3.6:  Age  of  Onset  of  adenocarcinoma  of  pancreas  [Mean  (SD)  years]  
Pancreas 
cancer 
patients 
grouped 
based on 
family 
history of 
malignancy 
status 
Smoking status 
Current 
smoker 
Current and 
Ex smoker 
Ex-
Smoker 
Non-
Smoker 
Ex and 
non-
smoker 
ANOVA 
p 
Combined 
caFDR+ 
and 
caFDR- 
(n=134) 
60.12 
(8.18)  
67.59 
(10.10) 
66.36 
(12.17)  0.005 
 64.51(10.01)  66.36 (12.17)  0.40 
60.12 
(8.18)    
67.08 
(10.95) 0.001 
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3.4	  Family	  history	  of	  cancer	  in	  caFDRs	  	  
A history of malignancy in FDR was present in 78 (m: f = 44:34) and absent in 56 (m: 
f=32:24) cases. Amongst controls the coFDR+ numbered 39 and coFDR- was 70.  The 
risk of development of adenocarcinoma of pancreas for caFDR+ individuals was nearly 
twice that of caFDR- individuals [OR 1.98 (95% CI: 1.15-3.38)]. However we do not 
have data on the total number of first-degree relatives, the ages at which they developed 
these malignancies and current health status of these individuals. Therefore we are not 
able to calculate life-time risk. 
Of the 78 cases caFDR+, 51 had a single relative with cancer, 17 had 2 relatives, 6 had 
3 and one had 4 relatives with cancer. In total there were 107 malignancies. The 
different malignancies in the caFDR+ group are depicted in Figure 3-3.  
3.5	  Interaction	  between	  tobacco	  smoking	  and	  family	  
history	  of	  cancer	  in	  caFDRs	  
The overall tobacco exposure was greater amongst cases (Mann-Whitney test p=0.002,) 
as seen in Table 3-5. More importantly amongst cases, there was a significantly 
decreased cumulative tobacco exposure in the caFDR+ group (Mann-Whitney test 
p=0.023) as compared to the caFDR- group: the overall cumulative pack-years of 
smoking was 32.79 (24.77) in the caFDR+ versus 45.69 (24.56) in the caFDR- group. 
Mean (SD) cumulative tobacco exposure in coFDR+ was 23.51(12.98) and that in 
coFDR- was 19.33 (16.11). This was not statistically different (Mann-Whitney test 
p=0.193) [Table 3.5]. The risk for adenocarcinoma of the pancreas was higher in 
smokers in both FDR+ [OR 2.85(95% CI 1.24 to 6.65)] and FDR- [OR 3.18 (95% CI 
1.48 to 6.82)] groups, but the amount of tobacco exposure was lower in the caFDR+. 
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Next we divided the cases with a family history of cancer in their FDR into 2 
groups – caFDR 1 (n=36): one FDR with cancer and caFDR>1 (n=24): cases with more 
than 1 FDR with cancer. We did not find a significant difference in the mean (SD) 
cumulative pack years of tobacco smoking in between these groups [FDR1: 33.70 
(29.24), FDR2: 25.07 (16.68); Mann-Whitney test p = 0.269]. 
3.6	  Summary	  of	  results:	  	  
 
1. The risk for an ever smoker (current and ex) for the development of 
pancreatic cancer is nearly 3 times that of a non-smoker [OR 3.01 (95% CI 
1.73 to 5.24)]. 
2. Amongst pancreatic cancer cases, there was a significantly decreased 
cumulative tobacco exposure in the caFDR+ group (p=0.023) as compared to 
the caFDR- group: the overall cumulative pack-years of smoking was 32.79 
(24.77) in the caFDR+ versus 45.69 (24.56) in the caFDR- group. 
3. Therefore, although we have attempted to examine family history of 
malignancy in the context of tobacco smoking towards risk for pancreatic 
cancer these results are severely limited by the limited data available on the 
total number of FDR’s in a family and their current health status. The findings 
from this study need to be replicated in a further robust data collection 
exercise where a comprehensive family history will be collected, including 
number of FDRs, age at diagnosis of malignancy in them and current health 
status of the individuals which will allow calculation of person-years of risk 
and Standardised incidence ratios. 
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CHAPTER	  4:	  GENOTYPING	  RESULTS
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Section	  4.1:	  rs2072668	  genotype	  (hOGG1)	  
The relevance of OGG1 genotype to pancreatic cancer was assessed by genotyping for 
rs2072668, which is in linkage disequilibrium with HOGG1 Ser326Cys (rs1052133). 
rs2072668 is an intronic hOGG1gene polymorphism on chromosome 3 at contig 
position 9738140 (rs1052133 is at contig position 9738773). KBiosciences performed 
genotyping for this SNP by allelic discrimation techniques. 
Genotypes for rs2072668 in the genotyped population (n=312) - cases (n=153) were in 
HW equilibrium (X2=1.95, p=0.162) and controls (n=159) were in HW equilibrium too  
(X2 = 0.36, p=0.548). The overall frequencies of wild-type, heterozygote and 
homozygous mutant genotypes are depicted in Table 4.1. The overall allele frequencies 
were major allele 497 (79.65%) and minor allele 127 (20.35%), amongst cases they 
were major allele 247 (80.72%) and minor allele 59 (19.2%), amongst controls they 
were 250(78.2%) and 68 (21.38%) respectively.  
Table 4.1: rs2072668 genotype frequency   
 
 
Case Control Total 
 
 
 
rs2072668 
genotype 
Missing 11 17 28 
Homozygous 
Wild-type 
97 97 194 
Heterozygous 53 56 109 
Homozygous 
Mutant 
3 6 9 
Total 164 176 340 
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4.1.1 Overall association between genotype and case/control status 
  
To overcome small numbers in the homozygous mutant category, heterozygotes and 
homozygous mutants were combined into a single group (Table 4.2). 
Table 4.2: rs2072668 Homozygous wild-type vs. Carriers of variant allele 
rs2072668  
Case Control 
Case Control Total 
 Carriers of 
variant allele 
56 62 118 
Homozygous 
Wild-type 
97 97 194 
Total 153 159 312 
 
No association (Fisher’s test p=0.726) was seen. The odds ratio for pancreatic cancer 
was 0.848 (95% CI 0.552 to 1.304), which was not significant.  
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4.1.2 Assessment of Gender on rs2072668 risk for pancreatic cancer 
 
	  
Performing sub-group analysis based on gender, there was no association between 
genotype and case/control status (Fisher’s test; Female p= 1.000, Male p = 0.627) 
(Table 4.3).  Calculating risk for pancreatic cancer; over all odds ratio for female 
carriers of variant allele was 0.975 (95% CI 0.502 to 1.894) and for males, was 0.833 
(95 % CI 0.41 to1.574). These risk estimates are not significant.  
	  
Table  4.3:  Comparison  of  genotype  frequencies  for  rs2072668  in  male  and  female  cases  and  controls 
 
 
rs2072668 
Total 
Carriers of 
variant allele  
Homozygous 
wild - type 
Female  Case 25 43 68 
Control 31 52 83 
Total 56 95 151 
Male  Case 31 54 85 
Control 31 45 76 
Total 62 99 161 
  
 
  
	  
  
	  
     118  
4.1.3 Assessment of Age on rs2072668 risk for pancreatic cancer: 
  
The mean (SD) age at diagnosis for pancreatic cancer cases was 66.1 (10.67) years and 
that of the controls was 62.07 (14.34) years. We sought to divide our study group into 2 
categories to ascertain the impact of age. We chose 65 years as a cut-off as it fell in 
between the means of the cases and controls and was a round figure. We therefore 
divided individuals into 2 age groups – up to 65 years and above 65 years.  
As summarized in Table 4.4; there were no significant differences in risk for the two 
age groups (Fisher’s test; less than 65 years p=0.862; more than 65 years p=0.743). 
Odds ratio for pancreatic cancer for the younger age group was 0.914 (95% CI 0.463 to 
1.805) and that for the above 65 years was 0.854 (95% CI 0.449 to 1.626).  
 
Table  4.4:  rs2072668  genotypes  in  cases  and  controls;  effect  of  age  
 
rs2072668 
Total Carriers of 
variant allele 
Homozygous 
Wild-type 
 65 years 
 
Case 32 35 67 
Control 33 33 66 
Total 65 68 133 
> 65 years 
 
Case 24 62 86 
Control 29 64 93 
Total 53 126 179 
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4.1.4 Smoking status: 
The relationship between tobacco smoking behaviour and case-control status was 
assessed. Some individuals (n=28) did not have full smoking history and were excluded 
from this analysis. The results obtained are shown in Table 4.5. 
Table  4.5:  rs2072668  genotypes  and  susceptibility  to  pancreas  cancer  -­‐  effect  of  smoking  status  
	  
  
 
 
 
 
 
 
Genotype distributions did not differ significantly between individual smoking groups 
(Fisher’s test p=0.417, 0.518 and 0.164 present, past and non-smokers respectively). 
Odds ratio for pancreatic cancer for individual smoking statuses were 1.342 (95% CI  
0.656 to 2.747), 0.729 (95% CI 0.312 to 1.705) and 0.317 (95% CI 0.071 to 1.407).  
	  
	  
	  
 
rs2072668 
Total Carriers of 
variant allele 
Homozygous Wild-
type 
Present-
smoker 
 
 Case 28 51 79 
Control 18 44 62 
                 Total 46 95 141 
Past-
smoker 
 
 Case 20 36 56 
Control 16 21 37 
                 Total 36 57 93 
Non-
smoker 
 
  Case 3 7 10 
Control 23 17 40 
                 Total 26 24 50 
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4.1.5 Smoking intensity  
 
Intensity of tobacco smoking was assessed by dividing smokers into 2 groups, 40 
pack-years history (light smokers) and above 40 pack-years (heavy smokers) of 
cumulative tobacco exposure (Table 4.6). 
Table  4.6:  rs2072668  genotypes  in  cases  and  controls  -­‐  effect  of  smoking  intensity  
 
rs2072668 
Total 
Carriers of 
variant allele 
Homozygous Wild-
type 
Light   Case 13 37 50 
Control 12 14 26 
                  Total 25 51 76 
Heavy  Case 38 57 95 
Control 45 68 113 
                  Total 83 125 208 
 
No significant associations were seen for either group (Fisher’s test, light smokers p = 
0.121, heavy smokers p=1.000). Odds ratios were 0.410 (95% CI 0.151 to 1.111) for 
light smokers and 1.007 (95% CI 0.577 to 1.759) for heavy smokers.  
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4.1.6 Family history of malignancy 
  
The effect of the presence (FHP) or absence (FHN) of a family history of malignancy 
on case-control status was explored (Table 4.7). 
  
Table  4.7:  rs2072668  genotypes  in  cases  and  controls  -­‐  effect  of  family  history  of  malignancy  
  
 
 
 
 
 
 
 
Some individuals n=93 did not have a full family history and they were excluded from 
this analysis. Amongst FHP (Fisher’s test, p=0.282) and FHN (Fisher’s test, p=0.709) 
no significant associations were seen for genotype and membership of cases. Odds ratio 
(95% CI) values were 0.585 (0.253 to 1.356) and 0.852 (0.406 to 1.786) respectively. 
 
 
rs2072668 
Total 
Carriers of 
variant allele 
Homozygous Wild-
type 
FHP  Case 24 41 65 
Control 17 17 34 
Total 41 58 99 
FHN  Case 21 38 59 
Control 24 37 61 
Total 45 75 120 
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4.1.7 Logistic regression 
Logistic regression was performed excluding incomplete and missing values (amongst 
genotype, age, gender, family history and smoking status) to ascertain the impact of 
these variables on the likelihood of developing pancreatic ductal adenocarcinoma. The 
total numbers of cases included was 207 (Table 4-8). The Hosmer Lemeshow test gave 
a X2= 3.701 (p=0.883) indicating a good fit of the data to the model. Also the model 
was statistically significant X2 = 39.457 p=0.0009. The model explained 23.5% 
(Nagelkerke R2 = 0.235) of variance in the development of pancreatic ductal 
adenocarcinoma and correctly classified 70.5% of cases. Sensitivity was 87.1%, 
specificity was 45.8%, positive predictive value was 70.58% and negative predictive 
value was 70.37%. Of the 5 predictor values only age and smoking status were 
significant – Table 4.8. Increasing age was associated with risk of pancreatic cancer, 
both present and past smokers were at increased risk but no specific risk was associated 
with the variant allele for rs2072668. Age (continuous variable) and its logit 
transformation are not related significantly (p=0.120), therefore they are linearly related 
confirming that this logistic regression is valid.  
Table  4.8:  Logistic  regression  analysis  on  hOGG1  genotype  and  relationship  to  pancreas  cancer  susceptibility  
  
B Sig. 
Odds 
ratio 
95% C.I. for odds 
ratio 
  Lower Upper 
 Female Gender -0.524 0.100 0.592 0.317 1.105 
Age  0.037 .008 1.038 1.010 1.067 
FHP 0.381 .232 1.464 .783 2.736 
Present smoker 2.059 .000 7.840 3.196 19.231 
Past smoker 1.570 .001 4.807 1.962 11.774 
rs2072668 Carriers of 
variant allele 
-.020 .952 .980 .511 1.878 
Constant -.568 .233 .567   
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Section	  4.2:	  XRCC1	  (Arg399Gln)	  rs25487	  
4.2.1 Overall association between genotype and case-control status 
  
The frequencies of the individual genotypes are depicted in Table 4.9. Both cases and 
controls were in Hardy-Weinberg equilibrium, cases (X2  =0.05, p=0.823), controls (X2 
= 0.68, p=0.409) and the overall frequencies for the major allele was 406 (65.48%) and 
minor allele 214 (34.52%). The allele frequencies amongst cases were major allele 196 
(64.9%) and minor allele 106 (35.1%). Amongst controls this was 210 (66.04%) and 
108 (33.9%) respectively. 
Table  4.9:  XRCC1Arg399Gln  genotype  frequency  
Case Control Frequency Percent 
Case Missing 13 7.9 
Homozygous Mutant 18 11.0 
Heterozygous 70 42.7 
Homozygous wild-type 63 38.4 
Total 164 100.0 
Control Missing 17 9.7 
Homozygous Mutant 16 9.1 
Heterozygous 76 43.2 
Homozygous wild-type 67 38.1 
Total 176 100.0 
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Excluding missing values, the frequency of the variant allele amongst controls; 108/318 
=33.9%, which is almost identical to the previously reported 34.7% (95% CI: 33.8 to 
35.6) (Hu et al., 2005). 
For further analysis, homozygous mutants and heterozygous carriers were combined 
into a single carrier group. Table 4.10 summarizes the overall frequencies.  
Table  4.10:  XRCC1  Arg399Gln  genotype:  Variant  allele  carriers  compared  with  homozygous  wild  types  
Case Control 
XRCC399HetMutant 
Carriers of variant allele Homozygous wild-type Total 
 Case 88 63 151 
Control 92 67 159 
Total 180 130 310 
 
No significant associations were apparent (Fisher’s test p = 1.000). Overall odds ratio 
for pancreatic cancer with the XRCC1 399 variant genotype was 1.017 (95% CI 0.648 
to 1.598).  
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4.2.2 Gender sub-group analysis: 
 
The influence of gender on the risk for pancreas cancer amongst the individual XRCC1 
399 genotype was assessed and the frequencies are shown in Table 4.11 
  
Table  4.11:  XRCC1  Arg399Gln  Genotypes  -­‐  effect  of  gender  
Gender 
XRCC1 Arg399Gln 
Carriers of variant 
allele 
Homozygous wild-
type Total 
Female  Case 42 25 73 
Control 48 35 94 
 Total 90 60 167 
Male  Case 46 38 91 
Control 44 32 82 
 Total 90 70 173 
 
No significant associations was discerned between the combined group and the wild-
type genotype in the gender sub-groups (female Fisher’s test p = 0.616, male Fisher’s 
test p=0.750) 
Estimating risk for female gender for pancreatic cancer; odds ratio = 1.125 (95% CI 
0.633 to 2.369), while that for males was 0.880 (0.471 to 1.647). 
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4.2.3 Age sub-grouping 
  
Table 4.12 shows data subdivided into age groupings – less than 65 years or above 65 
years across genotype categories. 
Table  4.12:  XRCC1  ARg399Gln  genotype  -­‐  effect  of  age  
 
XRCC1 Arg399Gln  
Carriers of variant 
allele 
Homozygous wild-
type Total 
65 years  Case 39 28 67 
Control 38 26 64 
 Total 77 54 131 
> 65 years  Case 49 35 84 
Control 54 41 95 
 Total 103 76 179 
 
No significant association is seen between age sub-groups and case-control status ( 65 
years Fisher’s test p=1.000, > 65 years Fisher’s test p=0.880).  
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4.2.4 Smoking status 
  
The effect of tobacco smoking was assessed by cross-tabulating smoking category and 
genotype. The frequencies across genotype sub-groups are shown in Table 4.13. 
  
Table  4.13:  XRCC1  Arg399Gln  -­‐  Smoking  status  
 
XRCC1 Arg399Gln  
Carriers of 
variant allele 
Homozygous 
Wild-type Total 
Present-smoker Case 27 19 49 
Control 26 22 53 
Total 53 41 102 
Past-smoker Case 29 26 59 
Control 33 30 72 
Total 62 56 131 
Non-smoker Case 28 14 46 
Control 20 8 31 
Total 48 22 77 
 
There were no significant associations seen between case/controls and genotype in all 
sub-groups based on smoking status [Fisher’s test; present smokers p = 0.755; past 
smokers p = 0.602 and non- smokers p = 0.937]. 
Estimating risk for the polymorphism; for present smokers overall OR (95% CI) = 
1.202 (0.531 to 2.721); for past smokers overall OR = 1.014 (0.491 to 2.092) and for 
non-smokers overall OR = 0.800 (0.282 to 2.266).  
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4.2.5 Smoking Intensity 
  
The effect of tobacco smoking was also explored by grouping based on tobacco 
smoking intensity - Light smokers =  40 pack-years, heavy = > 40 pack-years 
cumulative tobacco exposure.  
  
Table  4.14:  XRCC1  ARg399Gln  -­‐  effect  of  smoking  intensity  
 
XRCC399HetMutant 
Total 
Carriers of variant 
allele  
Homozygous wild-
type 
Light  Case 27 23 50 
   Control 15 11 26 
      Total 42 34 76 
Heavy  Case 57 36 93 
   Control 64 49 113 
      Total 121 85 206 
 
Cross tabulation reveals no association between genotype and case-control status 
amongst the smoking intensity sub-groups (Fisher’s test, Light smokers p =0.811 and 
Heavy Smokers p = 0.569). Estimating the overall odds ratio for each smoking strata 
that for light smokers was 0.861 (95% CI 0.331 to 2.240) and that for heavy smokers 
1.212 (95% CI 0.693 to 2.120). 
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4.2.6 Family history of malignancy  
  
Performing family history of cancer sub-group analysis, in individuals who had valid 
and complete data for this history, we obtain Table 4.15. Incomplete history was 
obtained from n=92 (cases 28, controls n=64) and these individuals were excluded from 
this analysis. 
  
Table  4.15:  XRCC1  Arg280His  -­‐  effect  of  family  history  of  malignancy  
 
 
 
No significant associations (Fisher’s test) were seen amongst genotype and case-control 
status in the FHP (p=0.525) and FHN (p=0.711) sub-groups. Estimating risk for 
pancreas cancer amongst FHP, OR = 0.747 (0.316 to 1.768) and amongst FHN, OR = 
0.823 (0.398 to 1.703).
 
XRCC1 Arg399Gln  
Total Carriers of 
variant allele 
Homozygous wild-
type 
FHP 
 
              Case 37 27 64 
          Control 22 12 34 
                     Total 59 39 98 
FHN 
 
           Case 33 26 59 
        Control 37 24 61 
                       Total 70 50 120 
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4.2.7 Binary Logistic regression: 
We performed binary logistic regression (n=206) to ascertain the effect of individual 
variables – age at recruitment, gender, smoking status, tobacco exposure, family history 
status and genotype – on risk for pancreatic cancer. Individuals with missing/incomplete 
data were excluded from the regression analysis.  
The Hosmer Lemeshow test gave a X2= 8.842 (p=0.356) indicating a good fit of the data 
to the model. Also the model was statistically significant X2 = 36.091 p=0.0009. The 
model explained 21.7% (Nagelkerke R2 = 0.217) of variance in the development of 
pancreatic ductal adenocarcinoma and correctly classified 69.4% of cases. Sensitivity 
was 87.8%, specificity was 42.2%, positive predictive value was 64.1% and negative 
predictive value was 70 %. Of the 5 predictor values only age and smoking status were 
significant – Table 4.16. Increasing age was associated with risk of pancreatic cancer, 
both present and past smokers were at increased risk but no specific risk was associated 
with the variant allele for XRCC1Arg399Gln. Age (the only continuous variable) and 
its logit transformation are not related significantly (p=0.154), therefore they are 
linearly related confirming that this logistic regression is valid.  
Table  4.16:  Logistic  regression  for  XRCC1  Arg399Gln  for  susceptibility  to  pancreatic  cancer  
 
 
B Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
 Age .889 .142 2.433 .743 7.966 
Female Gender -.438 .167 .645 .346 1.202 
FHP .288 .368 1.334 .712 2.498 
Present Smoker 2.089 .000 8.077 3.293 19.814 
Past Smoker 1.578 .001 4.843 1.979 11.853 
XRCCArg399GlnHomozygous mutant .347 .526 1.415 .484 4.141 
XRCCArg399Gln Heterozygous  -.109 .748 .897 .462 1.741 
Constant -
12.974 
.073 .000   
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Section	  4.3	  XRCCArg194Trp	  rs1799782	  
4.3.1: Overall association between genotype and case-control status. 
Table 4.17 depicts the frequencies of the alleles of XRCC1 Arg194Trp in our study 
population. There were 28 individuals in whom this genotype could not be determined. 
For the population (n=312) the individual genotypes were in Hardy-Weinberg 
equilibrium, cases (X2 = 0.59 , p=0.442) and controls (X2 =0.29, p=0.590) with overall 
frequencies of major allele being 393 (92.69%) and 31 (7.31%). For cases the major 
allele frequency was 292 (94.16%) and minor allele frequency was 18 (5.81%) whilst 
amongst controls this was 301 (95.86) and 13 (4.14%). 
Table  4.17:  XRCC1  Arg194Trp  genotype  frequencies  
Case Control Frequency Percent 
Case Missing 9 5.5 
Wild-type 137 83.5 
Heterozygous 18 11.0 
Total 164 100.0 
Control Missing 19 10.8 
Wild-type 144 81.8 
Heterozygous 13 7.4 
Total 176 100.0 
 
The heterozygote genotype frequency amongst controls (13/312 = 4.16%) is close to 
that found in Caucasians [6.6%; (95% CI: 5.9–7.4)] (Schneider et al., 2008). No 
homozygous mutants were detected in either group. As shown in Table 4.18, no overall 
significant association was seen (Fisher’s test p = 0.349) with overall odds ratio for 
pancreatic cancer 1.455 (95% CI 0.687 to 3.083).  
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Table  4.18:  XRCC1  Arg194Trp  genotypes  -­‐  frequencies  amongst  cases  and  controls  
  XRCC1 Arg194Trp   
  
Carriers of variant allele 
Homozygous Wild-
type Total 
 Case 18 137 155 
Control 13 144 157 
 Total 31 281 312 
	  
4.3.2 Sub-group analysis: Gender 
 
No association is seen on Fisher’s test female (p=0.773 and male p=0.134).  Overall 
odds ratio for female gender = 0.756 (95% CI 0.235 to 2.428) and that for males = 
2.392 (0.811 to 7.058). These risks are not significant.  
Table  4.19:  XRCC1  Arg194Trp  -­‐  effect  of  gender  
 
XRCC1 Arg194Trp   
Carriers of 
variant allele 
Homozygous 
Wild-type Total 
Female  Case 5 62 67 
Control 8 75 83 
 Total 13 137 150 
Male  Case 13 75 88 
Control 5 69 74 
 Total 18 144 162 
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4.3.3 Age sub-groupings: 
  
With 65 years as a cut-off age subgroup analysis was performed and the data is shown 
in Table 4.20 and no significant association is seen on Fisher’s test (65 years p=0.103, 
> 65 years p=0.797). 
Table  4-­‐20:  XRCC1  Arg194Trp  -­‐  effect  of  age  
 
XRCC1 Arg194Trp   
Carriers of 
variant allele 
Homozygous 
wild-type Total 
65 years  Case 11 59 70 
Control 4 60 64 
 Total 15 119 134 
> 65 years  Case 7 78 85 
Control 9 84 93 
 Total 16 162 178 
 
Calculating odds ratio for pancreatic cancer for individuals below 65 years of age we 
obtain 2.79 (95% CI 0.84 to 9.28) while that for those above 65 years of age is 0.83 
(0.29 to 2.35). These risk estimates are not significant. Although these risk estimates are 
not significant, the presence of the variant allele amongst the younger age group appears 
to suggest an increased predisposition to pancreatic cancer as compared to the older 
group. 
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4.3.4 Analysis by smoking status 
  
The impact of tobacco smoking and individual genotypes on risk for pancreatic cancer 
was explored and the data is shown in Table 4.21. 
Table  4.21:  XRCC1  ARg194Trp  -­‐  effect  of  smoking  status  
 
XRCC1 Arg194Trp  
Carriers of 
variant allele 
Homozygous 
Wild-type 
Total 
Present-smoker 
 
Case 10 70 80 
Control 6 55 61 
 Total 16 125 141 
Past-smoker 
 
Case 7 50 57 
Control 2 35 37 
 Total 9 85 94 
Non-smoker 
 
Case 1 7 8 
Control 4 37 41 
 Total 5 44 49 
 
No association of present, past and non-smoking statuses with genotype was found for 
disease risk (Fishers test p = 0.790, 0.474, 1.000 respectively). Estimating risk for 
pancreatic cancer in the various tobacco smoking exposure groups, the overall odds 
ratio (95% CI) for present smokers was 1.310 (0.448 to 3.825) for past smokers 2.450 
(0.480 to 12.501) and non-smokers 0.147 (0.015 to 1.374) all of which were not 
significant.  
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4.3.5 Smoking intensity 
  
The impact of tobacco smoking and genotype for XRCC1 194 was also assessed by 
subdividing individuals based on tobacco smoking intensity and the frequencies in the 
groupings (light = 40 pack-years and heavy = >40 pack-years) as shown in Table 4.22. 
 
Table  4.22:  XRCC1  Arg194Gln  -­‐  effect  of  tobacco  smoking  intensity  
 
XRCC1 Arg194Trp  
Total 
Carriers of variant 
allele 
Homozygous 
Wild-type 
Light  Case 4 47 51 
Control 2 23 25 
Total 6 70 76 
Heavy  Case 13 81 94 
Control 10 104 114 
Total 23 185 208 
 
No significant associations were seen for case-control status amongst light  (Fishers test 
p= 1.000) and heavy smokers (Fishers test p=0.272). Odds ratio (95% CI) for pancreatic 
cancer for light smokers was 0.979 (0.167 to 5.741) and that for heavy smokers was 
1.669 (0.696 to 4.000) which are not significant.  
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4.3.6 Analysis for family history sub groups: 
Table 4.23 depicts the frequencies of the individual genotypes for XRCC1 194 and 
history of malignancy in the first-degree relatives of the study population. Full family 
history was available for 205 individuals. 
Table  4.23:  XRCC1  Arg194Trp  -­‐  effect  of  family  history  of  malignancy  
Family history of cancer 
Case Control 
Case Control Total 
FHP 
Homozygous Wild-type 55 32 87 
Carriers of variant allele 11 1 12 
Total 66 33 99 
FHN 
Homozygous Wild-type 54 42 96 
Carriers of variant allele 6 4 10 
Total 60 46 106 
 
No significant associations are seen for case-control status among the family history 
groupings (FHP, Fishers test p=0.056 and FHN, Fishers test p=1.000). 
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4.3.7 Logistic regression model: 
Logistic regression was performed excluding incomplete and missing values (amongst 
genotype, age, gender, family history and smoking status) to ascertain the impact of 
these variables on the likelihood of developing pancreatic ductal adenocarcinoma. The 
total numbers of cases included was 207 (Table 4.24). The Hosmer Lemeshow test gave 
a X2= 5.448 (p=0.709) indicating a good fit of the data to the model. Also the model 
was statistically significant X2 = 42.487, p=0.000004. Age (the only continuous 
variable) and its logit transformation were not related significantly (p=0.868), 
confirming that this logistic regression is valid. 
The model explained 25.1 % (Nagelkerke R2 = 0.251) of variance in the development of 
pancreatic ductal adenocarcinoma and correctly classified 72 % of cases. Sensitivity 
was 91.1%, specificity was 43.4 %, positive predictive value was 70.6% and negative 
predictive value was 76.59 %. Of the 5 predictor values only age and smoking status 
were significant – Table 4.24. Increasing age was associated with risk of pancreatic 
cancer, both present and past smokers were at increased risk but no specific risk was 
associated with the variant allele for XRCC1 Arg148Trp genotype.  
Table  4.24:  Logistic  regression  on  XRCC1  Arg194Trp  genotype  and  relationship  to  pancreatic  cancer  susceptibility  
 
B Sig. 
Odds 
ratio 
95% C.I. for Odds 
ratio 
Lower Upper 
 Age .751 .251 2.119 .588 7.636 
Female Gender -.553 .087 .575 .306 1.083 
FHP .284 .379 1.328 .706 2.498 
Present Smokers 2.236 .000 9.359 3.676 23.829 
Past Smokers 1.818 .000 6.157 2.416 15.695 
XrCC1 Arg194Trp Het -.349 .505 .706 .253 1.968 
Constant -10.949 .162 .000   
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Section	  4.4	  XRCC	  1	  Arg280His	  
4.4.1 Overall association between genotype and case-control status  
  
The frequencies of the individual genotypes are depicted in Table 4.25. Both the cases 
(X2 = 0.93, p=0.334) and controls (X2 = 0.37, p=0.543) were in Hardy-Weinberg 
equilibrium and the overall allele frequencies were major allele 593 (94.42%) and minor 
allele 35 (5.57%). The allele frequencies amongst cases were major allele 294 (94.83%) 
and minor allele 16 (5.16%), amongst controls they were 299 (94.09%) and 19 (5.97%) 
respectively. 
Table  4.25:  XRCC1  Arg280His  genotype  frequencies  amongst  cases  and  controls  
  Case Control 
Total   Case Control 
 
XRCC1 
Arg280His 
 
Missing 9 17 26 
Homozygous Mutant 1 1 2 
Heterozygote 14 17 31 
Homozygous wild-type 140 141 281 
                         Total 164 176 340 
 
Combining heterozygotes and mutants into a combined group and ignoring missing 
values, we obtain Table 4.26. 
Table  4.26:  XRCC1  Arg280His  -­‐  variant  allele  risk  for  pancreatic  cancer  
  XRCC1 Arg280His 
Total 
  
Carriers of variant allele 
Homozygous wild-
type 
 Case 15 140 156 
Control 18 141 156 
        Total 33 281 314 
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No significant association between case/control status and genotype was seen (Fisher’s 
test p=0.714). Overall odds ratio for the variant allele for pancreatic cancer was 0.839 
(95% CI 0.407 to 1.731). 
 
4.4.2 Gender subgroup analysis:  
 
The impact of gender and genotype for XRCC1 Arg280His on risk for pancreatic cancer 
was explored, and the data is shown in Table 4.27. 
 
Table  4.27:  XRCC1  Arg280His  -­‐  effect  of  gender  
Gender 
XRCC1 Arg280His   
Carriers of variant 
allele 
Homozygous 
wild-type Total 
Female  Case 7 64 71 
Control 9 74 83 
 Total 16 138 154 
Male  Case 8 76 84 
Control 9 67 76 
 Total 17 143 160 
 
There were no significant associations between genotype and case/control status in 
either gender subgroups (Fisher’s test; Female gender: p = 1.000; Male gender: 0.798). 
Overall odds ratio for female gender for pancreatic cancer was 0.899 (95% CI 0.317 to 
2.552) while that for male gender was 0.784 (95% CI 0.286 to 2.146). 
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4.4.3 Age category subgrouping  
  
In order to ascertain if there were any particular age groups, which were associated with 
the mutant allele, we grouped our patients with 65 years as a cut off point into 2 groups 
The data re shown in Table 4.28. 
Table  4.28:  XRCC1  Arg280His  -­‐  effect  of  age  
 
Case Control  
Case Control Total 
 65 years 
 Carriers of variant allele 8 8 16 
Homozygous wild-type 60 56 116 
 Total 68 64 132 
>65 years 
 Carriers of variant allele 7 10 17 
Homozygous wild-type 80 85 165 
 Total 87 95 182 
 
No significant associations were seen in either the up to 65 years group (Fishers test p= 
1.000) or in the above 65 years group (Fisher’s test p = 0.618) between genotype and 
case/control status. The less than 65 years age group demonstrated an odds ratio for 
pancreatic cancer of 0.933 (95% CI 0.328 to 2.655) while that for those above 65 years 
was 0.744 (95% CI 0.270 to 2.048).  
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4.4.4 Smoking exposure sub groups 
The influence of tobacco smoking and genotype for XRCC1 Arg280His on risk for 
pancreas cancer was assessed and the data is shown in Table 4.29. Incomplete data was 
found in 28 samples and these were excluded from this analysis. 
Table  4.29:  XRCC1  ARg280His  -­‐  effect  of  smoking  status  
 
  
Case Control Total 
Present-smoker  Carriers of variant allele 12 8 20 
Homozygous wild-type 69 53 122 
 Total 81 61 142 
Past-smoker  Carriers of variant allele 2 3 5 
Homozygous wild-type 54 35 89 
 Total 56 38 94 
Non-smoker  Carriers of variant allele 0 2 2 
Homozygous wild-type 10 38 48 
 Total 10 40 50 
 
No significant associations were demonstrated for the different smoking statuses 
(Fisher’s test; present smokers p = 0.812, past smokers p = 0.390, non-smokers 
p=1.000). Odds ratios (95% CI) for the variant genotype amongst the respective 
smoking statuses were 1.152 (0.440 to 3.020), 0.432 (0.069 to 2.718) and 1.283 (1.09 to 
1.460). 
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4.4.5 Smoking intensity 
  
The influence of tobacco smoking was explored by assessing intensity of smoking and 
genotype for XRCC1 ARg280His and the data is shown in Table 4.30. 
Table  4.30:  XRCC1  Arg280His  -­‐  effect  of  intensity  of  tobacco  smoking  
 
Case Control 
Total Case Control 
Light (SN\UV	    Carriers of variant allele 4 4 8 Homozygous wild-type 47 22 69 
Total 51 26 77 
Heavy 
(>40 pkyrs) 
 Carriers of variant allele 10 9 19 
Homozygous wild-type 86 104 190 
Total 96 113 209 
 
No significant associations were seen (Fishers test; light smokers p = 0.431, heavy 
smokers = 0.631). Odds ratio for pancreatic cancer for light smokers = 0.468 (95% CI 
0.107 to 2.047) and for heavy smokers = 1.344 (95% CI 0.522 to 3.456). 
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4.4.6 Family history sub groupings 
The impact of a family history of malignancy and genotype for XRCC1 Arg280His and 
risk for pancreatic cancer was explored and the frequencies of the data are shown in 
Table 4.31. A family history was unavailable in n = 92 individuals and they were 
excluded from this analysis. 
Table  4.31:  XRCC1  Arg280His  -­‐  effect  of  family  history  of  malignancy  
 
Case Control  
Case Control Total 
FHP 
 
Carriers of variant allele 6 2 8 
Homozygous Wild-type 62 32 94 
 Total 68 34 102 
FHN 
 
Carriers of variant allele 8 6 14 
Homozygous Wild-type 51 55 106 
 Total 59 61 120 
 
No significant association was seen between genotype and family history of cancer for 
pancreatic cancer risk (Fishers test; FHP p= 0.715; FHN p = 0.579). Odds ratio for 
pancreatic cancer risk for FHP was 1.548 (95% CI 0.296 to 8.113) and that for FHN 
was 1.438 (95% CI 0.467 to 4.429).  
 
 
	  
  
4.4.7 Logistic regression 
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Logistic regression was performed excluding incomplete and missing values (amongst 
genotype, age, gender, family history and smoking status) to ascertain the impact of 
these variables on the likelihood of developing pancreatic ductal adenocarcinoma. The 
total numbers of cases included was 210 (Table 4.32). The Hosmer Lemeshow test gave 
a X2= 5.640 (p=0.687) indicating a good fit of the data to the model. Also the model 
was statistically significant X2 = 37.317 p=0.0000005. Age (continuous variable) and its 
logit transformation are not associated significantly (p=0.206), confirming that this 
logistic regression is valid. 
The model explained 22 % (Nagelkerke R2 = 0.220) of variance in the development of 
pancreatic ductal adenocarcinoma and correctly classified 70.5% of cases. Sensitivity 
was 88.2%, specificity was 43.4%, positive predictive value was 70.4% and negative 
predictive value was 70.58 %. Of the 6 predictor values only age and smoking status 
were significant – Table 4.32. Increasing age was associated with risk of pancreatic 
cancer, both present and past smokers were at increased risk but no specific risk was 
associated with the variant allele for XRCC1Arg399Gln.  
Table  4.32:  Logistic  regression  on  XRCC1  Arg280His  and  relationship  to  pancreatic  cancer  susceptibility  
 
B Sig. Odds ratio 
95% C.I.for Odds 
ratio 
Lower Upper 
 Age .029 .027 1.030 1.003 1.057 
Female Gender -.443 .156 .642 .348 1.185 
FHP .407 .193 1.502 .814 2.770 
Present Smoker 2.049 .000 7.760 3.217 18.719 
Past Smoker 1.530 .001 4.619 1.913 11.150 
XRCC1 ARg280His Het .648 .296 1.912 .567 6.448 
Constant -2.953 .002 .052   
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Section	  4.5:	  	  APE1	  Asp148Gln	  rs1130409	  
Table 4.33 shows the frequency of the individual genotypes for APEAsp148Gln. There 
were 30 individuals with missing genotype data. The population under study was in 
Hardy-Weinberg equilibrium; cases (X2 =0.38, p=0.537), controls (X2=0.41, p=0.522) 
and the overall frequencies for the major allele 299 (48.23%) and minor allele 321 
(51.77%). The allele frequencies amongst cases were major allele 144 (47.37%) and 
minor allele 160 (52.63%), amongst controls this was 155 (49.05%) and 161 (50.95%) 
respectively. 
Table  4.33:  APE1  Asp148Gln  overall  frequencies  
APE1Asp148Gln genotype  
Case Control 
Case Control Total 
 Missing 12 18 30 
Homozygous wild-type 36 36 72 
Heterozygous 72 83 155 
Homozygous Mutant 44 39 83 
Total 164 176 340 
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4.5.1 Overall associations between genotype and case-control status  
  
As shown in Table 4.34, when heterozygotes and homozygous mutants are combined 
group as carriers of the variant allele, no significant associations are seen (Fishers test 
p=0.893); overall odds ratio for pancreatic cancer 0.951(95% CI 0.561 to 1.611).  
Table  4.34:  APE1  Asp148Gln  genotype  frequencies  amongst  cases  and  controls  
  APE1 Asp148Gln  
  Carriers of variant allele Homozygous wild-type Total 
Case 
Control 
Case 116 36 152 
Control 122 36 158 
 Total 238 72 310 
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4.5.2 Gender subgroup and risk  
  
As shown in Table 4.35, there were no significant differences (Fisher’s test) between 
genotype groupings for the female (p= 0.571) and male gender (p=0.333). Amongst 
females; odds ratio for pancreatic cancer for pancreas cancer was 1.329 (95% CI 0.628 
to 2.810) and amongst males it was 0.639 (95% CI 0.294 to 1.387).  
 
Table  4.35:  Ape1  Asp148Gln  -­‐  gender  sub-­‐grouping  
 
APE1 Asp148Gln  
Carriers of variant allele Homozygous Wild-type Total 
Female  Case 52 15 67 
Control 60 23 83 
 Total 112 38 150 
Male  Case 64 21 85 
Control 62 13 75 
 Total 126 34 160 
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4.5.3 Age sub-group and risk 
  
We divided our patients into a less than 65 years and above 65 years to assess risk in 
age sub-groups and the frequencies are shown in Table 4.36. 
Table  4.36:  APE1  Asp148Gln  -­‐  age  sub-­‐grouping  
 
APE1 Asp148Gln   
Carriers of variant allele Homozygous Wild-type Total 
65 yrs 
 
 Case 46 19 65 
Control 48 17 65 
 Total 94 36 130 
>65 yrs 
 
 Case 70 17 87 
Control 74 19 93 
 Total 144 36 180 
 
There was no significant association between genotype and pancreas cancer status in 
either age-group (Fisher’s test;  65 years; p=0.844, > 65 years; p=1.000). Odds ratio 
for pancreatic cancer was 0.857 (95% CI 0.397 to 1.850) in the younger age group and 
1.057 (95% CI 0.509 to 2.197) in the older age group. 
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4.5.4 Smoking subgroups and risk 
  
There were 28 (8 cases and 20 controls) individuals with incomplete smoking exposure 
information and these have been excluded from further analysis. Table 4.37 shows the 
frequencies of the individual sub-groups. 
Table  4.37:  APE1  Asp148Gln  -­‐  smoking  status  groups  
 
APE1 Asp148Gln   
Carriers of variant 
allele 
Homozygous wild-
type 
Total 
Present-smoker 
 
Case 59 21 80 
Control 51 10 61 
 Total 110 31 141 
Past-smoker 
 
Case 41 13 54 
Control 26 11 37 
 Total 67 24 91 
Non-smoker 
 
Case 9 1 10 
Control 33 7 40 
 Total 42 8 50 
 
There was no significant association in the individual smoking exposure sub-groups 
between genotype and case/control status (Fisher’s test): present smokers p = 0.218, 
past smokers p = 0.630 and non-smokers p = 1.000. The odds ratio for pancreatic cancer 
risk with this polymorphism for the individual smoking statuses was as follows: present 
smokers 0.551 (95% CI 0.238 to 1.278), past-smokers 1.334 (95% CI 0.521 to 3.420) 
and non-smokers 1.909 (95% CI 0.207 to 17.598).  
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4.5.5 Smoking intensity 
 
As shown in Table 4.38, when the risk for light (up to 40 pack-years) and heavy (more 
than 40 pack-years) smoker’s was examined, no significant association was found 
(Fisher’s test; light smokers p = 1.000, heavy smokers p = 0.597). 
Table  4.38:  APE1  Asp148Gln  -­‐  smoking  intensity  sub-­‐groups  
 
APE1 Asp148Gln   
Carriers of variant 
allele 
Homozygous wild-
type 
Total 
Light 
 
Case 35 15 50 
Control 18 8 26 
 Total 53 23 76 
Heavy 
 
Case 74 20 94 
Control 92 20 112 
 Total 166 40 206 
 
The odds ratio with this polymorphism for pancreatic cancer for light smokers was 
1.037 (95% CI 0.370 to 2.903) and that for heavy smokers was 0.804 (95% CI 0.403 to 
1.606). 
     151  
4.5.6 Family history sub groups and risk 
  
A total of n=102 (cases 29, controls 63) individuals did not have a full family history 
and these were excluded from this analysis. Table 4.39 shows the frequencies of the 
individual sub-groups. 
Table  4.39:  APE1  Asp148Gln  -­‐  family  history  of  cancer  sub-­‐groups  
 
APE1 Asp148Gln   
Carriers of variant 
allele 
Homozygous wild-
type 
Total 
FHP 
 
Case 53 11 64 
Control 26 8 34 
 Total 79 19 98 
FHN 
 
Case 40 19 59 
Control 47 14 61 
 Total 87 33 120 
 
There was no significant association between genotype and case/control status amongst 
those who had a history of cancer in their family (FHP, Fisher’s test p = 0.592) and 
amongst those who did not have this history (FHN, Fisher’s test p=0.308). Estimating 
risks, overall odds ratio for pancreatic cancer with this polymorphism for FHP = 1.483 
(95% CI 0.532 to 4.130) and that for FHN = 0.526 (95% CI 0.211 to 1.310). 
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4.5.7 Logistic regression: 
Logistic regression was performed excluding incomplete and missing values (amongst 
genotype, age, gender, family history and smoking status) to ascertain the impact of 
these variables on the likelihood of developing pancreatic ductal adenocarcinoma. The 
total numbers of cases included was 229 (Table 4.40). The Hosmer Lemeshow test gave 
a X2= 5.148 (p=0.742) indicating a good fit of the data to the model. Also the model 
was statistically significant X2 = 39.19, p=0.0000002. Age (the only continuous 
variable) and its logit transformation are not related significantly (p=0.871), confirming 
that this logistic regression is valid. 
The model explained 23.4 % (Nagelkerke R2 = 0.234) of variance in the development of 
pancreatic ductal adenocarcinoma and correctly classified 69.4 % of cases. Sensitivity 
was 86.2%, specificity was 44.6 %, positive predictive value was 69.73 % and negative 
predictive value was 68.51 %. Of the 5 predictor values only age and smoking status 
were significant – Table 4.40. Increasing age was associated with risk of pancreatic 
cancer, both present and past smokers were at increased risk but no specific risk was 
associated with the variant allele for APE Asp148Gln genotype.  
Table  4.40:  Logistic  regression  on  APE1  Asp148Gln  and  relationship  to  pancreatic  cancer  susceptibility  
 
B Sig. 
Odds 
ratio 
95% C.I. for 
Oddds ratio 
Lower Upper 
 Age .034 .013 1.035 1.007 1.063 
Female Gender -.564 .076 .569 .305 1.061 
FHP .262 .410 1.300 .697 2.427 
Present Smoker 2.085 .000 8.041 3.340 19.363 
Past Smoker 1.526 .001 4.598 1.889 11.188 
APE Asp148Gln variant allele -.431 .270 .650 .302 1.397 
Constant -2.844 .004 .058   
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Section	  4.6	  Logistic	  regression	  including	  all	  genotypes	  
A model which included variables known to influence risk for pancreas cancer like age, 
gender, family history of cancer, tobacco smoking and the genotypes under 
investigation which had been analysed in our study population was tested to ascertain 
the combined effects of these factors. For this model we only included individuals who 
had valid data with regard to the variables incorporated. There were 192 individuals in 
total. 
The Hosmer Lemeshow test gave a X2= 7.128 (p=0.523) indicating a good fit of the 
data to the model. Also the model was statistically significant X2 = 40.85, p=0.000005. 
Age (the only continuous variable) and its logit transformation are not related 
significantly (p=0.326), confirming that this logistic regression is valid.  
The model explained 25.3 % (Nagelkerke R2 = 0.253) of variance in the development of 
pancreatic ductal adenocarcinoma and correctly classified 70.3 % of cases. Sensitivity 
was 87.7%, specificity was 44.9 %, positive predictive value was 69.93 % and negative 
predictive value was 71.42  %. Of the 9 predictor values only age and smoking status 
were significant – Table 4.41. 
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Table  4.41:  Logistic  regression  including  all  studied  genotypes  and  risk  for  pancreatic  cancer  
  
 
B Sig. 
Odds 
ratio 
95% C.I. for  
Odds ratio 
Lower Upper 
 Age .031 .046 1.032 1.001 1.064 
Female Gender -.718 .032 .488 .253 .940 
FHP .219 .521 1.245 .638 2.428 
Present Smoker 2.144 .000 8.531 3.198 22.759 
Past Smoker 1.769 .000 5.862 2.223 15.460 
APE1Asp148Gln variant allele -.136 .774 .873 .345 2.207 
hOGG1 (rs2072668)  variant 
allele 
1.242 .222 3.461 .472 25.388 
XRCC1Arg280His variant 
allele 
.708 .275 2.031 .569 7.253 
XRCC1Arg399Gln variant 
allele 
-.011 .986 .989 .304 3.220 
XRCC1Arg194Trp variant 
allele 
-.208 .699 .812 .283 2.329 
Constant -3.915 .018 .020   
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CHAPTER	  5:	  MAIN	  FINDINGS	  AND	  DISCUSSION	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Section	  5.1:	  Main	  findings	  
The main findings from this study are 
1. Tobacco smoking is a risk factor for pancreatic cancer 
a. The risk for an ever smoker (current and ex) for the development of 
pancreatic cancer is nearly 3 times that of a non-smoker [OR 3.01 (95% 
CI 1.73 to 5.24)]. 
b. Amongst pancreatic cancer cases, there was a significantly decreased 
cumulative tobacco exposure in the caFDR+ group (p=0.023) as 
compared to the caFDR- group: the overall cumulative pack-years of 
smoking was 32.79 (24.77) in the caFDR+ versus 45.69 (24.56) in the 
caFDR- group. 
2. No significant major overall risks were associated with the individual genotypes 
for the various BER genes that were typed both individually and when all 
genotypes were grouped into a single model (Binary logistic regression). 
3. On multi-variate analysis which included variables known to influence risk for 
pancreas cancer – age, tobacco smoking and the factors under consideration – 
family history of malignancy and the individual genotypes under investigation;  
a. Tobacco smoking showed an increased risk – present smokers exhibited 
an OR = 8.531 (3.198 to 22.759) and past smokers demonstrated an OR 
= 5.862 (2.223 to 15.460).  
b. Increasing age appeared to increase risk [OR (95% CI) = 1.032 (1.001 to 
1.064)] but this could be a result of the design of the study rather than a 
significant finding. 
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Section	  5.2	  Discussion:	  
In this prospective case-control study, we have included 164 cases of pancreatic ductal 
adenocarcinoma and compared them with 176 hospital-based controls. The vast 
majority of cases included (74%) were histologically/cytologically diagnosed, 42 (26%) 
were deemed to have pancreatic ductal adenocarcinoma on the basis of a combination of 
the presence of a progressive pancreatic mass (on serial imaging and or rising tumour 
markers in the presence of a compatible history). Logistical and research funding 
limitations meant that a population based control group could not be recruited and 
therefore a hospital based group was decided upon. Smoking exposure and family 
history data was recorded by personal interview of the subjects by one single 
investigator and data recorded concurrently on to an electronic database. Several 
limitations of this data collection are important to note – no usable alcohol exposure 
data was collected; family history data was deficient in that ages of onset of cancer in 
the FDR’s, the total number of FDR’s in the family and their current health status were 
not recorded. Therefore person life-years of risk have not been able to be calculated. 
Due to limitations of available time enough prospective controls could not be recruited 
and historical controls n=50 from a former study were included. Although demographic 
and tobacco smoking data for these historical controls was available detailed tobacco 
exposure data and family history of cancer information was not obtainable. Therefore 
the analysis of tobacco smoking, family history of malignancy and their interaction 
(Chapter 3) as risks for pancreatic cancer data suffer from a preponderance of cases 
(n=134) as compared to controls (119). All genotyping data included 164 cases and 176 
controls.  
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5.2.1 Family history and tobacco exposure 
  
It has been observed from epidemiological studies that the first-degree relatives of 
sporadic cancer patients have a 2 to 3-fold higher risk of developing cancer at the same 
site and this has also been described for pancreatic cancer but only in retrospective 
studies (Del Chiaro et al., 2007, Ghadirian et al., 2002, McWilliams et al., 2005b). In a 
prospective observational study Teresmette et al (Tersmette et al., 2001) showed that 
relatives of familial pancreatic cancer patients had a higher risk of developing 
pancreatic cancer. The PCs occurred in relatives who were usually living in different 
communities during their adult lives, and the cancers occurred in the sixth or greater 
decade of life and therefore the suggestion was that this increased risk had a genetic 
basis rather than the result of shared environmental exposure.  
Familial clustering observed in certain sporadic cancers without obvious Mendelian 
inheritance suggests that there is a genetic component in addition to environmental 
factors (Li, 1990). This could be explained on the basis that the family members with 
the similar genetic background are exposed to the differing environment and that this 
leads to the phenotypic manifestation of the disease. Analysis of genetic risk of cancer 
has shown that most non-hereditary, sporadic cancers develop in genetically 
predisposed individuals, this predisposition being the result of several low penetrant 
genes (Imyanitov et al., 2004, Houlston and Peto, 2004). These poorly (low) penetrant 
genes, which by themselves have small relative risks, by virtue of being common in the 
population, may have large population attributable risks (Del Chiaro et al., 2007).  
The interplay of environmental and genetic factors appears to play a critical role in the 
development of pancreatic cancer and this has been well described for its familial form 
(Brentnall, 2005). It is reasonable to suppose that the remaining cases of sporadic 
adenocarcinoma of pancreas, which form the majority, are due to gene-environment 
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interaction (GEI). These have been poorly characterized and therefore the majority of 
sporadic pancreatic cancers have been considered to have no identifiable cause and 
therefore no high-risk groups are identifiable. 
In our prospective hospital-based case-control study we have seen that pancreatic cancer 
patients smoked more than our control group and an ever-smoker individual had a 3-
times higher risk for the development of pancreatic cancer than a non-smoker. These are 
well-recognised findings. More importantly a family history of malignancy in first-
degree relatives appeared to decrease the amount of tobacco exposure (as measured by 
pack-years) required for the development of pancreatic cancer. The earlier onset of the 
disease was however not related to FDR status. In addition, however, there were other 
results; smokers on average developed the cancer about 6-7 years earlier than non-
smokers, which was independent of a family history of malignancy. This has been 
previously described on the basis of WHO cancer mortality data and SEER cancer 
incidence data (Raimondi et al., 2007).  However the findings from our study suffer 
from a limitation of non-availability of complete family history data, as mentioned 
above and therefore this finding has to be ignored. 
It is accepted that familial pancreatic cancer appears to develop at an earlier age as 
compared to its sporadic counterpart and tobacco exposure is the most important factor 
influencing the penetrance of the FPC gene (Brentnall, 2005). Smokers in FPC (James 
et al., 2004, Rulyak et al., 2003c) and in hereditary pancreatic cancer syndromes, 
specifically hereditary pancreatitis patients (Lowenfels et al., 2001) develop the disease 
about 10 years earlier demonstrating the interaction between an inherited susceptibility 
to cancer and an environmental carcinogen. A recent report has described gene-
environment interaction in a study of cases only, although the sample size was large 
(Yeo et al., 2009). From our study it appears that smokers who have a family history of 
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cancer develop the disease at a lower level of exposure. This might be due to continued 
or faster accumulation of genotoxic mutations secondary to a variety of factors, one of 
which might be an inefficient DNA repair mechanism. Other genetic and environmental 
factors might play a role and this will need further elucidating. For example, a recent 
report has shown an earlier age of onset of pancreatic cancer in those who had a high 
BMI during their teen and younger years (Li et al., 2009).  
The groups of index cases and controls with and without a family history of cancer were 
comparable given their similar age distribution and gender distribution.  We have 
obtained history of cancer in FDR from index cases and controls and it is known that 
such information is reliable and accurate especially with regard to FDRs (Murff et al., 
2004). The reliability of information obtained, however, decreases with regard to other 
relatives (Ziogas and Anton-Culver, 2003, Parent et al., 1997) and we have therefore 
restricted our study to data on first-degree relatives. It has been suggested that, if 
anything there is under reporting of family history of cancer especially with regard to 
colorectal neoplasms (Mitchell et al., 2004). Other details of the illness in the FDR such 
as age of onset (of the cancer in the relative obtained from the index case individual) is 
unreliable especially in older probands and we have therefore not utilised such data in 
our study (Parent et al., 1997). We have not performed genetic analysis in this group of 
patients to confirm that they are not familial cancers as most familial pancreatic cancers 
are not due to known mutations. It is likely that our patients represent sporadic 
malignancies due to the fact that there was no difference in the mean (SD) of the age at 
diagnosis of the index cases in the FDR+ and FDR- groups [65.93 (10.67) and 64.57 
(12.38) years].  
In the presence of a family history of any malignancy, irrespective of smoking, the risk 
for pancreatic cancer is double [OR 1.98 (95% CI: 1.15-3.38)].  In individuals with a 
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first-degree family history of malignancy (i.e. increased susceptibility), a decreased 
dose of an environmental carcinogen is sufficient to cause cancer [cumulative tobacco 
exposure in FDR+ = 32.79 (24.77) vs. FDR- = 45.69 (24.56) (Mann-Whitney test 
p=0.023) Table 3.5]. However due to non-availability of date on age of onset of 
malignancy in the FDR and the total number of FDR’s in the family, person-years of 
risk and standardized incidence ratios could not be calculated. Just under 2/3rds of 
FDR+ index cases (n=51; 65%) had just a single first-degree relative with malignancy. 
In the FDR+ group decreased tobacco exposure was required for the development of 
adenocarcinoma of the pancreas but this did not depend upon the number of relatives 
with malignancy, as the FDR>1 group did not demonstrate a significantly decreased 
cumulative tobacco exposure. It is well accepted that a family history of cancer is a risk 
factor for most cancer types. With respect to adenocarcinoma of the pancreas, a recent 
meta-analysis of seven case-control and two cohort studies involving 6,568 pancreatic 
adenocarcinoma cases concluded that a family history of adenocarcinoma of the 
pancreas conferred double the risk [1.80 (95% CI: 1.48-2.12)] for the disease in 
individuals with such a history compared to those without (Permuth-Wey and Egan, 
2008). A recent cohort study from the PanScan consortium (Jacobs et al.) and 
prospective follow-up of participants of Cancer Prevention Study-II (Jacobs et al., 2009)  
have suggested an association between family history of various cancers especially 
prostate cancer and pancreatic cancer.  
It is possible that the decreased tobacco dose demonstrated in the caFDR+ group is due 
to a genetic or other environmental factor which potentiates the genotoxic effect of 
tobacco derived carcinogen by either impairing the processing of tobacco derived 
carcinogen into inactive metabolites or causing the inefficient or incomplete repair of 
genetic damage induced by it.  
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5.2.2 SNP analysis  
  
In our cohort no overall statistically significant risk for hOGG1 (rs2072668), XRCC1 
Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, APE Asp148Gln genotypes and 
pancreatic cancer was detected.  
hOGG1 
  
The hOGG1 genotype studied did not confer any risk for pancreatic cancer. This is 
interesting as the 8-oxoguanine DNA glycosylase (OGG1) gene is a BER gene that 
removes oxidative DNA lesions (David et al., 2007) and it would appear that CC/CG 
genotype, combined with environmental exposure could increase susceptibility to 
pancreatic cancer. However although some functional studies suggest reduced repair 
function with variant alleles in hOGG1, the evidence is generally inconclusive (Weiss et 
al., 2005b). However recently it has been shown that the pancreatic adenocarcinoma cell 
line BxPC-3 is deficient in the repair of 8-OH-Gua relative to the non-malignant cell 
line AG11134. The deficient repair of 8-OH-Gua was shown to be associated with 
defects in expression levels and activity of hOGG1 since BxPC-3 cells exhibited 
undetectable level of hOGG1 and had severely down regulated hOGG1 mRNA(Nyaga 
et al., 2008). There is some clinical evidence in support of this finding from a hospital 
case–control study conducted at MD Anderson Centre in the United States, Li et al 
noted not only an increased risk for pancreas cancer with the CC/CG genotype, but also 
significantly reduced overall survival in patients with the OGG1 C315G (rs1052133) 
GG homozygous variant genotype (Li et al., 2007a). 
 The reason why this finding was not duplicated in our study might be due to the small 
numbers of individuals. The deficient oxidative repair capacity of the variant gene 
might be more apparent amongst smokers, as seen in the current study amongst current 
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smokers the risk for the variant genotype and pancreas cancer was 1.342 (0.656 to 
2.747) as compared to non-smokers [0.317 (0.071 to 1.407)]. 
Li etal also reported a weak interaction of the OGG1 CC/CG genotype with diabetes in 
pancreatic cancer(Li et al., 2007b). This group also found that XRCC2 Arg188His 
polymorphisms may be genetic modifiers for smoking-related pancreatic cancer(Jiao et 
al., 2008a). 
There is some evidence for the role of other genotype polymorphisms in pancreatic 
carcinogenesis too from other molecular epidemiological studies: the presence of 
XRCC2 Arg188His polymorphism modulates risk for pancreatic cancer amongst 
smokers (Jiao et al., 2008b); XPD gene polymorphisms – exon 10 Asp(312)Asn and 
exon 23 Lys(751)Gln polymorphisms influence risk for smoking associated 
adenocarcinoma of the pancreas (Jiao et al., 2007) and deletion polymorphism in 
GSTT1 is associated with an increased risk of adenocarcinoma of the pancreas amongst 
Caucasians (Duell et al., 2002a).  
XRCC1 Arg399Gln 
  
In our study genotype for XRCC1 Arg399Gln and its alleles did not demonstrate a 
significant risk for pancreatic cancer.  
 
On the basis of 6,120 lung cancer cases and 6,895 controls from 13 studies, skin 
malignancies (3 studies) and breast cancer (11 studies) no association between the 
399Gln allele and cancer risk was seen. However non-significant decreased risk of 
upper aero-digestive tract cancer and non-significant increased risk of bladder 
carcinoma for heterozygotes and mutants was detected. When risk was stratified by 
tobacco smoking for tobacco related cancers, the presence of the 399Gln allele seemed 
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to be associated with an increased risk of tobacco-related cancers among light smokers 
(OR  = 1.20, 95 % CI: 1.03-1.40), whereas it was associated with a decreased risk 
among heavy smokers (OR  = 0.81, 95 % CI: 0.64-1.04), with the effect being more 
prominent among carriers of the Gln/Gln genotype (OR  = 0.71, 95 % CI: 0.51, 0.99) 
(Hung et al., 2005a).  
A meta-analysis by Hung RJ et al (Hung et al., 2005b) observed a modification of the 
effect of XRCC1 399/399Gln genotype on risk for pancreas cancer by tobacco smoking. 
The mutant allele 399Gln is associated with higher mutagen sensitivity and DNA 
adduct levels (Wang et al., 2003, Lunn et al., 1999). One mechanism suggested is that 
increased levels of DNA damage from heavy smoking in Gln/Gln carriers may cause 
apoptosis during cell division rather than development of a clone of cancer cells. 
Another suggestion is that DNA damage causes up-regulation of DNA repair capacity 
and more efficient repair of nucleotide lesions. There is some evidence from some 
studies in support of these hypotheses (Wang et al., 2003, Nelson et al., 2002, van 
Zeeland et al., 1999).  
In a study of 309 cases of pancreatic adenocarcinoma and 964 population based 
controls, relative to never active or passive smokers with the Arg/Arg genotype, the 
age- and race-adjusted ORs (95% CIs) for heavy smoking (41 pack-years) were, for 
Gln/Gln or Arg/Gln genotypes in women 7.0 (2.4, 21) and men 2.4 (1.1, 5.0)] and for 
the Arg/Arg genotype in women 2.2 (0.73, 6.4) and men 1.5 (0.68, 3.2)] (Duell et al., 
2002b).  There was no overall association between genotype for XRCC1 Arg399Gln 
and pancreatic cancer. The suggestion here is that there is interaction between XRCC1 
399Gln and smoking that was stronger among women than men. However, these 
findings need to be confirmed in other studies, as the number of study subjects was 
small in the analysis exploring gene–environment interaction. 
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These results were not duplicated in our study population. Again our study population is 
very small and the numbers especially on gender and tobacco exposure sub-group 
analysis amongst the individual genotype categories of XRCC1 399 are not large 
enough to tease out these risks estimated on large population studies. In a hospital based 
study involving 101 cases and 307 controls very similar results to our own were found – 
non-significant decrease in risk for those carrying Gln/Gln genotype at XRCC1 
Arg399Gln site (OR 0.64, 95% CI 0.21 - 1.66, P = 0.30) compared with those having 
Arg/Arg genotypes, so no association between XRCC1 Arg399Gln genotype and 
pancreatic cancer risk (Wang et al., 2006a) was seen.   
XRCC1 Arg194Trp 
  
XRCC1 Arg194TRP did not demonstrate an overall association with development of 
pancreatic cancer. 
 
Previously published results have suggested either no association (Misra et al., 2003) or 
a protective effect on tobacco related cancers (Ratnasinghe et al., 2003) (Hung et al., 
2005a).  Mutagen sensitivity assays have suggested that the XRCC1 Arg194Trp variant 
allele has a protective effect on bleomycoin and BPDE-induced chromosomal damage 
i.e. less number of chromosomal breaks per cell on bleomycion and BPDE assays 
(Wang et al., 2003).  There was also no significant difference in the sister chromatid 
exchange assay prior to and after treatment with tobacco-specific nitrosamine, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), from volunteers with the variant 
XRCC1 Arg194Trp genotype (Abdel-Rahman and El-Zein, 2000). Studies in Chinese 
subjects in whom the incidence of the heterozygous genotype is high [31.22% (95% CI) 
29.6 to 32.8)] have suggested an increase in gastric cancer risk for heterozygotes for the 
XRCC1 194 polymorphism. In addition, this study also examined the XRCC1 399 
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polymorphism (the incidence of which is lower than Caucasian population; 24.6 vs 
34.1%) (Shen et al., 2000)  but the risk was not significant. In a Chinese study which 
explored risk for XRCC 399 (vide supra), no significant risks were associated with 
XRCC Arg194Trp genotype and pancreatic cancer (Wang et al., 2006a).  
An interesting finding from our study is that there is a non-significant trend towards an 
increased risk for the variant genotype in the < 65 years group [2.797 (0.843 to 9.280) 
as compared to those > 65 years was 0.838 (0.298 to 2.357)]. These sub-group results 
suggest there might be a higher degree of DNA damage in younger individuals with the 
variant allele. This merits further investigation. It has recently been demonstrated that 
older (more than 47 yrs) healthy Japanese workers with the XRCC1 Arg/Arg allele have 
a higher degree of DNA damage as measured by the comet assay(Weng et al., 2009), 
but our results are at odds with these findings. We however should entertain the idea 
that our result could be secondary to the design of our study rather than a genuine 
finding. 
XRCC1 Arg280His 
 
XRCC1 280 genotype did not confer a significant risk for pancreatic cancer.  
 
Our study has been the first to explore XRCC1 Arg280His and risk for pancreatic 
cancer. However risk for other tobacco related cancers eg lung cancer has been assessed 
for the genotype and XRCC1 Arg280His did not reveal either an overall effect or an 
interaction between genotype, tobacco smoking and risk for lung cancer (Schneider et 
al., 2005). Large-scale investigation of the risk for XRCC1 genes (including XRCC1 
Arg280his) has not revealed a significant role for these SNP’s in lung cancer risk (Hung 
et al., 2005b).   
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Recent meta-analysis of studies exploring the role of XRCC1 (Arg194Trp, Arg280His 
and Arg399Gln) have concluded that there is no increased risk for either gastric (Xue et 
al., 2011)  or colorectal (Wang et al., 2010) cancer associated with the genotypes. 
However one other meta-analysis suggested that the variant XRCC1 Arg194Trp allele 
was associated with an increased risk for gastric cancer, while agreeing hat there was no 
increased risk associated with the other two widely studied XRCC1 genotypes (Chen et 
al., 2011). 
APE1Asp148Gln	  	  
 
APE1 Asp148Gln did not demonstrate a significant risk for pancreas cancer.  
A previous study investigating this SNP in 384 cases and 357 controls has not found a 
main association or interaction between Ape1 Asp148Gln and tobacco smoking (Jiao et 
al., 2006b).  
Functional characterization of APE1 variants has not revealed significant chromosomal 
alterations associated with this SNP (Au et al., 2003), also no specific had no impact on 
endonuclease and DNA binding activities (Hadi et al., 2000).  
A recent study has explored the potential prognostic role of APE1 expression on 
pancreato-biliary cancers (Al-Attar et al., 2010) (pancreas adenocarcinoma, n=34) by 
immune-histochemical staining of formalin-fixed tissue. In pancreatico-biliary cancer, 
nuclear staining was seen in 44% (32 out of 72) of tumours. Absence of cytoplasmic 
staining was associated with perineural invasion (p=0.007), vascular invasion (p=0.05), 
and poorly differentiated tumours (p=0.068). A trend was noticed with advanced stage 
disease (p=0.077).  
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5.3:	  Summary	  and	  Further	  investigation	  
The present study has some strengths. For example we have minimized the outcome 
misclassification by attempting to obtain a histological diagnosis to a large extent, with 
122 of our 164 cases pathologically confirmed  (74.3%). Performing direct interviews 
for collecting exposure information reduced information obtainment bias and one single 
individual did all these interviews.   
Our study has important limitations. Voluntary participation of the patients and controls 
might have introduced bias to the association investigation. However, it seems unlikely 
that willingness to participate in research would affect genotype frequencies for DNA 
repair enzyme genes. Also our study has a mixture of current (those who attended 
hospital for illnesses not related to the pancreas) and historical controls from another 
research study. Importantly the possibility of chance findings cannot be excluded 
because of the small sample size and the low allele frequencies. The current study is 
underpowered in examining the gene-environment interaction. Alcohol consumption, 
which is a confounding factor, has not been factored into this study, as we have not 
obtained alcohol consumption information from our study participants. Another major 
deficiency in the current study is the incomplete family history data collection – 
specifically we did not collect the total number of FDR’s in a specific family and also 
the age of onset of malignancy in them (if any) and their current health status. If this had 
been collected an attempt to assess standardized risk ratios could have been made. Due 
to all these reasons, the interpretation of our findings needs caution. 
In our cohort of patients with pancreatic cancer, the total tobacco exposure was 
significantly lower amongst cases with a history of malignancy in FDR compared to 
cases who were smokers who did not have such a history. This sub-group of patients 
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should be a focus for further investigation to advance understanding gene-environment 
interaction in this disease. 
Investigation of this gene-environment interaction provides us with an opportunity to 
not only understand the disease better but also to stratify risks and develop strategies to 
improve outcome. This inter-individual genetic variation modulates risk for malignancy 
(Lochan et al., 2008) and identification of these genetic differences forms the basis of 
risk stratification thereby enabling targeted prevention or earlier diagnosis (Singh and 
Maitra, 2007, Vimalachandran et al., 2004). This is especially pertinent to pancreatic 
cancer, as it has a particularly poor prognosis and palliation of symptoms is the most 
common therapy patients receive – mainly because of late diagnosis although there are 
other biological factors that play a role.  Genetic factors such as poor DNA repair, 
impaired carcinogen metabolism and environmental factors may interact in the 
development of tobacco related cancers, including that of the lung, bladder and head 
and neck (Greer and Whitcomb, 2007) (Wiencke, 2002) (Hung et al., 2005c, Barnes and 
Lindahl, 2004).  
As discussed earlier (Section 1.6) conflicting results have emerged from studies on 
XRCC1 and other gene polymorphisms and cancer risks. Studies have been hampered 
by small sample sizes and study design. Another important challenge is that the 
measurement of environmental influences particularly, tobacco exposure, needs to be 
improved to better define gene–environment interaction. None of these studies, 
however, has ascertained the risk for smokers carrying these genotypes in the presence 
of a family history of malignancy. 
Sequence variants in DNA repair genes are thought to modulate DNA repair capacity 
and consequently are suggested to be associated with altered cancer risk. However, 
results from epidemiologic studies have been inconsistent and relatively small risks 
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have been identified (including our own), possibly because of 1) low statistical power 
for detecting a moderate effect, 2) false-positive results 3) heterogeneity across study 
populations, 4) failure to consider effect modifiers such as environmental exposures, 
and 5) publication bias. Reliable knowledge of which sequence variants influence 
cancer risk may help in identifying persons at high risk of developing cancer and shed 
light on cancer aetiology. 
The presence of a high-risk group for adenocarcinoma of the pancreas is well accepted, 
which needs further characterization and replication in much larger population based 
and molecular epidemiological studies. Identifying risk might help stratify individuals 
for pancreatic cancer screening but screening is not well established, the pickup rate is 
low and the false positive rate is relatively high. This will require identification of high-
risk groups in whom targeted screening can be employed and early/precursor lesions 
recognized (Klapman and Malafa, 2008) and this has been demonstrated successfully in 
familial forms of the disease (Canto et al., 2004) and has been found to be cost-effective 
(Rulyak et al., 2003b). A recent retrospective review comparing EUS and ERCP has 
demonstrated the superiority of EUS (Wakatsuki et al., 2005) for the diagnosis of 
pancreatic masses.  EUS of the pancreas has been utilised as a screening 
tool(Rubenstein et al., 2007), where it was used as part of 4 strategies: doing nothing, 
prophylactic total pancreatectomy, annual surveillance by EUS, and annual surveillance 
with EUS and fine needle aspiration (EUS/FNA).  FDR’s from a familial cancer kindred 
were subjected to one of the 4 strategies and the authors concluded that FDRs from 
familial pancreatic cancer kindreds, who have EUS findings of chronic pancreatitis, 
have increased risk for cancer, but their precise risk was unknown. Without the ability 
to further quantify that risk, the most effective strategy is to do nothing. However if we 
are able to better quantify the risk, the benefits might be greater for these patients as  
surgery usually means a total pancreatectomy with all its potential complications. 
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Identifying genetic and environmental factors and delineating their complex interaction 
is important in this regard.  
Similarly identification of high-risk groups such as smokers with a positive family 
history of cancer could have implications for the earlier diagnosis by making screening 
for the disease possible leading to the prospect of long-term survival, if not cure for 
more patients. Following significant advances in imaging to aid in patient selection for 
definitive treatment and improvement in surgical technique and peri-operative care, 
prognosis for resectable pancreatic cancer has improved appreciably. Chemotherapy has 
a significant role to play in selected cases (Aung et al., 2007). However it does appear 
that further significant improvement in outcome from the illness will be directly related 
to the ability to detect the disease early and institute prompt management. This will 
require identification of high-risk groups in whom targeted screening can be employed 
and early or precursor lesions recognized (Klapman and Malafa, 2008) and this has been 
demonstrated successfully in familial forms of the disease (Canto et al., 2004) and has 
been found to be cost-effective (Rulyak et al., 2003b).  
Also there is increasing evidence for the modulation of outcome from pancreatic cancer 
by genotype for DNA repair mechanisms (Li et al., 2007b, Li et al., 2006c) including 
response to chemotherapy and pre-operative chemo-radiation (Dong et al., 2009) 
(Okazaki et al., 2008). Defining these risks and benefits might allow selection of 
patients for specific neo-adjuvant and adjuvant treatment strategies. 
With the completion of the human genome project and advances in molecular 
epidemiological techniques, these low penetrant/polymorphic genes should become 
more frequently identified and their function understood; for example genome wide 
association studies (GWAS) have identified smokers with a non- O blood group as a 
significant high risk group for pancreas cancer as compared to non-smokers of non-O 
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blood group [OR 2.68 (95% CI, 2.03-3.54)] (Amundadottir et al.). The same group has 
carried out a further GWAS (Petersen et al., 2010) and have reported the association for 
pancreatic cancer and three new genomic regions on chromosomes 13q22.1 (rs9543325 
and rs9564966), 1q32.1 (5 highly significant SNPs map to this region) and 5p15.33 
(rs401681). The area identified on chromosome 1 contains the nuclear receptor 
subfamily 5, group A, member 2 (NR5A2) gene which plays a role in early 
development of embryos. The region identified on chromosome 5 has been identified in 
genome-wide association studies of a number of different cancers, including brain 
tumors, lung cancer, basal cell carcinoma, melanoma. Furthermore in an analysis of 
lung cancer in smokers, the signal on chromosome 5p15.33 has been shown to be 
strongly associated with the adenocarcinoma histology subtype. Also, SNP’s in this 
region, have been associated with levels of smoking-related bulky aromatic DNA 
adducts in lung cancer patients (Zienolddiny et al., 2006) and tobacco smoking is a 
known and relevant risk factor for pancreatic cancer. The area identified on 
chromosome 13 is frequently deleted in a range of cancers, including pancreatic cancer 
and may harbor a breast cancer susceptibility locus. In a GWAS from Japan three 
genomic regions, 6p25.3, 12p11.21 and 7q36.2, were shown to be significantly 
associated with increased risk of pancreatic cancer (Low et al., 2010) and rs9502893 the 
most significantly associated SNP is located within the FOXq1 gene complex. A 
member of this gene FOXM1 is overexpressed in pancreatic cancer. Another SNP from 
this GWAS, rs708224 was significantly associated with the disease and it is located 
within the BICD1 gene, which is linked to vacuolar trafficking and telomere function, 
and there has been some recent evidence to link this to pancreatic cancer.	  
Thus, the elusive search for a better understanding of this disease continues and it is 
undoubtedly the case that a better outcome from pancreatic cancer will result from a 
better understanding of the genetics and epidemiology of the disease.
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Appendix 1: Studies of hOGG1 polymorphisms and risk of malignancy 
  
Cancer  
type/site  
First  
author  
Year   Country   Ethnicity  of  
subjects  
Cases  
number  
Controls  
number  
Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygote  
Hardy-­‐
Weinberg  
p  value  
Ref  
Lung   Sugimura   1999   Japan   Asian   241   197   Hospital   No   54.3   13.7   0.08   (Sugimura  
et  al.,  
1999)  
   Ito   2002   Japan   Asian   138   240   Hospital   No  info   49.2   22.5   0.84   (Ito  et  al.,  
2002)  
   Sunaga   2002   Japan   Asian   198   152   Hospital   No   43.4   23.7   0.13   (Sunaga  
et  al.,  
2002)  
   Lan   2004   China   Asian   118   109   Population   Frequency   39.4   13.8   0.23   (Klein  et  
al.,  2004)  
   Le  
Marchand  
2002   Hawaii   Japanese,  
Caucasian,  
Hawaiian  
298   405   Population   Frequency   43.2   13.1   0.35   (Le  
Marchand  
et  al.,  
2002)  
   Park   2004   United  
States  
Caucasian,  
Other  
unspecified  
ethnic  
179   350   Screening   Individual   24.9   2.3   0.86   (Park  et  
al.,  2004)  
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groups  
   Wikman   2000   Germany   Caucasian   105   105   Hospital   Frequency   41.0   1.9   0.07   (Wikman  
et  al.,  
2000)  
   Hung   2005   Europe   Caucasian,  
Other  
unspecified  
ethnic  
groups  
2155   2163   Hospital   Frequency   33.1   3.7   0.22   (Hung  et  
al.,  
2005a)  
  
  
  Page  207  of  229  
OGG1  studies  (contd)  
  
Cancer  
type/site  
First  author   Year   Country   Ethnicity  of  
subjects  
Cases     Controls     Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygote  
H  W     Ref  
Oeso  Ca   Xing   2001   China   Asian   196   201   Hospital  
Healthy  
Frequency   52.7   13.4   0.15   (Xing  
et  al.,  
2001)  
NPC   Cho   2003   Taiwan   Asian   333   283   Community   Frequency   45.6   38.2   0.48   (Cho  
et  al.,  
2003)  
Oeso  Ca   Hao   2004   China   Asian   419   480   Population   Frequency   45.0   16.5   0.24   (Hao  
et  al.,  
2004)  
Orolaryn  
Ca  
Elahi   2002   United  
States  
Caucasian   167   331   Hospital  
healthy  
Frequency   23.0   1.8   0.94   (Elahi  
et  al.,  
2002)  
H  &  N    
Sq  Ca  
Zhang   2004   United  
States  
Caucasian,  
UEG  
706   1196   Hospiatl  
healthy  
Frequency   32.4   5.8   0.06   (Zhang  
et  al.,  
2004)  
Colon   Kim   2003   Korea   Asian   125   247   Hospiatl  
healthy  
Frequency   53.0   25.9   0.32     
Stomach   Takezaki   2002   China   Asian   101   198   Population   Frequency   60.6   24.2   <0.01   (Takez
aki  et  
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al.,  
2002)  
Stomach   Hanoaka   2001   Brazil   Asian   58   127   Hospital   Hospiatl     44.1   21.3   0.25   (Hana
oka  et  
al.,  
2001)  
Stomach   Hanoaka   2001   Brazil   Non-­‐
Japanese  
Brazilian  
208   205   Hospital   Individual   36.1   3.9   0.44   (Hana
oka  et  
al.,  
2001)  
Sporadic  
Prostate  
cancer  
Xu   2002   United  
States  
Caucasian   199   174   Hospital  
healthy  
No   36.2   8.6   0.32   (Xu  et  
al.,  
2002)  
  
  
  
OGG1  studies  (contd)  
  
Cancer  
type/site  
First  author   Year   Country   Ethnicity  of  
subjects  
Cases     Controls     Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygote  
H  W     Ref  
Hereditary  
prostate  
Xu   2002   United  
States  
Caucasian   99   174   Hospital  
healthy  
No   36.2   8.6   0.32   (Xu  et  
al.,  
  Page  209  of  229  
cancer   2002)  
Basal  cell  
carcinoma  
Vogel   2004   Denmark   Caucasian   319   319   Population   Individual   39.2   8.5   0.60   (Vogel  
et  al.,  
2004)  
Breast   Vogel   2003   Denmark   Caucasian   425   434   Population   Individual   38.9   4.6   0.18   (Vogel  
et  al.,  
2003)  
Breast   Choi   2003   Korea,  
Japan  
Asian   466   466   Hospital   No   52.1   24.1   0.36   (Choi  
et  al.,  
2003)  
NSCLC   Zienolddiny   2006   Norway   Caucasian   343   413   Population               (Zienol
ddiny  
et  al.,  
2006)  
Breast   Zhang   2006   United  
States  
                        (Zhang  
et  al.,  
2006)  
Breast   Zhang   2006   Poland                           (Zhang  
et  al.,  
2006)  
NHL   Wang   2006         1172   982   Population               (Wang  
et  al.,  
2006b)  
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Cancer  
type/site  
First  author   Year   Country   Ethnicity  of  
subjects  
Cases     Control
s    
Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygot
e  
H  W     Ref  
Hereditary  
prostate  
cancer  
Xu   2002   United  
States  
Caucasian   99   174   Hospital  
healthy  
No   36.2   8.6   0.32   (Xu  et  
al.,  
2002)  
Basal  cell  
carcinoma  
Vogel   2004   Denmark   Caucasian   319   319   Population   Individual   39.2   8.5   0.60   (Vogel  
et  al.,  
2004)  
Breast   Vogel   2003   Denmark   Caucasian   425   434   Population   Individual   38.9   4.6   0.18   (Vogel  
et  al.,  
2003)  
Breast   Choi   2003   Korea,  
Japan  
Asian   466   466   Hospital   No   52.1   24.1   0.36   (Choi  
et  al.,  
2003)  
NSCLC   Zienolddiny   2006   Norway   Caucasian   343   413   Population               (Zienol
ddiny  
et  al.,  
2006)  
Breast   Zhang   2006   United  
States  
                        (Zhang  
et  al.,  
2006)  
Breast   Zhang   2006   Poland                           (Zhang  
et  al.,  
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2006)  
NHL   Wang   2006         1172   982   Population               (Wang  
et  al.,  
2006b)  
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Appendix 2:  Studies of APE1/APEX1 polymorphisms and risk of malignancy
Cancer  
type/site  
First  author   Year   Country   Ethnicity  of  
subjects  
Cases     Controls     Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygote  
H  W     Ref  
Lung   Ito   2004   Japan   Asian   178   449   Hospital   Frequency   50.3   14.3   0.25   (Ito  et  
al.,  
2004)  
   Misra   2004   Finland   Caucasian   310   302   Population   Individual   53.0   25.5   0.29   (Misra  
et  al.,  
2003)  
   Popanda   2004   Germany   Caucasian   459   457   Hospital   No   51.0   23.2   0.66   (Popa
nda  et  
al.,  
2004)  
UGI  tract   Hao   2004   China   Asian   409   478   Population   Frequency   49.0   19.9   0.86   (Hao  
et  al.,  
2004)  
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Appendix 3: Selected studies of XRCC1 Arg194Trp polymorphisms and risk of malignancy 
Cancer  
type/site  
First  author   Year   Country   Ethnicity  of  
subjects  
Cases     Controls     Source  of  
controls  
Matching   Heterozygotes   Rare  allele  
Homozygote  
H  W     Ref  
Lung   Ratnasinghe   2001   China   Asian   108   216   Population   Individual   48.1   9.7   0.26     
   Chen   2002   China   Asian   109   109   Population   Individual   36.1   4.6   0.69     
   Hung   2005   Europe   Caucasian   2147   2132   Hospital   Frequency   13.7   0.6   0.93     
UGI  Tract   Lee   2001   Taiwan   Asian   105   264   Hospital   Frequency   45.5   7.2   0.17     
   Xing   2002   China   Asian   433   524   Population   Frequency   43.5   7.1   0.16     
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Appendix 4: Tobacco smoking and pancreatic cancer 
  
   Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
1.    Population  
based  Case-­‐
control  
study  
1984-­‐88   Central  
Netherlands  
189  cases,  702  
controls  
1.96         Bueno  De  
Mesquita  
1991  
2. 1   Multi-­‐centre  
Case-­‐control  
study.  
Population  
based  
Varied  acc  to  
centre.  1983-­‐
88  
Adelaide,  
Toronto,  
Utretcht,  
Opole,  
Montreal  
832  cases,  1679  
controls  
Non-­‐
smokers  1.0  
Ever  
smokers  
1.91-­‐2.70  
SEARCH  
programme  of  
IARC  
Risk  increased  in  a  
significant  trend  
with  increasing  
life-­‐time  exposure  
in  all  centres  
independently  and  
collectively.  
Quitting  for  15  
years  decreased  
risk  to  that  of  non-­‐
smokers  
Boyle  1996  
3.    Population  
based  case-­‐
control  
study  
1985-­‐88   Opole,  Poland   110  cases,  195  
cases  
OR  ever  
smoker  1.89  
Only  43  %  
cases  were  
pathologically  
confirmed  
Weak  association  
betwn  life-­‐time  
consumption  of  
cigs  and  risk  
Zatonski  
1993  
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4.    Hospital  
based  case-­‐
control  
study  
1982-­‐85   Paris,  France   161  cases,  268  
controls  
No  
increased  
risk  for  
tobacco  
smoking  
and  Panc  Ca  
Only  102  cases  
were  
histologically  
confirmed  
   Clavel  1988  
   Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
5.    Prospective  
Cohort  
study  
National  
Health  
Screening  
Service  
Survey  1984-­‐
1986.  12  
years  follow-­‐
up  
Nord-­‐
Trondelag,  
Norway  
31000  men  &  
32374  women  
RR  current  
smokers  2.1  
(men)  2.1  
(women).    
   Clear  statistical  
association  
between  dose  and  
response  for  both  
men  &  women  
Nilsen  2000  
6.    Cohort  
study  
Nurse  Health  
Study  (1976).  
Health  
Professionals  
Follow-­‐up  
Study  (1986)  
118339  
women.  
49428  men.  
US  men  and  
women.  
2  large  
prospective  
cohorts  –  Nurses  
Health  Study  
(1976)  and  
Health  
professionals  
Follow-­‐up  
Study(1986).    
RR  (overall)  
never  
smokers  1,  
Former  
smokers  
1.2,  current  
smokers  
2.5.  RR  
(women)  NS  
Every  2-­‐years  
follow-­‐up  
questionnaires  
were  sent  by  
mail  to  update  
info:.  
No  clear  dose-­‐
response  
relationship  
betwn  no:  of  cig’s  
and  RR  in  current  
smokers.    
Total  proportion  
of  pancreatic  
cancers  
Fuchs  
1996  
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1,  FS  1.1,  CS  
2.4.  RR  
(men)  NS  1,  
FS  1.3,  CS  3.  
attributable  to  
smoking  was  25%  
  
  
                       
   Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
  
  
  
Prospective  
Cohort  
study  
1968-­‐95   Iceland   11580  females,  
11366  males  as  
a  part  of  the  
Icelandic  
cardiovascular  
risk  factor  study  
Men:  RR  
former  
smoker  
2.37,  pipe  
2.52,  cigar  
4.87,  1-­‐14  
cigs/day  
7.18,  15-­‐24  
cigs/day  
10.2,  
25+/day  
12.5  
Patient  filled  in  
a  mailed  
questionnaire  
and  brought  it  
in  to  the  clinic.  
Dose  response  
relationship  in  
men  
demonstrated.  
Smoking  is  a  risk  
factor  in  females  
only  when  25+  
cig’s/day  (RR  4.52)  
but  the  95%  CI  is  
very  wide  (1.02-­‐
20.1)  and  after  
adjustment  for  
other  risk  factors  
the  RR  is  not  
significant  
Tulinius  
1997  
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7.    Prospective  
cohort  study  
1986-­‐94   Iowa.  Iowa  
women’s  
Health  Study  
33976  
postmenopausal  
women  from  
Iowa  
Less  than  20  
pack  years  
RR  1.14,  
more  than  
20  pack  
years  1.92  
(p  for  trend  
0.02)  
Mailed  
questionnaire  
Coffee  
consumption  and  
alcohol  
consumption  
increased  risk  
after  adjustment  
for  age  and  
smoking.  Dose  
response  
relationship  
demonstrated.    
Harnack  
1997  
     
  
  
  
                    
   Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
8.    Case-­‐control   1986-­‐89   Atlanta,  
Detroit  and  
Michigan.  USA  
526  cases,  2153  
controls.  
Population  
based.  
OR  1.1  –  
2.2.  Inc  
trend  with  
no:  cigs  
(p=0.001)  
Direct  
interviews  
with  subjects  
Relationship  
between  cig’s  
smoking  and  panc  
Ca:.  causal.  Dose-­‐
response  
relationship  
demonstrated.  
Silverman  
1994  
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Former  smokers  
who  stopped  
smoking  had  a  
30%  reduction  in  
risk  compared  to  
non-­‐smokers.  
9.    Cohort  
study  
1963  cohort   Swedish  men  
and  women  
27841  men  and  
28089  women.  
Smoking  habit  
survey  1963.  
RR  inc  from  
2.35  to  6.44  
with  inc  no:  
of  cig’s  in  
men.  
Smoking  and  
risk  of  
mortality  from  
panc  ca  
evaluated  
Dose  response  
relation  ship  in  
men.  Few  women  
smoking  a  very  
high  no;  of  
cig’s/day.  
Nilsson  
2005  
10.    Prospective  
cohort  study  
1982  cohort   U.S  men   137243  men.  
American  cancer  
Society’s  Cancer  
Prevention  
study    cohort  
RR  for  
“inhalers”  
2.7  (95%  CI  
1.5-­‐4.8)  
Cigar  smoking  
and  risk  of  
mortality  
evaluated  
No  increased  risk  
for  death  from  
pancreas  cancer  
fro  non-­‐inhalers  
Shapiro  
2000  
                          
   Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
11.    Case-­‐control   1991-­‐92   Athens,  
Greece.  
181  cases.  181  
hospital  patient  
controls  and  181  
hospital  visitors  
OR  and  RR  
not  
calculated  
   Increased  risk  for  
pancreatic  cancer  
in  smokers,  but  
not  quantified.  
Kalapothaki  
1993  
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as  controls   Suggestion  of  
earlier  age  at  
menarche  
associated  with  
inc  risk  and  parous  
women  at  lower  
risk.  
12.    Case-­‐control   1990-­‐93   Shanghai,  
China  
451  cases,  
controls  1552.  
Population  
based.  
OR  1.4  –  
5.0.  OR  
higher  in  
men  than  
women.  Inc  
trend  with  
no:  (p  
0.0001  in  
men  and  
p=0.05  in  
women)  
Direct  
interviews  
Dose-­‐response  
relationship  
demonstrated.  
Formwe  smokers  
who  stopped  
smoking  for  more  
than  10  years  had  
risks  comparable  
to  non-­‐smokers.  
Ji  1995  
     
  
  
  
  
                    
   Type  of  
Study  
Year/Study  
period  
Geographic  
population  
Size  of  study  
population  
Risk  for   Note      Reference  
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(Incident  
cases)  
studied   Pancreatic  
Cancer  
13.    Cohort  
study  
1966-­‐81   Japanese  men  
&  women  
265000   Males  1.1  to  
1.6  with  inc  
in  no:  of  
cis’s  (p  for  
trend  0.04).  
Females  1.4  
to  1.9  (p  for  
trend  0.02)  
Re-­‐analysis  of  
the  six  
prefecture  
cohort  data    
Smoking  more  
than  34  cigs  for  
men  and  more  
than  15  cigs/day  
in  women  did  not  
inc  risk  but  dec  
risk  of  rPanc  Ca.m  
Akiba  
1990  
14.    Cohort  
study  
1965-­‐93   Norwegian  
men  &  women  
26,000   RR  current  
smoker  1.3  
(men)  1.4  
(women)  
Self-­‐
administered  
mailed  
questionnaire  
A  subsequent  
analysis  (Heuch)  
of  the  same  
cohort  showed  an  
inc  RR  when  only  
histologically  
confirmed  cases  
were  included  in  
the  analyses  
Engeland    
1996  
15.    Cohort  
study  
1941-­‐75   Mortality  data  
analysis  
England  &  
Wales  
All  deaths  due  
to  panc.  Ca  
betwn  1941-­‐71.  
  
  
  
RR  of  1.6  for  
20  pack  
years  of  
smoking  
   Cohort  analysis  
  
VERY  
COMPLICATED  
STATS!!!  
Moolgavkar    
1981  
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Type  of  
Study  
Year/Study  
period  
(Incident  
cases)  
Geographic  
population  
studied  
Size  of  study  
population  
Risk  for  
Pancreatic  
Cancer  
Note      Reference  
16.    Longitudinal  
cohort  study  
1963-­‐79   Swedish  men   25129  men   Relative  
death  rate  
for  Curr  cig  
smok  3.3,  
for  curr  pipe  
smoker  2.8  
and  curr  
cigar  smok  
1.0  
Inc  risk  for  
death  from  
panc  ca  in  
both  cig  and  
pipe  smokers.  
Risk  inc  with  
increasing  
consumption  
of  tobacco  in  
curr  smokers  
and  for  ex-­‐
smokers  
No  influence  of  
age  of  
commencement  
of  smoking  on  risk  
of  death  from  
pancreatic  cancer  
Carstensen  
1987  
17.    Case-­‐control   1976  –  all  
cases  under  
65  years  of  
age  
Los  Angeles  
county,  North  
America  
490  cases,  
age,  sex  
matched  
controls  
Current:  
4.3-­‐5.7  (RR)  
Ex-­‐smokers  of  
!  10  yrs  no  
increased  risk.    
   Mack  
1986  
18.    Case-­‐control   1985-­‐93   New  York,   484  cases,   OR  upto  1.4  
(30-­‐39  cig  
Pancreatic  
cancer  is  
All  direct  
interviews  with  
Muscat  
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North  America   954  controls   yrs  in    
males)  2.4  
(20-­‐29  cig  
yrs).  Further  
increase  in  
exposure  
did  not  
increase  OR  
caused  by  
smoking  in  
women  too  
AND  the  risks  
are  higher  
than  in  men  
for  the  same  
amount  and  
duration  of  
tobacco  
consumption.  
incident  cases  and  
controls  (hospital  
derived).  
  
Males  and  females  
analysed  
separately.    
1997  
  
19.    Case-­‐control   1984-­‐88   Greater  
Montreal,  
Canada  
179  cases,  
239  controls  
OR  3.76  for  
highest  
quintile  
(unfiltered  
cig  5.08  )  
Statistically  
significant  
increase  in  
trend  of  OR  
with  increase  
in  number  of  
cigs  smoked  
Population  based  
controls  
Ghadirian  
1990  
20.    Case-­‐control   1983-­‐88   Greater  Milan,  
North  Italy  
214  cases,  1944  
controls  
Never  RR  1  
Ex  RR  1.23  
Current  RR    
Less  than  
15:  0.75  
15-­‐24:  1.16  
t  25  1.44  
Increasing  
exposure  lead  
to  increase  in  
RR  
Controls  –  
subjects  admitted  
to  hospital  with  
non-­‐acute  non-­‐
neoplastic  GI  
disorders  
Ferraroni  
etal  1989  
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21.    Prospective  
mortality  
study  
(cohort)  
1982-­‐86   North  
American  
women  
700,000   RR  not  
calculated.  
Attributable  
risk  (current  
smokers)  
55.2%  
Attributable  
risk  (former  
smokers)  
42.4%.  
All  subjects  
PAR%  25.6%  
   Stellman  
1989  
22.    Longitudinal  
study  
Cohort  
1960-­‐1989   Females  in  
Sweden  
26000   RR  for  
former  
smoker  
[2.47(1.14  –  
5.34)].  RR  
current  
smoker  
[1.77(1.09-­‐
2.87)]  
Former  
smokers  at  a  
higher  risk  for  
panc  Ca!!!  
Elevated  RR  for  
former  and  
current  smokers  
compared  with  
women  who  did  
not  smoke  
regularly  –  cancers  
of  lung,  upper  
aero-­‐digestive  
tract,  pancreas,  
cervix,  bladder.    
Nordlund  
  
1997  
23.    Cohort  
study  
1967  -­‐  75   Mormons  of  
Utah  
900000  popln.  
for  Utah.  19,940  
deaths  in  the  
study  period  
analysed  
30  %  -­‐  40  %  
decrease  in  
incidence  of  
pancreatic  
cancer  as  
compared  
to  national  
average  
(from  SEER,  
TNCS)  
Mormons  
refrain  from  
use  of  alcohol,  
tobacco,  non-­‐
medicinal  
drugs  and  
place  
emphasis  on  
family  values,  
strict  sexual  
mores  and  
Mortality  data  
compared  
between  
Mormons  &  Non-­‐
mormons  in  Utah.  
Lyon  1980  
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24.    Cohort  
study?  
1970-­‐82   Male  veterans  
utilizing  
Veterans  
Administration  
system  betn  
1970-­‐82  
37,04,000   No  
difference  
in  age-­‐
specific  
incidence  
rates  and  
curves  for  
pancreatic  
cancer  as  
compared  
to  SEER  
registry  
VA  users  
exhibit  a  very  
high  
proportion  of  
blacks  and  
prevalence  of  
chronic  
cigarette  
(nearly  
double)  
smoking,  
alcohol  use  
and  poor  
nutrition  
The  absence  of  an  
increase  in  panc  
Ca  (as  opposed  to  
the  nearly  double  
the  incidence  of  
upper  aero-­‐
digestive  and  Resp  
cancers)  as  
compared  to  SEER  
data  would  be  
explained  by  the  
competing  risks  of  
other  
malignancies  and  
illnessess  
Harris  etal  
1989  
25.    Correlation  
study  
1972-­‐76   5  ethnic  
groups  in  
Hawai  –  
Hawaian,  
Japanese,  
Chinese,  
Filipjno  and  
Caucasians  
Personal  
interviews  of  
9920  individuals  
Significant  
risk  of    
pancreatic  
cancer  
predicted  
for  use  of  
Tobacco.  
  
Predicted  
annual  
cancer  
Using  cancer  
incidence  data  
and  tobacco,  
alcohol  
consumption  
based  on  
personal  
interview  
   Hinds  etal.  
1980  
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incidence/  
100000  
popln    
10  PY:  19.2  
20  PY:  28.9  
26.    Population  
based  cross-­‐
sectional  
study  
            Lot  of  errors  in  
analysis  
methods  
   Roger  R  
Williams  
etal  1976  
27.    Population  
based  case-­‐
control  
study  
1986-­‐1989   Iowa   3574  cancer  
cases  (376  
pancreas  cases).  
Controls  2434  
[6.5  controls  :1  
case]  
OR:  males  
1.8  95%  CI  
1.2-­‐2.8;  
females  2.1  
1.4-­‐3.1  
mailed  
questionnaire  
Multi  site  CC  study   c-­‐h-­‐chiu  etal  
2000  
28.    Multi  site  
case  control  
study  
1979  -­‐  1985   Montreal   3730  cancer  
patients.  533  
controls  
OR:  1.6%  
PARP:  33%  
   Multi  site  CC  study   Siemiatycki  
J  et  al.  1995  
29.    Prospective  
mortality  
study  
Enrolment  
1982.  F/U  4  
years  
Across  all  50  
states  in  
America  
1.2  million  (men  
&  women)  
enrolled  &  
smoking  history  
collected.  
Analysis  
performed  on  
Attributable  
risk  of  death  
due  to  
pancreatic  
cancer  for  
current  
smokers  
55.2%  
   1527  deaths  due  
to  6  smoking  
related  cancer  
sites  
Stellman  
1989  
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685,748  women   (former  
smokers  
42.4)  
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Appendix 5: MONICA tobacco smoking questionnaire 
 
1.   Do  you  smoke  cigarettes  now?    
                    1  =  yes,  regularly                  Go  to  2.    
                    2  =  no                                                  Go  to  5.    
                    3  =  occasionally                      Go  to  3.    
  
|__|    
2.   On  average,  how  many  cigarettes  do  you  smoke  a  day?  
                                                                                            Go  to  7.                                          Number:    
  
|__|__|__|    
3.   On  how  many  days  a  week  do  you  smoke  cigarettes?    
                    1  =  usually  on  one  day  or  less  
                    2  =  usually  on  2  to  4  days  
                    3  =  almost  every  day    
  
|__|  
4.   On  average,  how  many  cigarettes  do  you  smoke  a  day?  
                                                                                                                                                                Number:    
  
|__|__|__|    
5.   Did  you  ever  smoke  cigarettes  regularly  in  the  past?    
                    1  =  yes                      Go  to  6.  
                    2  =  no                          Go  to  9.    
  
|__|    
6.   When  did  you  stop  smoking  cigarettes  regularly?              Year,  19-­‐-­‐    
                    If  in  the  last  12  months  
                    1  =  less  than  1  month  ago  
                    2  =  1-­‐6  months  ago    
                    3  =  6-­‐12  months  ago    
|__|__|    
  
|__|    
7.   What  is  the  highest  average  daily  number    
of  cigarettes  you  have  ever  smoked  for  as    
long  as  a  year?                                                                                                                          Number:    
  
|__|__|__|    
8.   How  old  were  you  when  you  began  to  smoke    
cigarettes  regularly?                                                                                                                      Age:    
  
|__|__|    
9.   Have  you  ever  smoked  cigars/cigarillos?    
                    1  =  now  smoke  regularly                      Go  to  10.    
                    2  =  no                                                                              Go  to  11.    
                    3  =  now  smoke  occasionally  (less  than  one/day)      Go  to  10.    
                    4  =  used  to,  but  not  now                      Go  to  11.    
  
|__|    
10.  How  many  do  you  smoke  per  week?                                                          Number:     |__|__|__|    
11.  Have  you  ever  smoked  a  pipe?    
                    1  =  now  smoke  regularly                      Go  to  12.    
                    2  =  no                                                                              Go  to  13.    
                    3  =  now  smoke  occasionally  (less  than  once  a  day)      Go  to  12.    
  
|__|    
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                    4  =  used  to,  but  not  now                      Go  to  13.    
12.  About  how  many  grams  of  tobacco  do  you  smoke    
per  week?                                                                                                                                          Grams:    
  
|__|__|__|    
13.  To  be  completed  by  occasional  and  non-­‐smokers  only  
(i.e.  when  item  1  is  coded  2  or  3):  
For  how  many  hours,  on  average  each  day,  are  you    
closely  subjected  to  other  people's  tobacco  smoke?    
  
  
|__|__|    
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